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Background: The optimal corticosteroid regimen for treating the presenting episode of steroid-sensitive
nephrotic syndrome (SSNS) remains uncertain. Most UK centres use an 8-week regimen, despite previous
systematic reviews indicating that longer regimens reduce the risk of relapse and frequently relapsing
nephrotic syndrome (FRNS).
Objectives: The primary objective was to determine whether or not an extended 16-week course of
prednisolone increases the time to first relapse. The secondary objectives were to compare the relapse rate,
FRNS and steroid-dependent nephrotic syndrome (SDNS) rates, requirement for alternative immunosuppressive
agents and corticosteroid-related adverse events (AEs), including adverse behaviour and costs.
Design: Randomised double-blind parallel-group placebo-controlled trial, including a cost-effectiveness
analysis.
Setting: One hundred and twenty-five UK paediatric departments.
Participants: Two hundred and thirty-seven children presenting with a first episode of SSNS. Participants
aged between 1 and 15 years were randomised (1 : 1) according to a minimisation algorithm to ensure
balance of ethnicity (South Asian, white or other) and age (≤ 5 or ≥ 6 years).
Interventions: The control group (n= 118) received standard course (SC) prednisolone therapy: 60mg/m2/day
of prednisolone in weeks 1–4, 40 mg/m2 of prednisolone on alternate days in weeks 5–8 and matching placebo
on alternate days in weeks 9–18 (total 2240mg/m2). The intervention group (n= 119) received extended course
(EC) prednisolone therapy: 60 mg/m2/day of prednisolone in weeks 1–4; started at 60 mg/m2 of prednisolone on
alternate days in weeks 5–16, tapering by 10mg/m2 every 2 weeks (total 3150mg/m2).
Main outcome measures: The primary outcome measure was time to first relapse [Albustix® (Siemens
Healthcare Limited, Frimley, UK)-positive proteinuria +++ or greater for 3 consecutive days or the presence
of generalised oedema plus +++ proteinuria]. The secondary outcome measures were relapse rate,
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incidence of FRNS and SDNS, other immunosuppressive therapy use, rates of serious adverse events (SAEs)
and AEs and the incidence of behavioural change [using Achenbach Child Behaviour Checklist (ACBC)].
A comprehensive cost-effectiveness analysis was performed. The analysis was by intention to treat.
Participants were followed for a minimum of 24 months.
Results: There was no significant difference in time to first relapse between the SC and EC groups (hazard
ratio 0.87, 95% confidence interval 0.65 to 1.17; log-rank p = 0.3). There were also no differences in
the incidence of FRNS (SC 50% vs. EC 53%; p = 0.7), SDNS (44% vs. 42%; p = 0.8) or requirement for
other immunosuppressive therapy (56% vs. 54%; p = 0.8). The total prednisolone dose received following
completion of study medication was 5475 mg vs. 6674 mg (p = 0.07). SAE rates were not significantly
different (25% vs. 17%; p = 0.1) and neither were AEs, except poor behaviour (yes/no), which was less
frequent with EC treatment. There were no differences in ACBC scores. EC therapy was associated with a
mean increase in generic health benefit [0.0162 additional quality-adjusted life-years (QALYs)] and cost
savings (£4369 vs. £2696).
Limitations: Study drug formulation may have prevented some younger children who were unable to
swallow whole or crushed tablets from participating.
Conclusions: This trial has not shown any clinical benefit for EC prednisolone therapy in UK children.
The cost-effectiveness analysis suggested that EC therapy may be cheaper, with the possibility of a small
QALY benefit.
Future work: Studies investigating EC versus SC therapy in younger children and further cost-effectiveness
analyses are warranted.
Trial registration: Current Controlled Trials ISRCTN16645249 and EudraCT 2010-022489-29.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 26.
See the NIHR Journals Library website for further project information.
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Plain English summary
S teroid-sensitive nephrotic syndrome (SSNS) is one of the most common childhood kidney diseases.The kidney filters leak protein into the urine, resulting in low levels of protein in the blood and
generalised swelling. If untreated, this can lead to serious complications, including infection and blood
clots. The disease responds well to prednisolone, a steroid drug; however, it is very common for disease
to recur (called a relapse).
Doctors are uncertain how long prednisolone should be given to treat children when they first present
with nephrotic syndrome. In the UK, a 2-month course has traditionally been used. However, a number
of research studies have suggested that giving prednisolone for ≥ 3 months may reduce the number
of children who relapse and also the number who develop lots of relapses (called frequently relapsing
nephrotic syndrome; FRNS).
We recruited 237 children presenting with SSNS. Half were given an 8-week standard course of
prednisolone and the other half a 16-week extended course (EC). We used placebo (dummy tablets) so
that the participants and doctors did not know which treatment group they were in. Participants were
followed for a minimum of 24 months and monitored for the development of relapses and prednisolone
side effects, including behavioural problems. A cost analysis was performed.
Giving EC prednisolone did not delay the development of disease relapse. There was also no difference in
the number of children who developed FRNS or steroid-dependent nephrotic syndrome or who needed to
be given other treatments. The rate of prednisolone side effects was the similar in the two treatment
groups. EC treatment was, however, cheaper by £1673.
Therefore, we conclude that there is no clinical benefit associated with the administration of EC prednisolone
therapy in UK children presenting for the first time with SSNS. However, EC therapy was cheaper than the
standard treatment.
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Scientific summary
Background
Idiopathic nephrotic syndrome (INS) is the most common glomerular disorder of childhood, with an
incidence of 2 per 100,000 child population in the UK. The disease presents at a median age of 2 to
3 years and is twice as common in boys as in girls. There is ethnic variability in the disease incidence,
with a fourfold to sixfold higher incidence in the UK South Asian population.
In excess of 90% of children who present with INS will respond to a course of high-dose corticosteroid
therapy. For this reason, the large majority are treated empirically with a course of corticosteroids without
a renal biopsy being performed. Those who are corticosteroid responsive are given a diagnostic label of
having steroid-sensitive nephrotic syndrome (SSNS).
Following initial successful treatment with corticosteroids, around 80% of children with SSNS experience
disease relapses, necessitating further courses of high-dose prednisolone, and around 50% develop frequently
relapsing nephrotic syndrome (FRNS), defined as two or more relapses within the first 6 months following
presentation or four relapses within any 12-month period. Similar to the presenting episode, nephrotic
syndrome relapses are associated with a risk of significant complications, including sepsis, thrombosis,
dyslipidaemia and malnutrition. The treatment of relapses with repeated courses of high-dose prednisolone is
associated with major adverse effects, including hip avascular necrosis, growth failure, hypertension, obesity,
diabetes and behavioural problems. When complications of repeated courses of corticosteroids develop, or
when they are expected, a range of immunosuppressive strategies are employed in an attempt to reduce the
frequency of disease relapses. These include the use of long-term, low-dose, alternate-day prednisolone, as
well as a range of non-corticosteroid immunosuppressive agents, including levamisole, cyclophosphamide,
ciclosporin, tacrolimus, mycophenolate mofetil and rituximab.
There remains uncertainty about the ideal corticosteroid regimen for the treatment of a child presenting
with SSNS. The majority of UK centres have continued to use the 8-week regimen first described by the
International Study of Kidney Disease in Children (Nephrotic syndrome in children: a randomised controlled
trial comparing two prednisolone regimens in steroid responsive patients who relapse early. J Pediatr
1979;95:239–43) in the 1960s. At the time of commencement of the PREDnisolone in NephrOtic
Syndrome (PREDNOS) study, a total of six randomised controlled trials (RCTs) had compared 2 months of
prednisolone with a variety of different regimens of ≥ 3 months in duration. A 2005 Cochrane review
(Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children.
Cochrane Database Syst Rev 2005;1:CD001533) concluded that intensification of the initial corticosteroid
therapy at disease presentation significantly reduced the rate of relapse at 12 to 24 months [risk ratio 0.7,
95% confidence interval (CI) 0.58 to 0.84]. There was an inverse linear relationship between treatment
duration and risk of relapse (risk ratio 1.26–0.112 duration; p = 0.03). Furthermore, there was a significant
reduction in the number of children with FRNS and the mean relapse rate per participant per year.
However, significant concerns have been raised about a number of methodological issues relating to these
six studies. Thus, there remains significant clinical equipoise, with the UK, parts of North America and
other countries continuing to use the 8-week International Study for Kidney Disease in Children (ISKDC)
regimen, while Germany, France and other countries use a regimen of ≥ 3 months in duration.
The PREDNOS study was designed to determine the optimum treatment regimen for UK children
presenting with SSNS.
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Objectives
The primary objective was to determine whether or not a 16-week extended course (EC) of prednisolone
increases the time to first relapse in children presenting with SSNS compared with the standard 8-week course.
The secondary objectives were to determine whether or not an EC of prednisolone reduces relapse rate;
reduces the proportion of participants who develop FRNS or steroid-dependent nephrotic syndrome
(SDNS); reduces the requirement for second- and third-line immunosuppressive agents; is associated with
an increased incidence of corticosteroid-related adverse events (AEs), including behavioural problems; and
is more cost-effective than standard course (SC) therapy.
Methods
A double-blind RCT was undertaken across 125 UK NHS district general hospitals and tertiary paediatric
nephrology units comparing an 8-week SC of prednisolone therapy with a 16-week extended course (EC)
of prednisolone therapy in children presenting with their first episode of SSNS. Children were eligible if they
had a urine albumin-to-creatinine ratio of > 200 mg/mmol or protein-to-creatinine ratio of > 200 mg/mmol
on an early-morning urine sample, had a serum or plasma albumin level of < 25 g/l, were aged between
1 and 15 years at the time of diagnosis, had not previously received therapy with corticosteroids or
immunosuppressive or cytotoxic agents for any form of renal disease, had no evidence of underlying
systemic disorder or exposure to agents known to be associated with newly presenting SSNS and provided
informed consent. Children with histological changes other than minimal lesion glomerulonephritis (when
renal biopsy has been undertaken), who had prior history of poor adherence with medical therapy or who
had a known allergy to prednisolone were excluded.
Participants were randomised in a 1 : 1 ratio to either the SC or EC group in accordance with a minimisation
algorithm to ensure balance of ethnicity (South Asian, white or other) and age (≤ 5 or ≥ 6 years). The SC
(control) group received a 60 mg/m2 dose of prednisolone daily (maximum 80 mg) for 4 weeks, followed
by 40 mg/m2 (maximum 60 mg) on alternate days for 4 weeks. The EC group received a 60 mg/m2 dose
of prednisolone daily (maximum 80 mg) for 4 weeks, followed by a further 12 weeks of alternate-day
prednisolone starting at 60 mg/m2 (maximum 80 mg) and tapering by 10 mg/m2 every 2 weeks. In both
groups, treatment in the first 4 weeks was open label and then blinded in the following 12-week phase,
with matching placebo in the control group.
The primary outcome measure was time to first relapse. Relapse of proteinuria was defined as Albustix®
(Siemens Healthcare Limited, Frimley, UK)-positive proteinuria (+++ or greater) for 3 consecutive days
or the presence of generalised oedema plus +++ proteinuria. Secondary outcomes were relapse rate,
incidence of FRNS (two or more relapses in the first 6 months or four or more relapses within any
12-month period) and SDNS (relapses on or within 14 days of discontinuation of corticosteroid therapy),
use of other immunosuppressive therapy, rates of serious adverse events (SAEs) and AEs and the
incidence of behavioural change [using Achenbach Child Behaviour Checklist (ACBC)]. A comprehensive
cost-effectiveness analysis was performed.
Participants were followed up with visits at 4, 8, 12 and 16 weeks, and then at 5, 6, 8, 10, 12, 18, 24, 30,
36, 42 and 48 months after commencing open-label prednisolone. Participants were followed up for a
minimum of 24 months and up to a maximum of 48 months; the study completed when the last participant
had completed 24 months of follow-up. At each trial visit, information was captured on relapses, treatments
for relapse, AEs (including SAEs), use of health services and trial treatment adherence. The ACBC was used
to assess behaviour change as a potential adverse effect of corticosteroid use. The Pediatric Quality of Life
Inventory and Child Health Utility 9D questionnaires were used to assess quality of life to inform the health
economic analysis. Questionnaires were completed at 4 and 16 weeks, and then at 12, 24, 36 and
48 months.
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Analyses were of all randomised participants, except for those who, following randomisation, were
subsequently found to be corticosteroid resistant, using the intention-to-treat (ITT) principle. The primary
outcome measure was the time from the start of open-label treatment to first relapse. Kaplan–Meier
survival curves were constructed for visual presentation of the time to first relapse. The primary analysis of
time to first relapse was assessed across the two treatment groups and compared using a log-rank test.
A Cox proportional hazard model was fitted to obtain a hazard ratio (HR) and a 95% CI.
Results
Two hundred and thirty-seven participants were recruited into the study from 86 UK centres between
2 August 2011 and 7 October 2014: 118 were randomised to SC and 119 to EC therapy. Fourteen participants
(SC, n= 9; EC, n= 5) were withdrawn during the first few weeks of the trial (following randomisation), as per
the protocol, owing to the development of corticosteroid resistance following an initial response to open-label
prednisolone therapy, leaving an ITT population of 223 participants. During the trial, 15 participants (6%) had
their consent to participate in the study withdrawn, 11 participants (5%) became lost to follow-up and four
participants (2%) withdrew from the study for other reasons. For these 30 participants, data that were
collected up until the time of their withdrawal from the study were included in the analysis. Therefore, in total,
44 (19%) participants were withdrawn from the trial (SC, n= 20; EC, n= 24).
The mean (standard deviation) age at randomisation of the ITT population was 4.9 (3.1) years; 65% were
male and 20% were of South Asian origin. The median body mass index percentile was 87.5 and the
mean open-label prednisolone dose was 58.2 mg/m2/day.
Eighty-six (39%) of the 223 participants did not complete their course of study medication. The number
of participants discontinuing study medication was greater in the SC group than in the EC group (50% vs.
28%; p = 0.001). The predominant reason for discontinuation was the development of relapse (79 relapses)
during the 12-week period when double-blind study medication was being administered. The number of
participants who discontinued because of relapse was higher in the SC group (n = 50) than in the EC group
(n = 29), which was mainly because the SC group was on placebo from week 8. When relapses developed
during this period of study drug administration, the protocol stated that study medication was to be
discontinued and relapse treatment commenced.
Adherence to study medication was generally high, with only a small proportion of participants (13%)
reporting missed doses. Rates of attendance at follow-up study visits were high, as were submission rates of
clinical data and participant questionnaires (> 90% of expected forms were received at each time point).
The number of participants who reported a relapse during the trial was 179: 88 out of 109 (81%) in the SC
group and 91 out of 114 (80%) in the EC group. There was no significant difference in time to first relapse
between the SC and EC groups (HR 0.87, 95% CI 0.65 to 1.17; log-rank p = 0.3). When prespecified
subgroup analyses were performed for the primary outcome for the two minimisation variables of ethnicity
(South Asian, white, other) and age (≤ 5 or ≥ 6 years), there was no clear evidence to suggest that the
treatment effect differed between the different participant subgroups.
The number of relapses per participant ranged from 0 to 15; there were eight participants in the SC group
and nine in the EC group who experienced ≥ 10 relapses. The mean number of relapses did not differ
between groups (SC 3.61 vs. EC 3.98; incidence rate ratio 1.09, 95% CI 0.86 to 1.39; p = 0.5). There was
also no significant difference between the two groups in the proportion of participants developing FRNS
(50% vs. 53%; p = 0.7), SDNS (44% vs. 42%; p = 0.8) or requiring other immunosuppressive therapy
(56% vs. 54%, p = 0.8). The total dose of prednisolone received during the trial (following completion of
study medication) was greater in the EC group than in the SC group (5475mg vs. 6674 mg; p = 0.07).
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There were 67 SAEs reported in 46 participants (21%): 39 SAEs in 27 participants in the SC group and
28 SAEs in 19 participants in the EC group (SC 25% vs. EC 17%; p = 0.1). The most common reasons for
SAE reporting were admission for disease relapse or bacterial infection. Five out of the 39 SAEs in the SC
group and six out of the 28 SAEs in the EC group were, in the opinion of the principal investigator, related
to study drug, although none resulted in study drug discontinuation. There was one accidental death that
was unrelated to the trial.
The most common AEs reported were increased appetite, poor behaviour (parent reported), Cushingoid
facies, hypertrichosis and abdominal pain. In the first 16 weeks of the trial, increased appetite was
reported in 87% of participants (SC 87% vs. EC 86%), poor behaviour in 83% (SC 90% vs. EC 75%),
Cushingoid facies in 67% (SC 66% vs. EC 68%), hypertrichosis in 26% (SC 23% vs. EC 30%) and
abdominal pain in 26% (SC 28% vs. EC 25%). By 24 months, these had increased to 94% (SC 94% vs.
EC 93%) for increased appetite, 87% (SC 93% vs. EC 82%) for poor behaviour, 72% (SC 72% vs. EC
73%) for Cushingoid facies, 39% (SC 38% vs. EC 39%) for hypertrichosis and 45% (SC 47% vs. EC 43%)
for abdominal pain. At 16 weeks, and at 6, 12 and 24 months, there were no significant differences
between the groups in the cumulative number of participants reporting any of the AEs, except for poor
behaviour, which was lower in the EC group. In the first 16 weeks, 90% in the SC group reported poor
behaviour compared with 75% in the EC group [relative risk (RR) 0.85, 95% CI 0.76 to 0.96]. Differences
were also seen at 6 months (91% vs. 81%, RR 0.90, 95% CI 0.82 to 1.00), 12 months (92% vs. 82%,
RR 0.90, 95% CI 0.82 to 0.98) and 24 months (93% vs. 82%, RR 0.90, 95% CI 0.82 to 0.98). There were
no differences in ACBC scores.
Cost-effectiveness analysis showed EC therapy to be associated with a mean increase in generic health
benefit [0.0162 additional quality-adjusted life-years (QALYs)] and cost savings (£4369 vs. £2696)].
Conclusions
The PREDNOS study has not shown any clinical benefit associated with the administration of EC
prednisolone therapy in UK children presenting for the first time with SSNS. There was no difference
between EC and SC regimens in the incidence of prednisolone-related AEs. Cost-effectiveness analysis
suggested that EC therapy may be cheaper, with the possibility of a small QALY benefit.
Trial registration
This trial is registered as ISRCTN16645249 and EudraCT 2010-022489-29.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Idiopathic nephrotic syndrome (INS) is the most common glomerular disorder of childhood, with anincidence of 2 per 100,000 child population in the UK. The disease presents at a median age of 2 to
3 years and is twice as common in boys than in girls.1,2 There is ethnic variability in the disease incidence,
with a fourfold to sixfold higher incidence in the UK South Asian population.1,3,4
The onset of INS is characterised by the acute onset of heavy proteinuria, resulting in the development of
hypoalbuminaemia and generalised oedema. There is not infrequently a delay in diagnosis, with the child
having being treated for allergy prior to eventual presentation to a paediatrician or paediatric nephrologist as
an emergency. The disease pathogenesis is poorly understood; however, both in vitro and in vivo experiments
have identified the immune system to be dysregulated at the time of disease onset.5 The presence of nephrotic
syndrome places the child at increased risk of a number of complications, including thromboembolic disease
and infection, particularly with Streptococcus pneumoniae. Prior to the development of adequate antibiotic
and remission-inducing therapy, the mortality rate from INS was of the order of 50%, the majority of deaths
being related to infection.6,7
In excess of 90% of children who present with INS will respond to a course of high-dose corticosteroid
therapy.8 For this reason, the majority are treated empirically with a course of corticosteroids without a
renal biopsy being performed. Those who respond to the treatment are given the diagnostic label of
having steroid-sensitive nephrotic syndrome (SSNS). Only those with atypical features at presentation
(age < 12 months or over 12 years, persistent hypertension or impaired renal function, gross haematuria,
low plasma C3, hepatitis B or C virus positivity) and those who do not respond to this initial course of
corticosteroid therapy undergo renal biopsy.9 This is in contrast to practice in adult patients with nephrotic
syndrome, in whom the causes of nephrotic syndrome are diverse and biopsy at presentation is routinely
performed to establish a histological diagnosis and to guide subsequent therapy. Little emphasis is placed
upon histological diagnosis in children with SSNS, as it has been shown that corticosteroid sensitivity rather
than histology is the key prognostic indicator.10 Those children who respond to corticosteroids generally
have a good long-term prognosis with a low risk of developing chronic kidney disease; in contrast, those
who are corticosteroid unresponsive suffer significant morbidity, and around 50% will progress to end-stage
kidney failure, necessitating dialysis and kidney transplantation over a 15-year period.11 The majority of these
children will have focal segmental glomerulosclerosis on renal biopsy. In an early seminal study, conducted by
the International Study of Kidney Disease in Children (ISKDC),2 a large cohort of children underwent renal
biopsy at presentation prior to the commencement of corticosteroid therapy. The majority of those who
responded to corticosteroids were noted to have minimal change disease (MCD) histology, so called because
the appearance of the kidney tissue at light microscopic level is essentially normal. Somewhat confusingly, in
much of the published literature, the terms MCD and SSNS are used interchangeably, although this is not
strictly correct, as a small number of children with MCD do not respond to corticosteroids and, similarly, a
small number of corticosteroid-sensitive children have a histological diagnosis other than MCD.
Following initial successful treatment with corticosteroids, around 80% of children with SSNS develop
disease relapses necessitating further courses of high-dose prednisolone, and around 50% develop
frequently relapsing nephrotic syndrome (FRNS), which is defined as two or more relapses within the
first 6 months following presentation or four relapses within any 12-month period, or steroid-dependent
nephrotic syndrome (SDNS), which is defined as relapses occurring within 14 days of discontinuation of
corticosteroid therapy.12 Similar to the presenting episode, nephrotic syndrome relapses are associated
with a risk of significant complications, including sepsis, thrombosis, dyslipidaemia and malnutrition.7
The treatment of relapses with repeated courses of high-dose prednisolone is associated with major
adverse effects, including hip avascular necrosis, growth failure, hypertension, obesity, diabetes and
behavioural problems.13,14 Furthermore, children frequently have to miss school during relapses, resulting
in impaired academic performance and parental absence from work.
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When complications of repeated courses of corticosteroids develop, or when they are expected, a range of
immunosuppressive strategies are employed in an attempt to reduce the frequency of disease relapses.
These include the use of long-term, low-dose, alternate-day prednisolone, as well as a range of
non-corticosteroid immunosuppressive agents, including levamisole, cyclophosphamide, ciclosporin,
tacrolimus, mycophenolate mofetil and rituximab.
Early follow-up studies8,15 suggested that the long-term prognosis for children with SSNS was excellent,
with all retaining normal kidney function and over 90% achieving long-term remission, with complete
cessation of relapses by the end of puberty. However, subsequent studies have reported higher rates of
relapsing disease persisting beyond childhood, with 19% of UK patients suffering ongoing relapses into
early adult life.16 In the majority of patients who achieve permanent remission during childhood, relapse
occurs at 13–16 years of age.17 However, by this time, the majority of affected children will have received a
significant cumulative corticosteroid dose, and many will have been exposed to other immunosuppressive
agents. The role of the paediatric nephrologist is to maintain the child with SSNS as being well and free
from relapses, while at the same time minimising the adverse effects of exposure to corticosteroids and
other immunosuppressive therapies, thus ensuring that they emerge as healthy adults free from relapses
and with no significant long-term treatment-related morbidity.
The ideal initial corticosteroid regimen for use at presentation of childhood INS should rapidly induce
urinary remission (defined as 3 consecutive days of zero or trace proteinuria) with resolution of oedema.
It must be sufficient to prevent frequent relapses necessitating the use of alternative immunosuppressive
agents, although not so intensive that serious corticosteroid-related AEs develop. The first standardised
corticosteroid treatment regimen was introduced by the ISKDC in the 1960s and consisted of a dose of
60 mg/m2 of prednisone (maximum 80mg) given daily for 4 weeks followed by 40 mg/m2 (maximum 60mg)
on 3 consecutive days out of 7 for a total of 4 weeks.18 Many centres made a minor modification whereby
40 mg/m2 was administered on alternate days rather than on 3 days out of 7 during the second 4-week
period. Centres in the UK adopted the use of prednisolone rather than prednisone, as this was and remains
the corticosteroid in routine use in UK paediatric practice, although children in the USA and other parts of
Europe have continued to receive prednisone. These two agents are very closely related, with prednisone
being metabolised to the active prednisolone following absorption.
Following the introduction of the ISKDC regimen, there has been significant debate regarding the optimal
prednisolone regimen at the time of presentation of SSNS, and a number of randomised controlled trials
(RCTs)19–28 have investigated whether giving a more or less intensive corticosteroid regimen at first
presentation of INS affects the number of children suffering both disease relapses and adverse effects
of corticosteroid therapy. One single RCT19 has shown that, compared with the ISKDC regimen, a less
intensive regimen comprising a daily dose of 60 mg/m2 of prednisone only until the urine was negative for
3 consecutive days (urinary remission, median time 14 days) followed by 4 weeks of 40 mg/m2 of prednisone
on alternate days resulted in a higher rate of disease relapse. No further studies have investigated this
therapeutic strategy. By 2005, when the PREDnisolone in NephrOtic Syndrome (PREDNOS) study was being
planned, a total of six RCTs20–25 had compared 2 months of prednisolone using the ISKDC regimen with a
variety of different regimens of ≥ 3 months in duration. These regimens intensified the initial prednisolone
regimen by increasing the duration of both the daily and alternate daily prednisolone phases. A Cochrane
review29 of these six studies concluded that intensification of the initial corticosteroid therapy at disease
presentation significantly reduced the rate of relapse at 12–24 months [risk ratio 0.7, 95% confidence
interval (CI) 0.58 to 0.84]. There was an inverse linear relationship between treatment duration and risk of
relapse [relative risk (RR) 1.26–0.112 duration; p = 0.03]. Furthermore, there was a significant reduction in
the number of frequent relapsers and the mean relapse rate per participant per year. In addition to these
six studies comparing the ISKDC regimen with longer duration corticosteroid regimens, a further four
studies23,26–28 compared 3 months’ treatment with prednisolone with 6 months’ treatment; two were
published only in abstract form.27,28 Longer therapy duration resulted in a significantly decreased risk of
relapse at 6 and 12 months (risk ratio 0.48, 95% CI 0.35 to 0.64, and risk ratio 0.57, 95% CI 0.45 to 0.71,
respectively). Furthermore, the number of participants who developed FRNS was also lower in the
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
2
6-month group than in the 12-month group (risk ratio 0.55, 95% CI 0.38 to 0.80). Further analysis
suggested that the benefits of more intensive corticosteroid therapy were more likely to be related to the
increased duration of treatment than the higher cumulative dose; however, collinearity between treatment
duration and dose prevented the Cochrane group29 from drawing definitive conclusions.
However, significant concerns were raised on a number of issues relating to the six studies contributing to
the meta-analysis comparing 2 months of treatment with treatment for ≥ 3 months. The total number of
participants was small, at only 520 participants across all six studies, and concerns were expressed about
the quality of a number of these trials. One was (and remains) unpublished,22 with data available only in
abstract form. None was placebo controlled or blinded in any way, and only two were at low risk of bias for
allocation concealment. Trials with inadequate allocation concealment can exaggerate the efficacy of the
experimental treatment by 30–40%, and meta-analysis of low-quality trials may overestimate the benefit of
therapy.30,31 Furthermore, only one of these trials was analysed on an intention-to-treat (ITT) basis; however,
this same study indicated, in the discussion, that parents could exert some influence on which treatment
group their child was allocated to, implying that the randomisation process was flawed.23 It was also unclear
whether or not there was a clinically useful reduction in the incidence of steroid-dependent disease and the
use of second-line immunosuppressive agents. The studies also reported somewhat different corticosteroid-
related adverse events, making interpretation of the impact that increased duration of corticosteroid therapy
had on adverse effect profile difficult. Therefore, the authors of the Cochrane review29 (Dr Elisabeth Hodson
and Professor Jonathan Craig) concluded that further well-designed and adequately powered RCTs were
required to establish the optimum dose and duration of treatment, and were consulted from an early stage
regarding the design of the PREDNOS study.
There has continued to be great debate regarding what the ideal corticosteroid regimen at disease
presentation should be, and there is considerable variation in the treatment regimens used. Kidney Disease
Improving Global Outcomes guidelines32 published in 2013 supported the conclusions of the Cochrane
review,29 recommending that INS in children be treated initially with 60 mg/m2 or 2 mg/kg of prednisone or
prednisolone for at least 12 weeks (4–6 weeks daily followed by 40 mg/m2 or 1.5 mg/kg every other day),
followed by a slow tapering of dose over the next 2–5 months. Despite these recommendations, in the
UK the majority of centres have continued to use the 8-week ISKDC regimen, as is the case in Canada,
Nigeria and South Korea. In contrast, Germany, the Netherlands, Spain and other European nations have
adopted a longer treatment regimen, as proposed by the Arbeitsgemainschaft für Pädiatrische Nephrologie
(APN, the German Society for Paediatric Nephrology) and investigated in its RCT.20 This consists of 6 weeks
of daily prednisolone at a dose of 60mg/m2 followed by 6 weeks of alternate daily prednisolone at 40mg/m2.
In France, a longer 18-week course of prednisone is in routine use.33 A questionnaire survey reported
significant heterogeneity in the regimens used in centres in the USA, with 13% using the ISKDC regimen,
7% using the APN regimen and many using either of these with a subsequent corticosteroid taper.34 This
genuine clinical equipoise confirmed the importance of conducting a high-quality RCT to determine whether
or not extending the course of prednisolone beyond that recommended by the ISKDC was associated with
improved clinical outcomes in UK children. We chose time to first relapse as our primary outcome measure
and, following consultation with the British Association for Paediatric Nephrology and our patient group
advisers from the Nephrotic Syndrome Trust (NeST) and the Renal Patient Support Group, we selected
secondary outcome measures that were felt to be of clinical importance, including the incidence of FRNS and
SDNS and the need for alternative, potentially more potent, immunosuppressive therapies. Given the paucity
of high-quality information on the adverse effect profiles of standard course (SC) and extended course (EC)
treatment courses of prednisolone, we also aimed to collect comprehensive adverse effect data, including
abnormal behaviour, which was assessed through the use of the Achenbach Child Behaviour Checklist
(ACBC). Abnormal behaviour is one of the most commonly reported adverse events (AEs) in routine clinical
practice; however, it was rarely reported on in previously conducted clinical trials. Finally, we aimed to
perform a detailed cost-effectiveness analysis to determine the relative cost and efficacy of the two regimens
in quality-adjusted life-year (QALY) terms.
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Since the commencement of the PREDNOS study, three further studies have reported their findings.33,35,36
A well-conducted double-blind placebo-controlled RCT33 performed in the Netherlands aimed to ascertain
whether the apparently better outcomes associated with prolonged prednisolone treatment occurred as a
result of the increased duration of treatment or the higher cumulative dose of prednisolone administered.
One hundred and fifty Dutch children were randomised to receive 3 months of prednisolone followed
by 3 months of placebo or 6 months of prednisolone; both groups received equal cumulative doses of
prednisolone (3360 mg/m2, the same dose as that administered in the APN regimen) and were followed
up for a median of 47 months. One hundred and twenty-six children commenced trial medication. A
primary end point of the development of FRNS was selected and no difference was detected (45% with
3 months of prednisolone vs. 50% with 6 months of prednisolone). There was no difference in the number
of participants who developed relapses (77% vs. 80%), the number requiring alternative immunosuppressive
agents or the number of AEs. The authors concluded that the reduced relapse rate associated with longer
prednisolone regimens observed in previous studies most likely occurred as a result of the increased cumulative
prednisolone dose administered rather than the lengthening of the duration of the treatment course.
More recently, two high-quality studies,35,36 published alongside one another in Kidney International with
an accompanying editorial by Hoyer,37 reported outcomes that differed significantly from those reported in
the Cochrane review.13 Sinha et al.35 from New Delhi and four other Indian centres enrolled 181 children
aged 1–12 years presenting for the first time with INS. Participants were treated with a dose of prednisone
2 mg/kg daily for 6 weeks followed by 1.5 mg/kg on alternate days for a further 6 weeks, and were then
randomised in a double-blind manner to receive either placebo or prednisone in decreasing doses for a
further 3 months. The total dose of prednisone received was 3530 mg in the 6-month group and 2792 mg
in the 3-month group. There was no difference between the two groups in the chosen primary end
point [the number of relapses per 12 months of follow-up (1.26 vs. 1.54, respectively; p = 0.21)] or the
percentage of participants with relapses or frequent relapses. There was no significant difference in the
mean time to first relapse. The authors concluded that extending initial prednisolone treatment from 3
to 6 months did not influence the course of illness in children with SSNS. The second study36 randomised
255 Japanese children presenting with INS to either the ISKDC regimen (total dose of 2240 mg/m2) or
a 6-month prednisolone regimen comprising 4 weeks of daily prednisolone followed by 20 weeks of
tapering alternate-day prednisolone (total dose of 3885 mg/m2). Median follow-up was 36.7 months in the
2-month group and 38.2 months in the 6-month group. The chosen primary end point was the time to
development of FRNS and was similar in both groups [hazard ratio (HR) 0.86, 90% CI 0.64 to 1.16]. The
time to first relapse was also similar in both groups, as was the number of relapses per year. The frequency
and severity of AEs were similar in both groups, despite the 6-month group receiving a significantly higher
median cumulative dose of prednisolone over 2 years. Yoshikawa et al.36 concluded that prolongation of
the initial corticosteroid regimen from 2 to 6 months did not improve patient outcomes.
Following the publication of these studies, in 2015 the Cochrane group performed an update of their
systematic review and meta-analysis.13 They reported that the addition of these three well-designed studies
had changed the conclusion of their review. They noted that studies of long versus shorter duration of
corticosteroid treatment had heterogeneous treatment effects, with the older studies that were rated as
having a higher risk of bias tending to overestimate the effect of longer-course therapy compared with
more recently published studies rated as having a low risk of bias. Among the studies rated as having a
low risk of bias, the group found that there was no significant difference in the risk of FRNS between
those given prednisolone for 2 or 3 months and those receiving treatment for longer durations or a higher
total dose, indicating that there is no benefit of increasing the duration of prednisolone beyond 2 or
3 months in the initial episode of SSNS.13
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Chapter 2 Methods
T rial-related information, including the protocol, study information sheets, consent and assent forms andthe case report forms, is available at the PREDNOS website (www.birmingham.ac.uk/prednos; accessed
17 August 2017).
Objectives
The aim of the PREDNOS study was to compare treatment with an EC (16-week) prednisolone regimen
with the SC (8-week) regimen, as proposed by the ISKDC for UK children presenting with their first
episode of SSNS.
The specific study objectives were:
1. to determine whether or not an EC of prednisolone increases the time to first relapse in children
presenting with SSNS
2. to determine whether or not an EC of prednisolone –
i. reduces the relapse rate
ii. reduces the proportion of children who develop FRNS or SDNS
iii. reduces the requirement for second- and third-line immunosuppressive agents, including levamisole,
cyclophosphamide, ciclosporin, tacrolimus, mycophenolate mofetil and rituximab
iv. is associated with an increased incidence of corticosteroid-related AEs, including behavioural
problems
v. is more cost-effective than SC therapy.
Trial design
Randomised double-blind, parallel-group, placebo-controlled trial with health economic evaluation.
The participant, clinician and study teams were masked to treatment allocation.
Participants
Inclusion criteria
Children presenting with their first episode of SSNS who met all of the following criteria were included in
the study:
l a urine albumin-to-creatinine ratio of > 200mg/mmol or a protein-to-creatinine ratio of > 200mg/mmol,
determined quantitatively on an early-morning urine sample
l a serum or plasma albumin level of < 25 g/l
l aged between 1 and 15 years at the time of diagnosis
l no prior therapy with corticosteroids or immunosuppressive or cytotoxic agents for any form of renal
disease (other than the 28 days of prednisolone therapy given initially as routine clinical practice)
l no evidence of underlying systemic disorder or exposure to agents known to be associated with newly
presenting SSNS
l informed consent by parent(s) (the term ’parent’ has been used throughout this report to reflect
mother, father or legal guardian) and assent by participant when age appropriate.
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Exclusion criteria
Study exclusion criteria were:
l histological changes other than minimal lesion glomerulonephritis when renal biopsy has
been undertaken
l a prior history of poor adherence with medical therapy
l known allergy to prednisolone.
Rationale for choice of inclusion and exclusion criteria
Children aged < 12 months were excluded, as nephrotic syndrome presenting in this age group is rarely
corticosteroid sensitive and treatment with an empirical course of corticosteroids is not standard clinical
practice. Infants in this age group are classified as having either congenital nephrotic syndrome (if < 3 months
of age at presentation) or infantile nephrotic syndrome (if between 3 and 12 months of age at presentation).
The causes of congenital and infantile nephrotic syndrome are frequently genetic, occurring as a consequence
of mutations in genes expressing proteins in the podocyte, and are commonly unresponsive to any form of
immunosuppressive therapy. Children ≥ 15 years of age were excluded because of the reduced likelihood
of their nephrotic syndrome being corticosteroid sensitive. In this age group, the causes of INS are much
more similar in relative frequency to the causes of INS in adults, with a higher incidence of membranous
nephropathy and focal segmental glomerulosclerosis and a correspondingly lower incidence of MCD. Because
of this, it is routine practice for renal biopsy to be performed to establish the histological diagnosis and to
guide subsequent therapy, rather than the administration of an empirical course of prednisolone therapy.
The inclusion and exclusion criteria were otherwise selected to ensure that the study population was truly
representative of the population of children presenting with SSNS in the UK for whom corticosteroid
treatment would be appropriate. Given the significantly increased incidence of SSNS in the UK South Asian
population, we made steps to ensure that we recruited a substantial number of participants from this
group, specifically targeting study sites in areas with large South Asian communities.
Recruitment and randomisation
Study sites
One hundred and twenty-four district general hospitals and tertiary regional paediatric nephrology centres
throughout the UK took part in the study. An additional centre participated in follow-up visits only.
A flexible arrangement was set up whereby a child could be referred into the regional paediatric nephrology
centre to allow them to participate in the study if this was not possible in the district general hospital.
Initial prednisolone treatment
Existing national and local protocols for the treatment for idiopathic childhood nephrotic syndrome all
commence with the administration of 60 mg/m2 of prednisolone (maximum 80 mg) daily for a total of
4 weeks. Therefore, all children who presented to PREDNOS study sites with INS were treated with this
regimen while consideration was given to whether or not they were a suitable candidate for the study.
The most important determinant of this was whether or not their nephrotic syndrome proved to be
corticosteroid sensitive, that is, the urine dipstick test became negative or trace for 3 consecutive days,
indicating resolution of the proteinuria and establishment of a diagnosis of SSNS. As a result, children
subsequently recruited into the study had all received a dose of 60 mg/m2 of prednisolone (maximum 80mg)
daily for 28 days in an open-label manner prior to the commencement of randomised study medications.
Investigators were asked to attempt to standardise the prednisolone preparation that they used in all
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
6
newly presenting children to ensure uniformity during this initial 4-week period. It was recommended that
non-enteric-coated prednisolone tablets be used and that, if required for younger participants and others
who were unable to swallow tablets whole, tablets be crushed with a proprietary tablet crusher. This
ensured that potential participants would be able to take the randomised study drug, which was provided as
a non-soluble non-dispersible tablet.
Recruitment and randomisation took place once it was thought that the child was corticosteroid sensitive;
this generally occurred at between 14 and 21 days following commencement of open-label prednisolone
therapy. This strategy ensured that participants recruited into the study had become, or were likely to
become, corticosteroid sensitive and also allowed sufficient time for the principal investigator to obtain
fully informed consent (see Informed consent). This timing of recruitment also meant that there was
sufficient time for the study drug to be delivered to the family home (by Royal Mail Special Delivery)
before day 29, the first day of scheduled treatment following the completion of 28 days of open-label
prednisolone treatment. This approach to recruitment and randomisation was felt to be preferable to
recruiting participants at the time of initial presentation, prior to the commencement of any prednisolone
therapy, as the alternative would have resulted in more participants who were not steroid sensitive being
included in the trial, which would have resulted in a higher drop-out rate.
Informed consent
The informed consent process was supported by the use of parent information sheets and patient
information sheets for older participants who were felt by the study principal investigator to be able to
understand these. Parents, and, when appropriate, participants, received a full explanation of the aim,
trial treatment, expected benefits and potential hazards of taking part in the trial. It was stressed that the
parent or participant was completely free to refuse to take part or withdraw from the trial at any time.
Ample time (up to 1 week in some cases, but always more than 24 hours) was provided to read the
parent/patient information sheet and to discuss participation with others outside the site research team.
Adequate opportunity was given to ask questions.
Written consent was obtained from the parent and written assent was obtained from the participant,
when age-appropriate, using the latest version of the informed consent/assent forms. Copies of these were
given to the parents and filed in the hospital notes and the original was placed in the investigator site file.
Randomisation
Following confirmation of a diagnosis of nephrotic syndrome, and of ongoing treatment with corticosteroids
without corticosteroid treatment failure at that point, and having obtained informed consent, study participants
were randomised online via a secure 24-hour internet-based randomisation service or by a telephone call to
the Birmingham Clinical Trials Unit. Participants were randomised in a 1 : 1 ratio to either the 8-week SC of
prednisolone or the 16-week EC of prednisolone. The randomisation used a minimisation algorithm to ensure
that there was balance between the two treatment groups with regard to ethnicity (South Asian, white or
other) and age (≤ 5 or ≥ 6 years). Both of these variables have previously been suggested to be linked to
different outcomes following presentation. The incidence of SSNS is significantly higher among South Asian
children than in white children or those of other ethnicities; however, there is some suggestion that their
disease may follow a less complicated course, with a lower frequency of relapse and a lower incidence of
frequently relapsing disease.38 At least one study has suggested that children who are < 4 years of age benefit
from prolonged initial prednisolone therapy26 and younger children have also previously been demonstrated
to have a higher rate of disease relapse and development of FRNS.39,40
Once the participant had been randomised, the local principal investigator sent a signed copy of the
clinical trial prescription form and the consent/assent form(s) to the central pharmacy at the Birmingham
Children’s Hospital to order the PREDNOS trial medication metered dose blister pack. Birmingham
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Children’s Hospital’s pharmacy was responsible for the dispensing of the randomised study drug for the
entire UK; the study drug was sent by Royal Mail Special Delivery directly to the participant’s home. Only
delegated staff within the pharmacy were able to view the treatment allocation in order to assemble the
study drug treatment blister packs and dispatch these. This was performed via a secure login link to the
randomisation programme once the participant had been randomised. This method of randomisation
ensured that investigators and the co-ordinating centre were masked to the participant’s randomised
treatment allocation.
Interventions
Treatment groups
Participants were randomised to receive either SC prednisolone therapy [the ISKDC regimen: a dose of
60 mg/m2/day of prednisolone (maximum dose 80 mg) for 4 weeks followed by 40 mg/m2 (maximum dose
60 mg) on alternate days for a further 4 weeks] or EC prednisolone therapy [a dose of 60 mg/m2/day of
prednisolone (maximum 80 mg) for 4 weeks followed by 60 mg/m2 (maximum 60 mg) on alternate days
for 2 weeks, with a subsequent gradual reduction in dose over a total of 12 weeks (tapering by 10 mg/m2
every 2 weeks), resulting in a total course of prednisolone of 16 weeks]. The trial schema is shown in
Figure 1.
All participants received the initial 4 weeks of prednisolone as open-label treatment prior to recruitment
and randomisation into the study and the dispensed study medication prescribed was of 12 weeks’
duration (4 weeks of prednisolone and 8 weeks of placebo in those randomised to the SC group and
12 weeks of prednisolone in those randomised to the EC group). The treatment schedule and the
prednisolone dose administered at each time point is outlined in Table 1. Matching placebo tablets were
used to maintain the double blind at each time point.
SC therapy EC therapy
Weeks 5 – 8: 40 mg/m2 of 
prednisolone (maximum 
60 mg) on alternate days 
for 28 days
Weeks 5 – 16: 60 mg/m2 
of prednisolone (maximum 
80 mg) on alternate days, 
tapering by 10 mg/m2 every 
2 weeks
Weeks 1 – 4, routine clinical
practice: 60 mg/m2/day 
of prednisolone
(maximum 80 mg)
Randomise
Child presents with
newly diagnosed
nephrotic syndrome
FIGURE 1 Trial schema.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
8
The entire course of study drug to be administered from weeks 5 to 16 was supplied in a blister pack by the
central clinical trials pharmacy at the Birmingham Children’s Hospital (Figure 2). Prednisolone was supplied
as 5-mg tablets alongside matching placebo, so that participants in both treatment groups received the
same number of tablets at any time point in the study. The central pharmacy controlled allocation
concealment and distributed trial medication once informed consent was obtained and randomisation had
occurred. Both the study drug and the placebo were manufactured by Essential Nutrition Ltd (Brough, UK).
Participants who were unable to swallow tablets whole were allowed to crush the study drug using a
tablet crusher, which was supplied upon request. Parents were instructed to administer the study drug to
participants first thing in the morning in keeping with routine clinical practice with prednisolone therapy.
Delivered with the study drug, every participant also received a standard study pack containing a
participant diary and a bottle of urinalysis sticks (Albustix®, Siemens Healthcare Limited, Frimley, UK;
Bayer Diagnostics, Tarry Town, NY, USA) for daily morning testing for proteinuria.
Blinding
All those involved in treating the participant, the participant and their parents/guardians were masked as
to the randomised treatment allocation.
Trial procedures and assessments
Following recruitment into the study, in keeping with routine clinical practice, families were asked to use a
dipstick to test the study participant’s first morning urine sample for proteinuria on a daily basis and to record
the results in the participant diary, alongside information about medications administered, any intercurrent
illness and consultations with health-care professionals [general practitioner (GP), nurse, hospital emergency
department, etc.] and details of all medicines prescribed or purchased over the counter. In keeping with
routine clinical practice, families were instructed to contact their hospital clinical team if their child developed
a relapse of nephrotic syndrome, which was defined using the internationally recognised definition of +++
proteinuria on Albustix for 3 consecutive days or the development of generalised oedema in association
with +++ proteinuria on Albustix, so that relapse treatment could be prescribed. They were also instructed
to call if there were other concerns, including the development of new AEs or other concerns about urine
protein readings.
TABLE 1 Prednisolone regimens in the SC and EC groups
Time (weeks)
Therapy prednisolone dose
SC EC
Open-label routine clinical treatment
0–4 60mg/m2/day (maximum 80mg) 60 mg/m2/day (maximum 80mg)
Randomised phase
5–6 40mg/m2/day (+placeboa) on alternate days 60 mg/m2/day on alternate days
7–8 40mg/m2/day (+placeboa) on alternate days 50 mg/m2/day on alternate days
9–10 Placebo on alternate days 40 mg/m2/day on alternate days
11–12 Placebo on alternate days 30 mg/m2/day on alternate days
13–14 Placebo on alternate days 20 mg/m2/day on alternate days
15–16 Placebo on alternate days 10 mg/m2/day on alternate days
a Placebo was added here to maintain the double-blinding, so that there was no difference in the number of tablets taken
between the SC and EC groups.
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FIGURE 2 Blister pack of study drug as supplied to participants.
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Participants were followed up with routine study visits at 4, 8, 12 and 16 weeks, and then at 5, 6, 8, 10,
12, 18, 24, 30, 36, 42 and 48 months after commencing prednisolone therapy. Participants were followed
up for a minimum of 24 months and up to a maximum of 48 months; the study was completed once the
last participant had completed 24 months of follow-up.
At each study visit, data were collected regarding recent relapses including prednisolone and other treatment
for relapses, recent medication history and the development of AEs, including serious adverse events (SAEs).
Specific information was documented regarding the development of significant bacterial, viral and fungal
infections, as well as exposure to varicella infection requiring the administration of prophylactic therapy
(intramuscular zoster immune globulin or oral aciclovir). A physical examination was performed, including
measurement of height using a calibrated stadiometer with the child in bare or stocking feet, weight using
calibrated scales and, from these, a calculation of body mass index (BMI) was made. Blood pressure was
measured using whichever automated or manual device was in regular use within that outpatient clinic.
There was a particular focus on the documentation of adverse effects of corticosteroid toxicity. This included
assessment of increased appetite (parentally reported), Cushingoid features, striae and hypertrichosis, all
assessed using a Likert scale (none, mild, moderate or severe). A parental subjective assessment of the
presence of abdominal pain and behavioural problems (yes or no) was sought, and the parental subjective
assessment was complemented by an objective questionnaire-based assessment. Dipstick analysis of the
urine was performed to detect the presence of glycosuria; when this was significant and persistent, plasma
glucose was measured, in keeping with routine clinical practice. A check of study medication adherence was
made at 4, 8, 12 and 16 weeks; families were asked to bring the study medication blister pack with them to
their child’s appointment. Ophthalmoscopy was performed by the principal investigator on an annual basis
to look for evidence of corticosteroid-induced cataract and any other abnormality.
Quantitative data on behaviour were collected through the administration of the ACBC at weeks 4 and
16 and months 12, 24, 36 and 48. The ACBC is a standardised measure made up of 120 items measuring
internalising (withdrawn, somatic complaints, anxiety/depression and thought problems) and externalising
(social problems, attention problems and delinquent and aggressive conduct) behaviour problems. A total
behavioural problem score is calculated from these problem scales and forms the basis of comparison with
age- and gender-matched normative data. The ACBC has been used in over 8000 publications on over
500 topic areas in a diverse range of cultural groups and is supported by extensive research on service needs
and outcomes, diagnosis, prevalence of problems, medical conditions, treatment efficacy, genetic and
environmental effects and epidemiology.
For the purposes of the health economic analysis, data were collected regarding all contact with health
professionals (in primary, secondary and tertiary care), prescriptions issued and over-the-counter medications
purchased. The Pediatric Quality of Life Inventory (PedsQL) and Child Health Utility 9D (CHU-9D) quality-of-life
(QoL) questionnaires were also completed by parents at weeks 4 and 16 and at months 12, 24, 36 and 48.
The PedsQL Measurement Model is a modular approach to measuring health-related quality of life (HRQoL)
in healthy children and adolescents and those with acute and chronic health conditions. The 23-item PedsQL
Generic Core Scales were designed to measure the core dimensions of health as delineated by the World
Health Organization, as well as role (school) functioning. The four multidimensional scales assess physical
functioning, emotional functioning, social functioning and school functioning, generating three summary
scores: total scale score, physical health summary score and psychosocial health summary score. The CHU-9D
questionnaire is a generic preference-based HRQoL instrument for 7- to 17-year-old children. These
questionnaires are discussed in further detail in Chapters 5 and 6.
Serious adverse events
Any AEs meeting the definition of a SAE were recorded on a standardised SAE form and faxed to the
Birmingham Clinical Trials Unit within 24 hours of the local principal investigator or member of their
research team becoming aware of the event. The principal investigator was responsible for assigning
causality and expectedness to the SAE before reporting.
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Blood samples
The study protocol included the collection of a single 10-ml ethylenediaminetetraacetic acid (EDTA) blood
sample for a genetic substudy [not funded as part of the National Institute for Health Research (NIHR)
award]. This was obtained at the time of routine venous sampling for clinical purposes whenever possible;
however, the ethics approval did allow a standalone blood test to be collected solely for the purposes of the
research project. Any potential discomfort associated with blood sampling was minimised by the use of
clinical staff that were experienced in paediatric venepuncture and the use of both distraction therapy and
topical anaesthetic agents as is routine clinical practice. The small volume of blood collected on one single
occasion was not deemed sufficient to cause hypovolaemia or anaemia in participants of 1–14 years of age.
Study withdrawal
Participants were withdrawn from the study under the following circumstances:
l Early withdrawal. Participants who initially appeared to be corticosteroid sensitive, that is, who
developed at least 3 consecutive days of zero or trace proteinuria following the commencement
of open-label prednisolone treatment and were, therefore, recruited and randomised, but who
subsequently developed significant proteinuria again following randomisation. These participants were
withdrawn from the study on the basis that they did not meet the standard definition of corticosteroid
sensitivity and were likely to require additional therapy as part of their initial corticosteroid regimen,
for example intravenous methylprednisolone, and also potentially require a renal biopsy and/or other
investigations. As per the protocol, these participants were not included in any analyses.
l Later withdrawal. Participants were withdrawn from the study at later time points if parental consent
was withdrawn or at the request of the principal investigator. All of the data collected up until the time
of withdrawal were included in the analysis.
Unblinding
Arrangements were made to facilitate the unblinding of participants should the need arise, for example a
medical emergency when it was imperative that the treating clinician was aware of whether the participant
was receiving active prednisolone or placebo. A code break was available through the Birmingham
Children’s Hospital pharmacy.
Source data
The case report forms were not the source data for clinical information. However, in some instances,
information on relapses and medication changes was entered directly onto case report forms from
self-reported patient information from diaries, and so, in these instances, the case report forms were
considered to be the source data. Source verification for diary data did not take place as the diaries were
not retained. The questionnaires (ACBC, PedsQL and CHU-9D questionnaires) were considered source
data; data were entered directly onto these case report forms. Source data were kept as part of the
participants’ medical notes generated and maintained at each site.
Outcome measures
The primary outcome measure for the study was the time from commencement of open-label prednisolone
therapy to first relapse of proteinuria. Relapse of proteinuria was defined as Albustix-positive proteinuria
(+++ or greater) for 3 consecutive days or the presence of generalised oedema and +++ proteinuria.
Secondary outcome measures were:
l relapse rate
l incidence of FRNS (defined as two relapses or more in the first 6 months following presentation or four
relapses within any 12-month period)
l incidence of SDNS (defined as relapses on or within 14 days of completion of corticosteroid therapy)
METHODS
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l incidence of use of second-line immunosuppressive agents, including levamisole, cyclophosphamide,
ciclosporin, tacrolimus, mycophenolate mofetil and rituximab
l rate of SAEs
l rate of AEs
l incidence of behavioural change (as assessed by the ACBC)
l cost per relapse of proteinuria
l cost per QALY gained.
Sample size
The primary analysis was based on a log-rank test of time to relapse. A relapse rate of 60% at 1 year was
expected in the SC group. To detect an absolute difference of 20% (considered a clinically meaningful
difference) in the relapse rate, from 60% in the SC group to 40% in the EC group, with 80% power
and 2p = 0.05 required a total of 200 participants. Allowing for 10% drop-out, the total number of
participants required was 224 (112 per group).
Monitoring of the drop-out rate during the trial showed that > 10% of participants were dropping out of
the trial. Therefore, it was decided to increase the drop-out rate to 15%, which meant that the total
number of participants required increased to 236. This change was implemented with the release of
PREDNOS protocol version 2.1 (1 September 2013).
Statistical methods
The primary outcome measure was the time from commencement of open-label prednisolone therapy to
first relapse. Kaplan–Meier survival curves were constructed for visual presentation of the time to first
relapse. The primary analysis of time to first relapse was assessed across the two treatment groups and
compared using a log-rank test. A Cox-proportional hazard model was fitted to obtain a HR and 95% CI.
As a secondary analysis, a Cox-proportional hazard model, adjusting for the minimisation variables of
ethnicity (South Asian, white or other) and age (≤ 5 or ≥ 6 years), was also fitted. If there were any other
important prognostic factors that were unbalanced between the groups at baseline, then these would also
be included in the model. It is unlikely that a participant will relapse while on corticosteroids; however, it is
possible that participants in the SC group may experience an early relapse in weeks 9–16 when receiving
placebo, which could potentially bias the results in favour of the EC group. Corticosteroid dependency
was also a secondary outcome measure (defined as relapsing on or within 14 days of completion of
corticosteroid therapy) and there may be a difference between the groups in corticosteroid dependency.
Therefore, to avoid the potential for bias in these situations, if a participant relapsed before 18 weeks,
their relapse time was set to 18 weeks. Participants in the EC group received corticosteroids up to week 16,
so this also accounts for any possible difference between the groups in corticosteroid dependency.
A secondary analysis was performed which analysed time to first relapse using the actual relapse date.
The relapse rate was reported as the mean number of relapses per participant. The relapse rate between
the two groups was compared using a negative binomial model (as this was a better fit than the Poisson
model, which was stated in the protocol) to obtain an incidence rate ratio (IRR); an offset was included in
the model to allow for participants having different lengths of follow-up in the trial. Categorical data items
(e.g. FRNS, SDNS) were compared between the groups using a chi-squared test and a RR was reported.
If there were any imbalances between the groups in any prognostic factors, then a log-binomial model
was fitted.
The SAE data were summarised descriptively. The SAE data were also analysed as a dichotomous variable,
with each participant classed as either having experienced a SAE or not. The two groups were compared
using a chi-squared test. The number of SAEs that a participant had experienced during the trial was
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compared between the groups using an appropriate count model. The AE data were reported using a
Likert scale (none, mild, moderate or severe). For this report, these data were dichotomised into whether
or not the participant had experienced an AE or not. The number of participants who had experienced an
AE in the first 16 weeks (at the end of study medication), and then at 6, 12 and 24 months, was reported
along with a RR and 95% CI.
The ACBC was analysed using repeated-measures methods, including the baseline score (4-week data)
as a covariate in the model. Separate analyses, using t-tests, were carried out at each time point to allow
for the possibility that adverse effects (as measured by the ACBC) had differing short- and long-term
responses to the treatment. Mean differences and 95% CI were reported.
Two a priori subgroup analyses were planned for the primary outcome. These subgroups were for the
minimisation variables of ethnicity (South Asian, white or other) and age (≤ 5 or ≥ 6 years). A treatment
group by subgroup interaction parameter was included in the Cox proportional hazard model to assess
whether or not there were any differences in the treatment effect across the different strata.
The other outcomes included height, weight, BMI and blood pressure. These were all expressed as standard
deviation scores (SDSs) for the purposes of the analysis. For height, weight and BMI, SDSs were generated
using UK World Health Organization data41 and as normal range data for blood pressure, according to age,
sex and height, as produced by the US National High Blood Pressure Education Program Working Group
on High Blood Pressure data.42 These data are summarised descriptively and presented graphically using
longitudinal plots.
Analyses were of all randomised participants using the ITT principle, except for those who, following
randomisation, were subsequently found to be corticosteroid resistant. Exclusion of these participants
results in no bias as (1) these drop-outs occurred prior to the commencement of randomised treatment
and (2) clinicians were unaware of the treatment assigned to their participants. Estimates of treatment
effects are presented with 95% CIs; p-values are two-tailed, with p < 0.05 considered statistically
significant. No corrections for multiple tests were made. All analyses were carried out using SAS® version
9.4 (SAS Institute Inc., Cary, NC, USA) or Stata® version 14 (StataCorp LP, College Station, TX, USA). SAS
and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS
Institute Inc. in the US and other countries. ® indicates US registration.
Patient and public involvement
The trial protocol was discussed extensively with a number of representatives of the UK NeST and the UK
Renal Patient Support Group, which provided valuable input regarding trial design, acceptability of study
visit frequency and blood testing. It was the input of these groups that led us to perform such detailed
investigation of the adverse behavioural effects of the two corticosteroid regimens.
Ethics approval, regulations and trial registration
Steroid-sensitive nephrotic syndrome is a disease that is of greatest prevalence during early childhood;
therefore, it was considered ethically justified to use children rather than adults as study participants.
Both the SC and EC prednisolone regimens under investigation in the PREDNOS study have been in use in
multiple centres across the world for more than 10 years, and children participating in the study were
considered to be at minimal risk.
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The parents’ written informed consent for their child to participate in the trial and the participant’s assent,
as appropriate to their assessed competence by the principal investigator, were both obtained prior to
randomisation and after a full explanation had been given of the study, the treatment options and the
manner of treatment allocation. This was supported by a parent information leaflet and information
leaflets for both older and younger participants.
Ethics approval for the study was granted by the North West 7 Research Ethics Committee (reference number
10/H1008/122). The trial was carried out under a Clinical Trial Authorisation in accordance with the Medicines
for Human Use (Clinical Trials) Regulations 2004 (21761/0255/001-0001).43
The trial was conducted in accordance with the recommendations guiding physicians in biomedical research
involving human subjects, adopted by the 18th World Medical Association General Assembly, Helsinki,
Finland, June 1964, and its subsequent amendments, the Research Governance Framework for Health and
Social Care; and the applicable UK Statutory Instruments including the Medicines for Human Use (Clinical
Trials) Regulations 200443 and its subsequent amendments, the Data Protection Act 1998,44 the Human Tissue
Act 200445 and the International Conference on Harmonisation’s Guidelines for Good Clinical Practice.46
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Chapter 3 Results
Recruitment
The PREDNOS study opened to recruitment in July 2011 and the first participant was recruited into the trial
on 2 August 2011. Two hundred and thirty-seven participants were recruited and randomised, the last
entering the study on 7 October 2014. The rate of recruitment was relatively constant with no evidence of
seasonal variation (Figure 3). One hundred and eighteen participants were randomised to the SC group
and 119 to EC group. The 237 participants were recruited from 86 (69%) of the 124 recruiting study
sites; recruitment at the 86 sites varied between 1 and 19 participants. Individual site recruitment data
are shown in Appendix 1. Participants had completed at least 2 years’ follow-up by October 2016.
Participant flow
Of the 237 participants randomised into the study, 44 (19%) were withdrawn from the trial (Figure 4).
Following consent and randomisation, 14 participants (6%; nine in the SC group and five in the EC group)
who had initially responded to open-label prednisolone, suggesting that they were corticosteroid sensitive,
developed proteinuria (with time from commencing open-label prednisolone to withdrawal in these
participants ranging from 26 to 35 days). These participants were deemed to be corticosteroid resistant
and were withdrawn from the study as per the protocol. Their data were not included in any of the
subsequent analysis, and so the ITT population was based on 223 participants.
During the trial, 15 participants (6%) had their consent to participate in the study withdrawn (12 in year 1,
one in year 2 and two in year 3), 11 participants (5%) became lost to follow-up (one in year 1, one in year 2,
five in year 3 and four in year 4) and four participants (2%) withdrew for other reasons (two emigrated, one
was withdrawn at the principal investigator’s discretion and one participant was randomised in error prior to
entering remission with open-label treatment). For these 30 participants, the data collected up until the time
of their withdrawal from the study were included in the analysis. Withdrawn participants were distributed
evenly between the two groups (Table 2).
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FIGURE 3 Recruitment of participants into the study.
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• Participant withdrawn, n = 3
   • Withdrew consent, n = 3
• Patient had relapsed, n = 33
• Participant withdrawn, n = 3
   • Withdrew consent,b n = 3
• Patient had relapsed, n = 11
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• Participant withdrawn, n = 1
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• Patient had relapsed, n = 16
• Participant withdrawn, n = 2
   • Withdrew consent, n = 1
   • Lost to follow-up, n = 1
• Patient had relapsed, n = 4
• Patient had relapsed, n = 3
FIGURE 4 A Consolidated Standards of Reporting Trials diagram of participant flow through the trial. a, Two
patients had discontinued their study medication. b, Two patients had discontinued their trial medication owing to
relapse. Time points are at times post start of open-label treatment.
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Completeness of data
Attendance rates for follow-up study visits were high, as were submission rates of clinical data and
participant questionnaires, with data completion rates being over 90% for all time points. There was no
difference in data return rates between the two groups. The median length of follow-up was 37.5 months
for the SC group and 36.7 months for the EC group.
Baseline data
The mean [standard deviation (SD)] age at randomisation of the ITT population was 4.9 (3.1) years, with
65% of participants being < 6 years of age. In keeping with the known pattern of presentation of SSNS,
there was an excess of male participants (65%) and 20% were of South Asian origin and 14% were
of other non-white origin. Fifty-four per cent of participants were overweight or obese; the median
BMI percentile was 87.5. The mean dose of prednisolone administered in the open-label phase was
58.2 mg/m2/day (Table 3).
Discontinuation of study medication
Eighty-six (39%) out of the 223 participants did not complete their course of study medication. The number
of participants discontinuing study medication was higher in the SC group than in the EC group (SC 50% vs.
EC 28%; p = 0.001). The predominant reason for discontinuation was the development of relapse during the
12-week period when double-blind study medication was being administered (n = 79, 35%). When relapses
developed during this period of study drug administration, the protocol stated that study medication was to
be discontinued and relapse treatment was to be commenced. The incidence of study drug discontinuation
was comparable in the two groups up until week 8 (week 4 of randomised study drug), when participants in
both groups were receiving active prednisolone. However, thereafter, there was an increase in the number of
discontinuations of study medication in the SC group (Figure 5). The number of participants who discontinued
owing to relapse was higher in the SC group (n = 50) than in the EC group (n = 29). Participants in the
SC group were scheduled to receive active prednisolone until week 8 (week 4 of randomised study drug)
followed by placebo for weeks 8–16 (weeks 4–12 of randomised study drug), whereas those in the EC group
were scheduled to receive active prednisolone right through until week 16 (week 12 of randomised study
drug). The majority of participants in the SC group (38/50) who discontinued the study drug because of
relapse over this 16-week period did so during weeks 9–16, once active prednisolone had been discontinued
and they were receiving placebo. In contrast, in the EC group, discontinuations owing to relapse were spread
over the 12-week study drug period.
TABLE 2 Participant withdrawal
Reason for withdrawal
Group (n)
Total (N= 237), n (%)SC EC
Corticosteroid resistant 9 5 14 (6)
Withdrew consent 9 6 15 (6)
Lost to follow-up 1 10 11 (5)
Other reason 1 3 4 (2)
Exclusions (total) 20 24 44 (19)
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The other seven participants (3%; SC, n = 4, vs. EC, n = 3) who prematurely discontinued study medication
did so in a deviation from the study protocol. In four participants, it proved impossible to administer the
study medication, including in crushed form; one participant refused to take the study medication and two
families withdrew consent during the 12-week period of study drug administration (one participant refused
to take their medication and the other participant’s parent stopped the trial medication without consulting
the site).
TABLE 3 Baseline characteristics of the ITT population
Characteristic
Group
TotalSC EC
Total randomised N= 118 N= 119 N= 237
Corticosteroid sensitive participants (ITT cohort) n= 109 n= 114 n= 223
Age
Mean (years) (SD) 4.7 (2.9) 5.1 (3.2) 4.9 (3.1)
1–2 years, n (%) 29 (27) 28 (25) 57 (26)
3–5 years, n (%) 43 (39) 45 (39) 88 (39)
6–11 years, n (%) 34 (31) 35 (31) 69 (31)
12–17 years,a n (%) 3 (3) 6 (5) 9 (4)
≤ 5 years,b n (%) 72 (66) 73 (64) 145 (65)
≥ 6 years, n (%) 37 (34) 41 (36) 78 (35)
Gender (male), n (%) 78 (72) 68 (60) 146 (65)
Ethnicity,b n (%)
South Asian 21 (19) 23 (20) 44 (20)
White 73 (67) 75 (66) 148 (66)
Other/not stated 15 (14) 16 (14) 31 (14)
BMI percentile, median (IQR) 85.3 (66.3–97.3) 90.0 (69.5–97.5) 87.5 (66.6–97.3)
BMI percentile, n (%)
Underweight (< 5th) 2 (2) 0 (0) 2 (1)
Healthy (5th–84th) 52 (48) 48 (42) 100 (45)
Overweight (85th–95th) 19 (17) 24 (21) 43 (19)
Obese (≥ 95th) 36 (33) 42 (37) 78 (35)
Open-label prednisolone dose (mg/m2/day), mean (SD) 58.5 (5.9) 58.0 (6.8) 58.2 (6.4)
IQR, interquartile range.
Data are presented as mean (SD), median (IQR) or n (%), as appropriate.
a Participants were eligible for the study if they were aged 1–15 years.
b Minimisation variable.
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Weeks from starting open-label treatment to discontinuation
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FIGURE 5 Time to discontinuation of study medication.
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Adherence to study medication
Adherence to study medication was good, with only a small proportion of participants reporting missed
doses (13%). In the majority of cases, only one or two doses were reported as missed; however, two
participants in the EC group reported missing 12 and 14 doses. There was no difference between the
two groups in the number of participants who reported missing doses (SC 10% vs. EC 16%; p = 0.2);
however, the total number of doses missed was numerically greater in the EC group than in the SC group
(30 vs. 57 missed doses; mainly owing to two participants in the EC group who missed 12 and 14 doses).
Primary outcome
The number of participants who reported a relapse during the trial was 179: 88 out of 109 (81%) in the
SC group and 91 out of 114 (80%) in the EC group. There was no significant difference in time to first
relapse between the SC and EC groups (Figure 6a; unadjusted HR 0.87, 95% CI 0.65 to 1.17; log-rank
p = 0.3). Analyses adjusting for the minimisation variables gave similar results (HR 0.86, 95% CI 0.64 to
1.16). The median [interquartile range (IQR)] time to first relapse was 87 (64.5–134) days for the SC group
and 139 (90–179) days for the EC group. The time to first relapse using the actual relapse date is shown in
Figure 6b.
Secondary outcomes
The number of relapses experienced by participants in each treatment group is shown in Table 4. The
number of relapses that participants experienced during the trial ranged from 0 to 15; there were eight
participants in the SC group and nine in the EC group who experienced 10 or more relapses. The mean
number of relapses did not differ (SC 3.61 vs. EC 3.98; IRR 1.09, 95% CI 0.86 to 1.39; p = 0.5)
(see Table 4).
There were no significant differences between the two treatment groups in the proportion of participants
developing FRNS (SC 50% vs. EC 53%, RR 1.04, 95% CI 0.81 to 1.35; p = 0.7) or SDNS (44% vs. 42%,
RR 0.96, 95% CI 0.71 to 1.29; p = 0.8) (see Table 4). The median time to the development of FRNS was
129 days for the SC group and 173 days for the EC group (HR 0.93, 95% CI 0.64 to 1.34). There was no
difference between groups in the proportion of participants requiring alternative immunosuppressive
agents (56% vs. 54%; p = 0.8). The most common immunosuppressive agents used were levamisole and
cyclophosphamide. The total dose of prednisolone received during the study (following completion of
study medication) was larger in the EC group (6674.1 mg) than in the SC group (5474.6 mg) but this was
not statistically significant (p = 0.07).
Serious adverse events
There were 67 SAEs reported in 46 participants (21%): 39 SAEs in 27 participants (25%) in the SC group
and 28 SAEs in 19 participants (17%) in the EC group (p = 0.1). The most common reasons for SAE
reporting were admission for disease relapse or bacterial infection. Five SAEs in the SC group and six SAEs
in the EC group were felt by the principal investigator to be related to the study drug, although none
resulted in study drug discontinuation. There was one accidental death that was unrelated to the trial.
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FIGURE 6 Time to first relapse. (a) When using time to relapse as 18 weeks if relapse occurred before 18 weeks; and (b) using actual date of relapse.
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Adverse events
The most common AEs reported were increased appetite, poor behaviour (parent reported), Cushingoid facies,
hypertrichosis and abdominal pain (Table 5). In the first 16 weeks of the trial, increased appetite was reported
in 87% of participants (SC 87% vs. EC 86%), poor behaviour in 83% (SC 90% vs. EC 75%), Cushingoid
facies in 67% (SC 66%, vs. EC 68%), hypertrichosis in 26% (SC 23%, vs. EC 30%) and abdominal pain in
26% (SC 28%, vs. EC 25%). By 24 months, these had increased to 94% (SC 94%, vs. EC 93%) for increased
appetite, 87% (SC 93%, vs. EC 82%) for poor behaviour, 72% (SC 72%, vs. EC 73%) for Cushingoid facies,
39% (SC 38%, vs. EC 39%) for hypertrichosis and 45% (SC 47%, vs. EC 43%) for abdominal pain. At
16 weeks and at 6, 12 and 24 months, there were no significant differences between the groups in the
cumulative number of participants reporting any of the AEs, except for poor behaviour, which was lower
in the EC group than in the SC group. In the first 16 weeks, 90% in the SC group reported poor behaviour,
compared with 75% in the EC group (RR 0.85, 95% CI 0.76 to 0.96). Differences were also seen at 6 months
(91% vs. 81%, RR 0.90, 95% CI 0.82 to 1.00), 12 months (92% vs. 82%, RR 0.90, 95% CI 0.82 to 0.98)
and 24 months (93% vs. 82%, RR 0.90, 95% CI 0.82 to 0.98).
TABLE 4 Secondary outcome measures
Secondary outcome measures
Group
Estimate (95% CI) p-valueSC (N= 109) EC (N= 114)
Relapses
Number of relapses 394 454
Number of participants experiencing a
relapse (%)
88 (81) 91 (80) HR 0.87 (0.65 to 1.17) 0.3
Mean (SD) number of relapses per
participant
3.61 (3.25) 3.98 (3.30) IRR 1.09 (0.86 to 1.39) 0.5
Number of participants who developed
FRNS (%)
55 (50) 60 (53) RR 1.04 (0.81 to 1.35) 0.7
Number of participants who developed
SDNS (%)
48 (44) 48 (42) RR 0.96 (0.71 to 1.29) 0.8
Second-line immunosuppressive agents
Number of participants who received
second-line immunosuppressants (%)
61 (56) 62 (54) RR 0.97 (0.77 to 1.23) 0.8
Type of immunosuppressant received
Ciclosporin 6 (6%) 4 (4%)
Tacrolimus 8 (7%) 18 (16%)
Levamisole 35 (32%) 34 (30%)
Cyclophosphamide 31 (28%) 29 (25%)
Mycophenolate mofetil 13 (12%) 15 (13%)
Rituximab 5 (5%) 1 (1%)
Corticosteroid dose n = 90 n = 94
Mean (SD) total prednisolone dose (mg)a 5474.6 (3697.3) 6674.1 (4998.2) Mean difference
1199.5
(–83.8 to 2482.8)
0.07
a Total dose of prednisolone received during the study (following completion of study medication).
A ratio of less than one favours the EC group. A negative mean difference favours the EC group.
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TABLE 5 Adverse event data: cumulative number of participants reporting AEs
AE
Time point
Week 16 6 months 12 months 24 months
Group, n reporting
AEs (%)
RR (95% CI)
Group, n reporting
AEs (%)
RR (95% CI)
Group, n reporting
AEs (%)
RR (95% CI)
Group, n reporting
AEs (%)
RR (95% CI)
SC
(N= 109)
EC
(N= 114)
SC
(N= 109)
EC
(N= 114)
SC
(N= 109)
EC
(N= 114)
SC
(N= 109)
EC
(N= 114)
Cushingoid
facies
72 (66) 77 (68) 1.04
(0.87 to 1.25)
75 (69) 79 (69) 1.03
(0.87 to 1.22)
76 (70) 81 (71) 1.05
(0.89 to 1.23)
78 (72) 83 (73) 1.02
(0.88 to 1.19)
Striae 3 (3) 8 (7) 2.69
(0.73 to 9.87)
4 (4) 11 (10) 2.72
(0.90 to 8.27)
6 (6) 11 (10) 1.80
(0.69 to 4.67)
7 (6) 14 (12) 1.92
(0.81 to 4.54)
Hypertrichosis 25 (23) 34 (30) 1.35
(0.87 to 2.09)
30 (28) 40 (35) 1.28
(0.87 to 1.89)
37 (34) 42 (37) 1.12
(0.80 to 1.59)
41 (38) 45 (39) 1.05
(0.77 to 1.45)
Acne 3 (3) 6 (5) 2.02
(0.52 to 7.86)
6 (6) 9 (8) 1.49
(0.55 to 4.02)
7 (6) 11 (10) 1.52
(0.62 to 3.77)
7 (6) 12 (11) 1.64
(0.68 to 3.99)
Increased
appetite
95 (87) 98 (86) 0.99
(0.89 to 1.09)
98 (90) 100 (88) 0.98
(0.90 to 1.07)
102 (94) 104 (91) 0.99
(0.92 to 1.07)
103 (94) 106 (93) 1.00
(0.94 to 1.07)
Poor
behaviour
98 (90) 86 (75) 0.85
(0.76 to 0.96)
99 (91) 92 (81) 0.90
(0.82 to 1.00)
100 (92) 93 (82) 0.90
(0.82 to 0.98)
101 (93) 94 (82) 0.90
(0.82 to 0.98)
Glycosuria 10 (9) 9 (8) 0.92
(0.39 to 2.16)
11 (10) 13 (11) 1.24
(0.59 to 2.61)
12 (11) 17 (15) 1.49
(0.76 to 2.91)
14 (13) 19 (17) 1.34
(0.72 to 2.48)
Cataracta – – – – – – 1 (1) 0 (0) – 1 (1) 1 (1) 0.96
(0.06 to 15.00)
Abdominal
pain
31 (28) 28 (25) 0.92
(0.60 to 1.42)
35 (32) 38 (33) 1.08
(0.74 to 1.56)
46 (42) 44 (39) 0.95
(0.70 to 1.29)
51 (47) 49 (43) 0.91
(0.69 to 1.20)
a Ophthalmoscopy was performed annually. Data on cataract were only available on 57 and 52 participants in the SC group and 60 and 54 participants in the EC groups at 1 and 2 years,
respectively.
A ratio of less than one favours the EC group.
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Achenbach Child Behaviour Checklist
Quantitative data on behaviour were collected using the ACBC. There were no significant differences in
the ACBC t-scores (p = 0.9) or total scores (p = 0.3) (Figure 7a and b; see also Table 21 in Appendix 2).
There were also no differences in the proportion of participants reporting normal ACBC scores
(see Table 22 in Appendix 2).
Subgroup analyses
When prespecified subgroup analyses were performed for the primary outcome for the two minimisation
variables of ethnicity (South Asian, white or other) and age (≤ 5 or ≥ 6 years), there was no clear evidence
to suggest that the treatment effect differed between the different participant subgroups (Table 6).
However, there may be some suggestion (p = 0.08) that in the EC group time to first relapse was extended
in those participants aged ≤ 5 years (HR 0.72, 95% CI 0.50 to 1.05), with no difference between the two
groups in participants aged ≥ 6 years (HR 1.26, 95% CI 0.77 to 2.07).
A post hoc subgroup analysis was also performed for gender, as a number of non-randomised studies
have reported that boys had a worse clinical outcome than girls.16,47 We found no evidence of a difference
in treatment effect according to gender (see Table 6).
Other outcomes
Growth data
After the 16-week study medication period, the mean height z-score (Figure 8a) and percentile (see Figure 8b)
scores gradually increased over time. At 12, 18 and 24 months, the mean height z-scores were –0.06
(SD 1.11), –0.06 (SD 1.13) and 0.12 (SD 1.09), respectively, in the SC group and –0.02 (SD 0.95), 0.05
(SD 0.93) and 0.02 (SD 0.99), respectively, in the EC group.
The mean weight z-scores at 8 weeks (when the corticosteroid dose between the two treatment arms
are the most different, i.e. after 4 weeks of study medication) were 0.64 (SD 1.09) in the SC group and
0.98 (SD 1.03) in the EC group. At 12, 18 and 24 months, the mean weight z-scores were 0.64 (SD 1.04),
0.61 (SD 1.19) and 0.70 (SD 1.19), respectively, in the SC group and 0.85 (SD 1.09), 0.80 (SD 1.06) and 0.76
(SD 1.12), respectively, in the EC group (Figure 9a). The mean weight percentile data are shown in Figure 9b.
The mean BMI z-scores at 8 weeks (when the corticosteroid dose between the two treatment arms
are the most different, i.e. after 4 weeks of study medication) were 1.24 (SD 1.27) in the SC group and
1.53 (SD 1.07) in the EC group. At 12, 18 and 24 months, the mean BMI z-scores were 0.82 (SD 1.21), 0.78
(SD 1.31) and 0.69 (SD 1.39), respectively, in the SC group and 1.20 (SD 1.22), 1.11 (SD 1.10) and 0.99
(SD 1.20), respectively, in the EC group (Figure 10a). The mean BMI percentile data are shown in Figure 10b.
Blood pressure
The mean systolic blood pressure z-scores at 4 weeks (at the end of the open-label prednisolone period)
were 1.25 (SD 0.86) in the SC group and 1.30 (SD 0.92) in the EC group. At 12, 18 and 24 months, the
mean systolic blood pressure z-scores were 0.75 (SD 0.96), 0.67 (SD 1.03) and 0.70 (SD 0.97), respectively,
in the SC group and 0.67 (SD 1.06), 0.53 (SD 0.96) and 0.53 (SD 0.89), respectively, in the EC group
(Figure 11a). The mean systolic blood pressure percentile data are shown in Figure 11b.
The mean diastolic blood pressure z-scores at 4 weeks (at the end of the open-label prednisolone period) were
1.12 (SD 0.93) in the SC group and 1.12 (SD 0.91) in the EC group. At 12, 18 and 24 months, the mean
systolic blood pressure z-scores were 0.61 (SD 0.99), 0.48 (SD 0.93) and 0.58 (SD 1.02), respectively, in the
SC group and 0.57 (SD 0.96), 0.37 (SD 1.03) and 0.42 (SD 0.83), respectively, in the EC group (Figure 12a).
The mean diastolic blood pressure percentile data are shown in Figure 12b.
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FIGURE 7 ACBC scores. (a) t-score; and (b) total score. Higher scores indicate more abnormal behaviour.
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TABLE 6 Subgroup analyses for primary outcome: time to first relapse
Characteristic
Group, n/N (%)
Interaction p-value HR (95% CI)SC (N= 109) EC (N= 114)
Participants experiencing at least one relapse
Age category (years)
≤ 5 60/72 (83) 55/73 (75) 0.08 0.72 (0.50 to 1.05)
≥ 6 28/37 (76) 36/41 (88) 1.26 (0.77 to 2.07)
Ethnicity
South Asian 16/21 (76) 15/23 (65) 0.6
White 60/73 (82) 63/75 (84)
Other 12/15 (80) 13/16 (81)
Gender
Male 64/78 (82) 54/68 (79) 0.5
Female 24/31 (77) 37/46 (80)
A HR of less than one favours of the EC group.
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FIGURE 8 Height. (a) z-score; and (b) percentile. a, Randomisation counted as week 0.
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FIGURE 9 Weight. (a) z-score; and (b) percentile. a, Randomisation counted as week 0.
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FIGURE 10 BMI. (a) z-score; and (b) percentile. a, Randomisation counted as week 0.
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FIGURE 11 Systolic blood pressure. (a) z-score; and (b) percentile.
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FIGURE 12 Diastolic blood pressure. (a) z-score; and (b) percentile.
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Chapter 4 Pilot study
P rior to submission of the application for NIHR funding for the PREDNOS study, a pilot study was conductedto test the proposed study methodology. At the time, the large majority of UK district general hospital
paediatric departments had little or no experience in the conduct of RCTs involving an investigational medicinal
product, and investigators were keen to ascertain that patients could be successfully recruited and followed
in accordance with the study protocol. This was of great importance given that the majority of patients with
nephrotic syndrome present to district general hospitals rather than to tertiary paediatric nephrology centres.
This pilot study, which was funded jointly by Kidney Research UK and Kids Kidney Research, used an identical
methodology to that of the proposed main study, randomising participants to either an 8-week SC or a
16-week EC of prednisolone therapy, and aimed to:
l provide ‘proof of principle’ of successful recruitment of participants and collaboration in district
general hospitals
l develop a network of investigators, initially in the North West of the UK, although then extending
beyond this region
l provide information on recruitment rates
l provide further evidence on the incidence of trial outcomes that could be used to inform the definitive
trial design; these outcomes included sustained remission rate at 6 and 12 months, time to relapse,
incidence of FRNS, incidence of SAEs and incidence of need for other immunosuppressive medications.
This pilot trial was carried out under a Clinical Trial Authorisation carried over from a Doctors and Dentist
Exemption (reference number MF8000/13293), in accordance with the Medicines for Human Use Clinical
Trials regulations.43 Ethics approval for the study was granted by the Thames Valley Multi-centre Research
Ethics Committee (reference number 04/12/025). The trial was sponsored by Great Ormond Street Hospital
for Children NHS Foundation Trust (reference number 03/NU/13). Both study drug and placebo were
manufactured by Essential Nutrition Ltd. The study was registered on ClinicalTrials.gov as reference number
NCT00308321 and EudraCT as reference number 2004-001813-33.
The pilot study recruited its first participant in August 2006. Trial recruitment was assisted significantly
by the development of the NIHR Medicines for Children Research Network (MCRN), which formally
adopted the study into its portfolio in March 2007. A successful collaborative trial network was
established, with principal investigators appointed at a total of 37 sites. By study completion, 26 sites
were fully set up, and, by June 2008, 18 sites had recruited 55 participants. A further 13 sites had
expressed active interest in participation in the study.
Of the 55 participants recruited, one was recruited and randomised in error before site set-up and never
received the study drug or entered the trial and two proved resistant to corticosteroid therapy after providing
informed consent, although prior to starting trial medication. These three participants were excluded from
the trial and any analyses. Two experienced difficulties in taking solid tablets and withdrew from the study
and two participants changed their area of residence and were lost to follow-up. Therefore, the ITT cohort
consisted of 52 participants. The mean age was 6.1 (SD 3.0) years; 31 (60%) were male, 38 (73%) were
white and 10 (19%) were South Asian. The median BMI percentile was 77.8 and the mean dose of
prednisolone administered in the open-label phase was 60.3 mg/m2/day (Table 7).
There were 35 relapses in 52 participants. There were no suspected unexpected serious adverse reactions,
although three participants experienced a SAE (trapped finger stitched in theatre, hospital admission for
abdominal pain and hospital admission for viral wheeze).
A decision was made to not unblind the pilot data prior to the commencement of the main study, but to
allow these data to be added to the results of the main study using meta-analysis methods. One minor
modification was made to the protocol for the main study following the pilot study, in that the visit
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schedule between months 6 and 12 was reduced from monthly to 2-monthly; monthly visits were felt to
be too onerous for participants and in excess of the visit schedule for routine clinical care for the large
majority of patients with SSNS at this stage post presentation.
The data from the 223 participants in the PREDNOS study and the 52 participants in the PREDNOS pilot
study were combined using random-effects meta-analysis methods. In the pilot study, date of relapse was
not recorded, so the date that relapse treatment was commenced was used for the relapse date in the
time to first relapse analysis here. This meta-analysis included 275 participants (136 in SC group and 139
in EC group) and showed no significant difference in time to first relapse between the two treatment
groups (pooled HR 0.76, 95% CI 0.50 to 1.17; p = 0.21) (Figure 13).
TABLE 7 Baseline characteristics of the PREDNOS pilot ITT population
Baseline characteristic
Group
TotalSC EC
Total randomised N= 27 N= 27 N= 54
Steroid-sensitive participants (ITT cohort) n= 27 n= 25 n= 52
Age (years)
Mean (SD) 5.7 (2.8) 6.5 (3.1) 6.1 (3.0)
≤ 5 years, n (%) 19 (70) 10 (40) 29 (56)
≥ 6 years, n (%) 8 (30) 15 (60) 23 (44)
Gender (male), n (%) 16 (59) 15 (60) 31 (60)
Ethnicity, n (%)
South Asian 5 (18) 5 (20) 10 (19)
White 21 (78) 17 (68) 38 (73)
Other/not stated 1 (4) 3 (12) 4 (8)
BMI percentile,a median (IQR) 82.1 (62.6–90.7) 77.0 (59.5–93.6) 77.8 (59.5–93.6)
BMI percentile,a n (%)
Underweight (< 5th) 0 (0) 0 (0) 0 (0)
Healthy (5th–84th) 15 (60) 16 (64) 31 (62)
Overweight (85th–95th) 5 (20) 4 (16) 9 (18)
Obese (≥ 95th) 5 (20) 5 (20) 10 (20)
Open-label prednisolone dose (mg/m2/day), mean (SD) 60.3 (7.2) 60.4 (3.3) 60.3 (5.5)
a Two missing in the standard arm.
PILOT STUDY
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FIGURE 13 Meta-analysis of time to first relapse for the PREDNOS and PREDNOS pilot study. df, degrees of freedom; IV, inverse variance.
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Chapter 5 Economic analysis: the
mapping exercise
The economic analysis is organised into two chapters. Chapter 5 provides detail on the mapping exercisethat was conducted to inform the outcomes for the main economic evaluation. Chapter 6 describes the
economic evaluation to estimate the cost-effectiveness of extending prednisolone therapy over a 16-week
period compared with the standard 8-week regimen for treating children with SSNS.
Background
The economic evaluation alongside the PREDNOS study consists of a cost–utility analysis with outcomes
expressed as ‘cost per QALY’. To construct QALYs, utility values are derived from preference-based
HRQoL instruments. The paediatric QoL PedsQL Generic Core Scale is a widely used instrument designed
to measure HRQoL, and it is valid for children aged between 2 and 18 years.48 However, as it is not a
preference-based instrument, it is not suitable for estimating QALYs. The CHU-9D questionnaire is a
preference-based instrument that has been developed primarily to support cost–utility analyses. However,
it is valid only for 5- to 17-year-olds. As the population of the PREDNOS study included participants who
were aged between 2 and 18 years, both instruments were employed. In order to derive utility scores for
children aged < 5 years, a prediction algorithm, also known as a ‘mapping’ algorithm, was developed to
estimate the CHU-9D score based on the responses to the PedsQL instrument. This chapter describes the
method for constructing this prediction algorithm.
Condition-specific and generic instruments
Cost-effectiveness analysis is a comparative assessment of both costs and benefits linked to health-care
interventions. Evidence of the benefits is often synthesised from clinical trials and may be captured as
HRQoL using either ‘condition-specific’ or ‘generic’ survey instruments. Condition-specific instruments
focus on health dimensions relevant to a particular disease, whereas generic instruments assess core
dimensions of health that are relevant to all conditions.49 Clinical trials often use condition-specific
instruments as an outcome measure because these instruments are focused on the specific domains of
QoL that are affected by a condition and are, therefore, sensitive to treatment effect in these domains.
On the other hand, generic instruments measure a broader HRQoL construct;50 therefore, they allow
comparisons of treatment benefit across a wide range of interventions across multiple conditions.
Furthermore, generic instruments can be classed as either ‘preference-based’ or ‘non-preference-based’.
Preference-based versus non-preference-based instruments
Preference-based generic instruments attach weights to the domains of health to reflect a stronger
preference for one domain of HRQoL over another, in order to generate a single weighted score, also
known as a utility score.51 In contrast, non-preference-based instruments simply sum the scores from all the
health domains and, thus, assume an equal weighting. For cost–utility analysis, preference-based generic
instruments are required to measure QoL, from which utility can be derived. The majority of generic
instruments used in clinical trials are non-preference based,52 and are consequently of limited use for
estimating the cost-effectiveness of diverse interventions on a common scale.
Validity of Child Health Utility 9D and Pediatric Quality of Life Inventory questionnaires
across paediatric age groups
To capture both length and QoL associated with treatment, economists use QALYs,53,54 whereby
cost-effectiveness of the treatment is expressed as cost per additional QALY gained. Within paediatric
medicine, however, most HRQoL instruments developed for children and adolescents are non-preference
based55 and, therefore, cannot be used for economic evaluation56 when QALYs are the desired outcome.
However, a prediction algorithm/mapping function can be used to predict utility scores from responses to a
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non-preference-based instrument. This algorithm reflects the relationship between the preference and the
non-preference-based instrument, using responses from a prior population.
Rationale for mapping within the PREDNOS study
Participants recruited into the study were aged between 2 and 15 years at baseline, with the oldest
participant being 18 years old at the last follow-up. Therefore, in order to generate utility values for the
2- to 18-year-olds within the trial, HRQoL information was collected either from both the PedsQL and the
CHU-9D questionnaires for participants aged ≥ 5 years or from just the PedsQL instrument for participants
aged 2–4 years. Therefore, utility values were directly elicited for all participants aged ≥ 5 years; for
participants aged 2 to 4 years, the mapping algorithm was applied to predict the CHU-9D utility score
based on the responses to the PedsQL instrument.
Methods
Outcome measures
The CHU-9D questionnaire was initially designed for children aged 7–11 years; however, further research
has now extended its validity to children as young as 6 years57 and in adolescents up to age 17 years.58 The
self-reported and proxy-reported versions of the CHU-9D questionnaire each consist of nine dimensions:
sad, worried, annoyed, tired, sleep, pain, school, routine and activity. Each dimension contains five severity
levels, resulting in almost two million unique health states associated with the measure. Responses from
the CHU-9D instrument are transformed into QoL (utility) weights derived from a UK general population
sample using an algorithm developed by Stevens.59 This gives a possible utility value set of between 0.33
(the worst health state) and 1 (the best health state).
The PedsQL Generic Core Scale is a well-validated non-preference-based measure. The self-reported version
of the questionnaire has been validated in 5- to 18-year-olds, whereas the parent- or proxy-reported version
is valid for use in 2- to 18-year-olds. Both versions of the instrument comprise 20 questions across four
subscales or domains of health. There is a different PedsQL module for toddlers (aged 2–4 years), young
children (aged 5–7 years), older children (aged 8–12 years) and adolescents (aged 13–18 years). The number
of items within the health domain varies in some modules based on age of the respondent. The physical
functioning domain has eight items, and both the emotional functioning and the social functioning domains
have five items each. School functioning has five items for all age groups except toddlers, for whom there are
only three items. Similar to the CHU-9D instrument, responses to each of the 23 items are on a five-point scale
of increasing severity: never a problem, almost never a problem, sometimes a problem, often a problem and
almost always a problem. Total scores are on a 0–100 scale, with 100 reflecting best-possible health state.
Data
In accordance with the study protocol, the proxy-reported version of the PedsQL and the CHU-9D
questionnaires were used to collect HRQoL data at weeks 4 (baseline) and 16, and at months 12, 24,
36 and 48 for participants in both treatment groups. PedsQL was completed for participants across all the
age groups in the trial (2–18 years), with the appropriate age-specific module for the instrument applied,
whereas the CHU-9D questionnaire was completed only for participants who were aged ≥ 5 years. Data
on participants who had completed both instruments across all the time points were considered relevant
for the mapping exercise. In order to optimise the sample size, the data for this eligible cohort for the five
time points in the RCT were combined and randomised into groups A and B. Observations with valid
CHU-9D and PedsQL index scores, that is, after excluding missing items, in groups A and B will from here
on be referred to as the estimation sample and the validation sample, respectively. Together, the two
samples form the total mapping sample.
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Model specification
First, to assess the conceptual overlap between the two instruments across the whole sample, the
interdimensional correlations between the nine CHU-9D and the four PedsQL domains were explored using
Spearman’s correlation. Next, the prediction mapping exercise involved regressing the CHU-9D utility scores
(independent variable) against the PedsQL total, subscale or item scores (dependent variables) to generate an
algorithm that could be subsequently used to predict the CHU-9D values. In order to select the model with
the best goodness-of-fit statistic, three ‘functional forms’ were explored. The first was the ordinary least
squares (OLS) regression with predicted utility scores censored at the value of 1. Although the OLS regression
minimises the sum of squared errors, and represents the most common method within mapping studies,60 it
has been shown that it does not cope well with multimodal distributions61 and does not always predict perfect
health. The second was the generalised linear model (GLM),62 as it accommodates skewness in the estimation
sample. The GLM requires specification of a distribution ‘family’ that captures the relationship between the
mean and variance, and a link function between the linear part and the mean. The Modified Park test was
applied to identify the preferred ‘family’ based on the lowest chi-squared value. The Hosmer–Lemeshow and
Pearson correlation tests63,64 were used to select the link function, assumed as a good fit if both tests yielded
non-significant p-values. The third form chosen for the prediction function was the tobit model, a censored
regression that accommodates both the lower and upper limit utility scores.65 Tobit models have been
suggested for mapping despite concerns about inconsistencies in the presence of non-normality and
heteroscedasticity.66 In summary, six model specifications (covariates) were developed based on the OLS,
tobit and the GLM ‘functional forms’, thus generating 18 models in total:
l model 1 – PedsQL total scale score
l model 2 – model 1, age, and sex
l model 3 – PedsQL subscale scores
l model 4 – model 3, age and sex
l model 5 – PedsQL subscale score square terms and interaction terms
l model 6 – model 5, age and sex.
The PREDNOS data are a longitudinal data set that can be viewed as having a two-level structure, for which
the data collection time points (level 1 units) are nested within participants (level 2 unit). Random intercept
mixed-effect models are often used to account for this hierarchical data structure, but this was not considered
appropriate in this context because, for mapping purposes, the error variance was expected to be constant
over time: the CHU-9D and the PedsQL data were collected from each individual at discrete time points
and any variance in the estimation error over time was, therefore, assumed to be constant. In line with the
assumption of constant variance over time, the PREDNOS data were considered to have only one hierarchical
level, which is at the participant level. The within-participant correlation was taken into account by including
the ‘clustering’ option for each of the 18 model specifications. For example, the model 1 specification was:
regress [CHU-9D score] [PedsQL score], vce (cluster, [participant ID]), (1)
where [participant ID] was a unique participant identifier.
Assessing model performance
The following selection criteria were applied to assess the estimation performance of the models:67
l Step 1. The models were assessed on the exactness of the predicted mean value in the
estimation sample.
l Step 2. One model from each functional form was selected based on its prediction accuracy in the
estimation and validation sample. The indicators of prediction accuracy were the mean absolute error
(MAE) and the mean squared error (MSE). The MAE is the mean absolute difference between the
observed and the predicted values, while MSE is the mean squared difference between the observed
and the predicted CHU-9D utility score. Larger MAE and MSE indicate poorer fit. MAE was prioritised
over MSE, which has been shown to be less sensitive to outliers often found within the utility data.68
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l Step 3. To assess and compare the shortlisted models estimated in step 2, a number of criteria
were considered:
¢ The distribution of the predicted and the observed CHU-9D scores were plotted to examine how
well the predicted scores matched the observed scores.
¢ The proportion of predictions deviating from observed values by < 0.03, < 0.05 and < 0.1 were
calculated as a representation of how often the models produce reliable predictions.
¢ The MAEs were presented for different CHU-9D value ranges to assess how well the models
perform at the top and bottom of the index score range.
All of the analysis described follows the MApping onto Preference-based measures reporting
Standards (MAPS).69
Results
Sample characteristics
There were 643 observations across the five data collection time points from participants who were aged
≥ 5 years. These observations were randomised into groups A (n = 321) and B (n = 322). The longitudinal
nature of the study meant that the number of missing data in the groups varied across the data collection
points. After removing missing items, 279 observations with pairs of valid PedsQL and CHU-9D index
scores in the first group formed the estimation sample, while the 284 observations in the second group
formed the validation sample. The estimation and validation samples constitute the total mapping sample
(n = 563). Figure 14 shows the distribution of the CHU-9D and PedsQL scores in the estimation and
validation samples.
Table 8 reports the descriptive statistics for each sample at each time point. Overall, it seems that the
randomisation ensured a balanced distribution of demographic characteristics between the estimation
and the validation samples.
The mean CHU-9D utility score across all time points was 0.9374 (SD 0.0790) and 0.9409 (SD 0.0717) in
the estimation and validation samples, respectively. The corresponding mean PedsQL score across all time
points was 80.93 (SD 16.76) in the estimation sample and 80.31 (SD 17.79) in the validation sample.
Within each sample, the mean PedsQL total score was lower than the mean CHU-9D utility score when
both scores were standardised on a 100-point scale. Although both HRQoL measures were negatively
skewed, the ceiling effect was more prominent with CHU-9D. Tables 23 and 24 in Appendix 3 summarise
the CHU-9D responses for the estimation and validation samples across all data collection time points.
Level 1 or ‘no problem’ always had the highest proportion of responses, hence the observed ceiling effect
for the CHU-9D index score.
Performance and validation
Table 25 in Appendix 3 summarises the performance measures for all the model specifications, for both the
estimation and the validation samples. Within the estimation sample, the models were able to reasonably
predict the mean CHU-9D value (0.93742, SD 0.07898). Of the 18 models, 12 were able to predict the
precise mean value by up to 1/10,000th of a QALY. The exceptions were the six tobit models. However,
within the validation sample, the models were less able to predict the mean CHU-9D value (0.94094, SD
0.07174). The model GLM 2 had lowest mean predicted value (0.93409), whereas the model Tobit_3 had
the highest mean predicted value (0.96575), giving a difference between the observed and predicted mean
values of 0.0069 and 0.0245, respectively. These differences were below the threshold of 0.03, for which
differences smaller than this level are considered to be a minimally important difference.70,71 A further
observation was that some OLS models and all the tobit models had maximum predicted values beyond the
upper limit of the CHU-9D utility scale (0.33–1.00). However, none of the models predicted a utility value
below the lower limit of the CHU-9D utility scale.
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FIGURE 14 Distribution of CHU-9D and PedsQL scores in the estimation and validation samples. (a) Estimation
sample, CHU-9D; (b) validation sample, CHU-9D; (c) estimation sample, PedsQL; and (d) validation sample, PedsQL.
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TABLE 8 Demographic characteristics of estimation and validation sample by data collection time point
Characteristic
Time point
Baseline
(4 weeks) 16 weeks 12 months 24 months 36 months 48 months
Estimation
sample N = 55 N = 47 N = 58 N = 54 N = 39 N = 26
Age (year)
Mean (SD) 7 (2.1) 7.6 (2.1) 7.4 (2.1) 7.2 (1.9) 7.3 (1.9) 8.1 (2.0)
Median (IQR) 6 (3) 7 (4) 7 (3) 7 (2) 7 (3) 8 (3)
Range 5–12 5–12 5–12 5–12 5–12 5–12
Gender
Male, n (%) 35 (63.6) 33 (70.2) 36 (62.1) 32 (59.2) 23 (58.9) 18 (69.2)
CHU-9D score
Mean (SD) 0.940 (0.063) 0.929 (0.103) 0.941 (0.080) 0.950 (0.068) 0.922 (0.081) 0.937 (0.077)
Median (IQR) 0.952 (0.106) 0.952 (0.100) 0.952 (0.081) 0.968 (0.073) 0.931 (0.108) 0.967 (0.107)
Range 0.786–1.000 0.534–1.000 0.509–1.000 0.68–1.000 0.702–1.000 0.697–1.000
PedsQL score
Mean (SD) 77.11 (16.16) 82.4 (16.8) 81.94 (15.91) 84.24 (14.31) 78.49 (20.58) 80.85 (17.72)
Median (IQR) 79.35 (28.26) 89.13 (29.35) 87.5 (20.65) 88.04 (18.48) 82.61 (30.43) 82.61 (29.35)
Range 40.22–100.00 45.65–100.00 41.3–100.00 43.48–100.00 31.52–100.00 39.13–100.00
Validation
sample N = 36 N = 46 N = 50 N = 70 N = 56 N = 26
Age
Mean (SD) 6.9 (1.8) 7.1 (1.9) 7.3 (2.0) 7.6 (2.2) 7.4 (2.2) 8 (1.9)
Median (IQR) 7 (3) 7 (2) 7 (3) 7 (3) 7 (3) 8 (2)
Range 5–11 5–12 5–12 5–12 5–13 5–13
Gender
Male, n (%) 25 (69.4) 30 (65.2) 32 (64.0) 44 (62.9) 29 (51.8) 15 (57.7)
CHU-9D score
Mean (SD) 0.924 (0.081) 0.945 (0.067) 0.941 (0.075) 0.938 (0.076) 0.951 (0.067) 0.945 (0.06)
Median (IQR) 0.952 (0.1) 0.96 (0.079) 0.96 (0.081) 0.952 (0.102) 0.967 (0.071) 0.959 (0.097)
Range 0.711–1 0.69–1 0.739–1 0.65–1 0.712–1 0.828–1
PedsQL score
Mean (SD) 75.88 (16.91) 81.35 (14.53) 78.28 (19.01) 80.6 (17.25) 83.13 (19.11) 81.68 (20.3)
Median (IQR) 77.72 (27.36) 83.7 (18.48) 83.7 (28.26) 86.96 (27.17) 91.85 (27.17) 90.76 (20.65)
Range 42.39–97.83 41.3–100 21.74–100 33.7–100 40.22–100 29.35–100
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Models were initially assessed in terms of their ability to predict the mean value in the estimation sample.
All GLM and OLS models were consequently shortlisted for further comparison and progress to ‘step 2’.
The two models (GLM 6 and OLS 3) that had the ‘best’ performance in terms of MAE, in both the
estimation and validation samples, were selected for a final comparison: ‘step 3’. Table 9 contains the
model performance results for both of these models.
For the GLM, a logit transformation of the variable containing the CHU-9D utility scores was applied
before the variable was used as the dependent in the prediction equation. As such, any predicted value
from that equation will be a transformed value and, therefore, requires a back-transformation to estimate
utility values. The information on the back-transformation step is as follows. Given that GLM 6 has a logit
link, the CHU-9D utility values are calculated as shown below:
CHU-9D utility score ½GLM = e
CHU-9D utility value
1+ eCHU-9D utility value
(2)
For the final models in step 3, in addition to assessing how accurately the models estimated the mean
CHU-9D score in the validation sample, the distribution of the predicted score was also examined (see
Figure 17, Appendix 3). GLM 6 had a wide range of predicted CHU-9D scores compared with OLS 3.
Approximately 56% of the predicted values from GLM model 6 in the validation sample had absolute
errors less than the minimally important difference value of 0.03; the corresponding values for the OLS
model 3 was 53%. GLM model 6 remained the preferred model specification when the error threshold
was extended to 0.05.
Although the prediction accuracy of the mean scores was similar in both models, the accuracy level was
not uniform across the CHU-9D utility range, as shown in Table 10. The number of observations with
utility score of < 0.7 was small; therefore, the comparison between the best two models was restricted to
TABLE 9 Model performance of the two best-fitting models
Statistics
Sample
Estimation Validation
Observed GLM 6 OLS 3 Observed GLM 6 OLS 3
Mean 0.937419 0.937419 0.937419 0.940941 0.937612 0.939018
SD 0.078978 0.051926 0.047318 0.071737 0.054762 0.046323
CV 0.084251 0.055393 0.050477 0.076240 0.058406 0.049331
Minimum value 0.509400 0.660930 0.812068 0.650000 0.705160 0.788717
P25 0.907600 0.910639 0.900076 0.912300 0.914908 0.905183
P50 0.952100 0.957229 0.946303 0.952100 0.958496 0.950063
P75 1.000000 0.978902 0.980433 1.000000 0.977276 0.977413
Maximum value 1.000000 0.989350 0.995221 1.000000 0.985504 0.993891
MSE – 0.00353 0.00398 – 0.00345 0.00310
MAE – 0.04078 0.04245 – 0.04182 0.03981
< 0.03 AE (%) – 53.40 51.61 – 55.89 53.17
< 0.05 AE (%) – 72.04 70.25 – 73.23 70.77
< 0.10 AE (%) – 92.27 90.32 – 91.20 93.31
< 0.03 AE (%), percentage with absolute error below 0.03; < 0.05 AE (%), percentage with absolute error below 0.05;
< 0.10 AE (%), percentage with absolute error below 0.10; CV, coefficient of variation; P25, 25th percentile; P50, 50th
percentile; P75, 75th percentile.
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observations with higher utility values. GLM 6 was superior to OLS 3 in the estimation sample; however,
in the validation sample there were diverging results. OLS 3 had a better prediction accuracy when utility
values were > 0.8, but less than full health, while the GLM 6 was superior at predicting full health and
utility values between 0.7 and 0.8. So, although OLS 3 had a better prediction accuracy in the validation
sample overall, it was found to be only marginally better than GLM 6.
In summary, relative to GLM 6, OLS 3 lacked the ability to predict the wider range of CHU-9D values
(0.7–1), and a higher proportion of its predicted values had absolute errors above the minimally important
difference. Furthermore, it was less able to predict full health, which is particularly important for utility data
that tend to have ceiling effects. Taking all these factors into account, the GLM 6 model was selected as
the preferred model for mapping from PedsQL to CHU-9D. Table 11 shows the coefficients for generating
deterministic and probabilistic utility predictions using the GLM 6 model. Coefficients for OLS 3 have also
been presented in situations in which this might be desired.
Discussion
Although complying with current guidance for conducting and reporting mapping analyses,69 the results of
this analysis show that CHU-9D utility scores can be estimated from PedsQL subscale scores with sufficient
accuracy. Six models, each with three functional forms, were explored. All of the models produced
reasonably similar predictions of the mean utility scores. The GLM 6 and OLS 3 models, with MAE of
0.04078 and 0.04245, respectively, were the two models that performed particularly well. Overall, GLM 6
was chosen as the preferred mapping model because of its better prediction accuracy over a wider range
of CHU-9D utility scores.
In comparison with other similar published studies, the GLM 6 model (MAE 0.04078; MSE 0.00353) predicted
the CHU-9D utility scores with more accuracy. For example, in one study that looked at the relationship
between the CHU-9D and the Strengths and Difficulties Questionnaire, the MSE was 0.124;72,73 whereas
TABLE 10 Distribution of errors by observed CHU-9D range
CHU-9D range n
Model
GLM 6 OLS 3
MSE MAE MSE MAE
Estimation
0.5≤ value < 0.6 3 0.09443 0.30095 0.11168 0.33058
0.6≤ value < 0.7 6 0.01873 0.12096 0.02823 0.16497
0.7≤ value < 0.8 11 0.00726 0.07674 0.00988 0.09602
0.8≤ value < 0.9 49 0.00301 0.04441 0.00259 0.04034
0.9≤ value < 0.10 111 0.00154 0.02853 0.00155 0.03015
Full health 102 0.00242 0.03847 0.00279 0.03899
Validation
0.6≤ value < 0.7 3 0.05502 0.23049 0.05277 0.22693
0.7≤ value < 0.8 12 0.01185 0.09583 0.01376 0.10958
0.8≤ value < 0.9 47 0.00468 0.05691 0.00329 0.04316
0.9≤ value < 0.10 115 0.00187 0.03057 0.00131 0.02942
Full health 107 0.00223 0.03593 0.00237 0.03643
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another study that estimated CHU-9D utility scores from the KIDSCREEN questionnaire had a MAE of 0.095.74
The GLM 6 model produced from this analysis also performed better than a previous model that had
predicted EuroQoL-5 Dimension Youth version utility scores from PedsQL (MAE 0.115).67
Despite these strengths, there are some limitations. The sample size was small compared with other
mapping studies,52 thereby limiting the ability to robustly demonstrate the relationship between CHU-9D
and PedsQL scores. A larger sample size may have reduced the prediction error of the model. Another
caveat was the ceiling effect. A wider spectrum of health profiles was lacking because a considerable
number of participants had perfect or near-perfect health, with none having utility scores of < 0.5 in the
estimation sample. This was reflected in the distribution of scores across the five response levels for each
of the CHU-9D domains and each PedsQL subscale score. This implies that caution should be exercised
when using the algorithm in a less healthy population. Future research can focus on refining this mapping
algorithm should data for children with more severe health states become available.
Mapping is not a substitute for direct utility estimation. Therefore, it is advised that, when possible,
preference-based outcomes be collected for the measurement of cost-effectiveness. However, in the event
that this is not feasible, the algorithm from the model presented here provides a valuable, justifiable and
scientifically robust approach to predicting CHU-9D utility values. This mapping algorithm will be applied
to generate utility scores for the PREDNOS trial population, who are aged between 2 and 4 years. The
standard errors (SEs) for the coefficients have been reported, making it imperative for such evaluations to
account for the uncertainty around the predicted values.
TABLE 11 Coefficients for the two best-fitting models
Covariate
Model
GLM 6 OLS 3
Coefficient SE Coefficient SE
PedsQL PF squared 0.0001615 0.000103 – –
PedsQL EF squared 0.0004766*** 0.000127 – –
PedsQL SF squared –0.0000402 0.000145 – –
PedsQL FU squared –0.0001646 0.000101 – –
PedsQL PF × EF –0.0001103 0.000147 – –
PedsQL PF × SF –0.000114 0.000173 – –
PedsQL PF × FU 0.0000371 0.000143 – –
PedsQL EF × SF –0.0002461 0.000209 – –
PedsQL EF × FU –0.0001158 0.000167 – –
PedsQL SF × FU 0.0004356*** 0.00013 – –
PedsQL PF – – 0.0007133* 0.000297
PedsQL EF – – 0.0016477*** 0.000228
PedsQL SF – – –0.00011 0.000383
PedsQL FU – – 0.000261 0.000276
Age 0.0279345 0.039717 – –
Sex –0.0546336 0.146341 – –
Constant 0.7135215 0.399623 0.7422337*** 0.028841
*p < 0.05, **p< 0.01, ***p< 0.1.
EF, emotional functioning; FU, school functioning; PF, physical functioning; SE, standard error; SF, social functioning.
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Chapter 6 Economic evaluation
C hapter 6 describes the economic evaluation alongside the PREDNOS trial. The overall aim was toestimate the cost-effectiveness of an extended prednisolone regimen over a 16-week period compared
with a standard 8-week regimen for treating children with SSNS. The primary evaluation was a cost–utility
analysis, with the outcome measured in terms of QALYs. All costs were expressed in 2015 prices.
Missing data were addressed using multiple imputation techniques. Uncertainty surrounding the
cost-effectiveness estimates was examined using probabilistic sensitivity analysis75 and presented using
cost-effectiveness acceptability curves (CEACs). The analysis of cost-effectiveness was conducted according
to current best practice methods for conducting economic evaluations alongside clinical trials.76
Aim
To estimate the cost-effectiveness of an extended prednisolone regimen over a 16-week period compared
with the standard 8-week regimen for treating children with SSNS.
Methods
Data collection
To conduct the economic evaluation, data on both resource use and outcomes77 were collected within the
study on case report forms. In line with standard practice, only resource use that was incurred in delivering
the intervention was considered in the base-case scenario. To calculate the overall cost of the treatment,
resource use data were multiplied by relevant unit costs. To calculate QALYs, health utility data were
collected using the CHU-9D instrument59 at baseline (commencement of the study drug regimen at week 4),
at week 16 and at months 12 and 24.
Health economic outcomes
Measuring quality-adjusted life-years
Health-related QoL information was collected using both the generic non-preference-based PedsQL Generic
Core Scale and the preference-based CHU-9D questionnaire. The PedsQL and the CHU-9D (for children
aged ≥ 5 years) questionnaires were proxy completed by parents or guardians at the relevant time points.
Two approaches were used to estimate utility values according to the age group of the trial population.
For participants aged ≥ 5 years, utility values were estimated directly using the responses to the CHU-9D
instrument and applying an existing UK value set59 (referred to as the direct estimation method). For
participants aged between 2 and 4 years, a crosswalk/mapping technique was applied using the responses
to the PedsQL questionnaire. For more detail on the mapping algorithm, see Chapter 5.
Assessing quality-adjusted life-year differences
Quality-adjusted life-years over 24 months were calculated for each participant using the area-under-the-curve
method.78 A univariate and multivariate regression model was then conducted to estimate QALY differences
between the two treatment groups. In the univariate model, the utility scores over the trial period were
regressed against intervention group status. In the multivariate regression model, the following variables were
added as additional independent variables: baseline CHU-9D score, baseline age and gender.
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To summarise, the two models reported are:
1. a univariate linear regression model
2. a multivariate linear regression model controlling for baseline utility, baseline age and gender.
Resource use data and cost analysis
A combination of micro (bottom-up) and macro (top-down) costing methodology was used to estimate
the costs associated with each treatment group of the trial. Resource use items were grouped into three
categories: primary care, secondary care and medication costs. Resource use data were collected at
baseline, at weeks 4, 8, 12 and 16 and at months 5, 6, 8, 10, 12, 18 and 24. The cost analysis adopted
a UK health sector perspective and costs reported are in 2015 prices.
Primary care resource cost
At each data collection time point, the primary care resource use was captured in terms of the recorded
number of visits to the GP, practice nurse or other primary care staff for each participant between the
relevant time point and the preceding data collection time point. Since the specific reason for the visit was
not reported, the average unit cost was used and multiplied by the frequency of visits over each time
period. The total primary care cost for each participant was then derived by simply summing the costs
incurred by visits to the GP, nurse or other primary care staff over the 24-month period.
Secondary care cost
All resource use associated with secondary care was categorised into outpatient hospital care, emergency
visits and hospital admissions. The cost of outpatient hospital care was then estimated by multiplying
the number of visits by the unit cost of one visit. Different unit costs were used for consultant and
non-consultant led visits. For emergency episodes and hospital admissions, these were further categorised
into renal-related or non-renal-related admissions depending on whether or not the primary carer of the
child reported that the admission was related to nephrotic syndrome. The cause of admission was assumed
to be of renal aetiology if the carer did not report this information. Only nephrotic syndrome-related
admissions were considered in the base-case analysis.
The cost of a hospital admission was estimated using the time interval between the admission and
discharge date. An admission was considered as a zero bed-stay if the participant was admitted and
discharged within 24 hours. A 5-day admission episode, which is the maximum expected length of stay for
nephrotic syndrome in the UK,79 was assumed in situations in which the admission date was recorded but
the discharge data were unavailable. The number of bed-days was considered as zero when both the
admission and discharge dates were missing. Admission episodes with ≤ 5 bed-days were within what is
known as a ‘trim point’ and were priced at a flat rate. Admission episodes with > 5 bed-days first incurred
the trim-point flat rate, and then the excess bed-days were priced per additional bed-day at a ‘regular
day rate’. Zero bed-stays incurred one regular day rate tariff. SAEs require either outpatient or inpatient
hospital care. Therefore, to avoid double-counting, the cost of SAEs was not costed separately. Instead,
it was assumed that this was captured by the recorded inpatient and outpatient hospital care data.
Medication cost
Prednisolone costs were estimated from the British National Formulary based on dose, quantity consumed
and drug formulation. Information on other prescribed medications other than the study medication,
such as second-line immunosuppressants, was captured as free text on the trial forms. The free-text
sections were reviewed manually to establish the name, the dose and the formulation of the medication.
This microcosting approach was considered important because the treatment of SSNS is associated
with medications that have high daily costs. Therefore, it was considered essential to account for these
high-cost drugs in the economic evaluation. After extracting prescription information from the free-text
sections, the medications were classified into 31 groups. An index drug was identified in each group, to
which a unit cost was attached. The unit cost of the index medication was then applied to all prescriptions
within the group.
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Data on non-prescribed medications were recorded as total out-of-pocket expenditure on medication.
Costing of this item was not necessary, as the item was already captured in Great British pounds. This cost
is included for descriptive purposes only and was not included in the economic evaluation, as this falls
outside the health-care perspective for the analysis.
Unit costs
Primary care unit costs for pharmacist, nurse or GP consultations (telephone, home visit or practice based)
were sourced from the Unit Costs of Health and Social Care 2015.80 The National Schedule of Reference
Costs79,81 was used to cost hospital-related activities. Within the reference cost schedule, resource use items
within the NHS are coded into Healthcare Resource Group (HRG), onto which costs/tariffs are attached.
The tariff for the nephrotic renal disease HRG code (PL69C) was chosen as the unit cost for all renal
admissions. The British National Formulary82 provided unit costs for medicines by using doses reported in
the case report form. Table 12 outlines the unit cost details that apply to all resource use items.
Assessing cost differences
The total health-care cost at each time point was obtained by summing the medication cost and primary
and secondary care costs. Similar to the estimation of between-group QALY differences, the mean cost
difference between the two treatment groups was estimated using a regression-based technique while
controlling for baseline age and gender.
Multiple imputation
The cost data were considered missing if participants reached a particular time point without having
withdrawn from the study but did not return the study case report form. If information on resource use
was missing from the returned questionnaires then the items in question were assumed not to have been
used and consequently were allocated a cost of zero. In the case of the CHU-9D questionnaire, however,
no response for one or more items resulted in a missing CHU-9D index score, as all nine items are
necessary for computing the index score.
In line with the study protocol, missing data were imputed at each time point.83 QALYs and resource use
data were collected across 6 and 14 time points, respectively, over the study duration; therefore, these
were imputed separately. While assuming that data were missing at random, multiple imputation was used
to generate 40 imputed data sets for each cost item and QALY variable. The predictive mean matching
method for multiple imputation was used to account for the non-normality of the distribution of costs and
QALY scores. This method ensures that the imputations took only values from the data that were available
in the original trial data. The imputation of costs was conducted at the level of resource group type (e.g.
hospital admission, emergency visits, medication). Other variables included in the imputation model were
age, sex and treatment group because these were thought a priori to be associated with missingness.
Rubin’s rule84 was used to combine the 40 imputed data sets into one final imputed variable. A visual
inspection of the histograms of the non-imputed and combined imputed variables was conducted to
confirm that both distributions were similar.
Cost-effectiveness analysis
The mean differences in costs and QALYs between the extended and the standard prednisolone regimens
over 24 months were estimated according to the ITT principle, meaning that data from all randomised
participants were analysed irrespective of protocol deviations or participant withdrawal or death during the
trial. The ratio of the mean difference in cost and the mean difference in QALYs between the two groups
was calculated to estimate the cost per additional QALY gained. Resource use data (costs) and QALY data
were skewed; therefore, the 95% CI of the arithmetic mean difference between the treatment groups
for these parameters was obtained from non-parametric bootstraps, each with 5000 replications. The
incremental cost-effectiveness ratio (ICER), which is the mean difference in cost and the mean difference in
QALYs between the two groups, was then calculated to produce the cost per additional QALY gained.
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TABLE 12 Details of unit costs assigned to health-care resource data
Staff time
Details and assumptions
Source
Mean duration of contact and mean cost of contact
per hour
Cost per
contact
GP 17.2-minute contact with GP at £171/hour £49.02 PSSRU
201580
Practice nurse 15.5-minute contact with band 5 staff at £36/hour £9.29 PSSRU
201580
Other staff 15.5-minute contact with band 4 staff at £29/hour £7.49 PSSRU
201580
Secondary care resource
use Details and assumptions
Cost per
visit
Renal emergency visit HRG code PA69Z (non-elective spell) £1321.00 2015 tariff81
Renal elective admission HRG code PA69Z (ordinary elective spell) £648.00 2015 tariff81
Renal elective admission after
trim-point
HRG code PA69Z (per day long-stay tariff) £285.00 2015 tariff81
Paediatric outpatient General paediatric outpatient £220.00 2015 tariff81
Medication Drug (strength); dose/pack (cost in £); prescription
Cost per
month
Aciclovir Acyclovir (800 mg); 35 doses (£4.38); 1 tablet QDS £15.01 BNF 201582
Analgesics Ibuprofen (200 mg); 84 doses (£3.50); 1 tablet TDS £3.75 BNF 201582
Antacid and antiemetic Ranitidine (150mg); 60 doses (£34.09); 2 tablets BD £34.09 BNF 201582
Antibiotics (other oral) Cefixime (200mg); 7 doses (£13.23); 1 tablet OD £56.70 BNF 201582
Antibiotics (other topical) Clindamycin (30 ml); 60 doses (£4.34); 1 application BD £4.34 BNF 201582
Anticoagulants Heparin (1000 IU); 1 dose (£1.49); 1 ampoule BD £89.40 BNF 201582
Antihypertensive (angiotensin-
converting enzyme inhibitor)
Lisinopril (2.5 mg); 28 doses (£0.89); 1 tablet OD £0.95 BNF 201582
Antihypertensive (beta-blockers) Atenolol (50 mg); 28 doses (£0.87); 1 tablet OD £0.93 BNF 201582
Antihypertensive (calcium
blockers)
Amlodipine (5 mg); 28 doses (£0.91); 1 tablet OD £0.97 BNF 201582
Antihypertensive (others) Metolazone (5 mg); 28 doses (£10.42); 1 tablet BD £22.32 BNF 201582
Bath gel and Emollients Calmurid® (Galderma, Watford) (100 g); 60 doses
(£33.40); 1 application BD
£33.40 BNF 201582
Bronchodilators (inhaled) Salbutamol (100 µg); 200 doses (£1.50); 2 puffs QDS £1.80 BNF 201582
Ciclosporin Ciclosporin (50 mg); 30 doses (£25.50); 1 tablet BD £51.00 BNF 201582
Co-trimoxazole Co-trimoxazole (480 mg); 28 doses (£3.14); 1 tablet BD £6.73 BNF 201582
Cyclophosphamide Cyclophosphamide (50 mg); 100 doses (£139.00);
1 tablet OD
£41.70 BNF 201582
Food supplements and
probiotics
Abidec® (Omega Pharma Ltd, London) (25 ml); 20 doses
(£3.33); 2 drops OD
£9.99 BNF 201582
Furosemide Furosemide (40 mg); 28 doses (£0.83); 1 tablet TDS £2.67 BNF 201582
Methylprednisolone (i.v.) Methylprednisolone (500 mg); 1 dose (£9.60); 1 vial OD £96.00 BNF 201582
Levamisole Levamisole (50 mg); 1 dose (£1.18); 1 tablet SD £11.16 BNF 201582
Mycophenolate mofetil Mycophenolate (500mg); 50 doses (£9.31); 1 tablet BD £11.17 BNF 201582
Omeprazole Omeprazole (10 mg); 28 doses (£1.18); 1 tablet OD £1.26 BNF 201582
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A probabilistic sensitivity analysis was conducted by jointly bootstrapping the mean difference in cost
and QALYs to produce 5000 paired estimates. This was to account for the uncertainty due to sampling
variation in the participant-level data. The bootstrapped pairs of mean cost and QALYs were then
graphically presented on a cost-effectiveness plane, and a CEAC was constructed from the plotted points.
The incremental net benefit was used to construct the CEAC because of well-established limitations when
ICERs from bootstrap replicates are spread over the four quadrants of the cost-effectiveness plane.85,86
The CEAC shows the probability of the extended prednisolone regimen being cost-effective at different
cost per QALY thresholds. In the UK, interventions are considered cost-effective if the cost per additional
QALY gained is < £20,000.76
A 3.5% discount rate was applied to all costs and outcomes, in accordance with National Institute for
Health and Care Excellence’s guidelines for health technology appraisal.76 Stata version 13 was used to
perform the analysis.
Subgroup analysis
A series of sensitivity analyses (as per protocol) were conducted to assess the robustness of the base-case
results to some assumptions made. To test the impact of imputing missing data, the analysis was
conducted only on participants for whom we had complete data. Another subgroup analysis was based
on the a priori assumption that prednisolone may have a different response in participants from different
ethnic backgrounds. Ethnicity may also influence how households control exposure to infection in children
who become immunosuppressed. The ethnic groups that were examined were South Asian, white and all
other ethnic groups. The primary analysis results were also examined to see whether or not the results
differed between participants who were 5 years or younger and those who were older. This is because the
age at initial presentation has an important impact on the underlying cause of the disease, which may in
turn have an impact on relapse rates, QoL and health-care consumption.
TABLE 12 Details of unit costs assigned to health-care resource data (continued )
Staff time
Details and assumptions
Source
Mean duration of contact and mean cost of contact
per hour
Cost per
contact
Penicillin Penicillin V (250 mg); 28 doses (£1.18); 1 tablet QDS £5.06 BNF 201582
Rituximab Rituximab (375mg); 1 dose (£873.15); 1 infusion weekly £3492.60 BNF 201582
Spironolactone Spironolactone (50 mg); 28 doses (£2.13); 1 tablet OD £2.28 BNF 201582
Steroid (inhaled) Seretide (250 µg); 60 doses (£35.00); 1 puff BD £35.00 BNF 201582
Steroid (other oral) Dexamethasone (500 µg); 28 doses (£56.54); 2 tablets BD £121.16 BNF 201582
Steroid (topical) Hydrocortisone (15 g); 30 doses (£5.39); 1 application BD £10.78 BNF 201582
Tacrolimus Capexion (1 mg); 50 doses (£68.20); 3 capsules BD £245.52 BNF 201582
Trimethoprim Trimethoprim (100 mg); 28 doses (£8.44); 1 tablet BD £18.09 BNF 201582
Zoster immune globulin Influenza vaccination (0.5 ml); single dose £6.29 BNF 201582
Study drug Drug (strength); dose/pack (cost in £); prescription
Cost per
milligram
Prednisolone Prednisolone (5 mg); 28 doses (£1.61); as per study
prescription
£0.01 BNF 201582
BD, bis die (twice a day); BNF, British National Formulary; IU, international unit; i.v., intravenous; PSSRU, Personal Social
Services Research Unit; QDS, quater die sumendus; OD, omne die (once daily); TDS, ter die sumendum (three times a day).
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Results
Impact of extended prednisolone therapy on health-related quality of life
A total of 207 participants had been followed up to the 24-month primary end point, which was 92.8%
of the ITT study population. The proportion of the study population that returned the study questionnaires
at each time point gradually declined over the 24 months but did not fall below 90%, as shown in
Table 13. Complete items on the entire eight CHU-9D domains were required for the calculation of
the CHU-9D index score in older participants. The four PedsQL domain scores were also required for
indirect estimation of CHU-9D score for younger participants. After excluding missing items, 90% of the
participants within the study had a valid CHU-9D score at baseline. This proportion declined to 85% at
month 24. One hundred and sixty-eight (75.3%) participants had a valid CHU-9D index score at baseline,
at week 16 and at months 12 and 24.
Table 14 describes the mean utility value at each time point for each treatment group. It further classifies the
data into utility scores for participants aged ≥ 5 years (collected using the CHU-9D questionnaire), and for all
the participants in the study with a valid CHU-9D utility score – both mapped and direct CHU-9D utility
scores. The mean utility at week 4 (baseline) for all participants across all age groups was 0.9242. At baseline,
TABLE 13 Number of follow-ups, returned questionnaires and valid CHU-9D utility scores by data collection time
point for health-related quality-of-life instruments (PedsQL and CHU-9D)
Time point
Followed up,
n (%)
Followed up
and returned
questionnaire, n (%)
Valid CHU-9D
index score
calculated, n (%)
No valid CHU-9D index score
(as % of participants in treatment
group), n (%)
SC (N= 109) EC (N= 114)
Week 4 223 (100.0) 222 (99.6) 201 (90.1) 13 (11.9) 9 (7.9)
Week 16 215 (96.4) 211 (94.6) 199 (89.2) 12 (11.0) 12 (10.5)
Month 12 209 (93.7) 207 (92.8) 202 (90.6) 9 (8.3) 12 (10.5)
Month 24 207 (92.8) 203 (91.0) 190 (85.2) 13 (11.9) 20 (17.5)
Complete case – – 168 (75.3) 30 (27.5) 25 (21.9)
TABLE 14 Mean CHU-9D index score per participant follow-up time-point by treatment group
Time point
Group
Whole sampleSC EC
n Mean score (SD) n Mean score (SD) n Mean CHU-9D score (SD)
Direct CHU-9D estimation
Baseline (week 4) 42 0.9289 (0.0752) 58 0.9301 (0.0686) 101 0.9296 (0.0710)
Week 16 47 0.9394 (0.0665) 54 0.9353 (0.0984) 101 0.9372 (0.0846)
Month 12 56 0.9442 (0.0703) 63 0.9396 (0.0826) 119 0.9418 (0.0768)
Month 24 69 0.9341 (0.0784) 70 0.9548 (0.0666) 139 0.9445 (0.0732)
Direct and indirect CHU-9D estimation
Baseline 96 0.9231 (0.0675) 105 0.9252 (0.0656) 201 0.9242 (0.0664)
Week 16 97 0.9333 (0.0567) 102 0.9391 (0.0760) 199 0.9363 (0.0672)
Month 12 100 0.9383 (0.0639) 102 0.9425 (0.0688) 202 0.9405 (0.0663)
Month 24 96 0.9316 (0.0708) 94 0.9492 (0.0624) 190 0.9403 (0.0672)
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the mean utility for the SC group was 0.9231 compared with 0.9252 for the EC group. This baseline
difference was adjusted for within the main cost–utility analyses.78
Table 15 describes the unadjusted and the adjusted mean QALYs for each treatment group of the study.
Participants in the study were required to have been followed up for at least 24 months. At month 24,
the mean adjusted QALY difference between the groups was 0.0162 in favour of EC therapy; however,
this difference was not significant at the 5% level. The lack of significance was attributable to the way
the QALYs were calculated using the ‘area-under-the-curve’ method, which adjusts for imbalances in the
CHU-9D score at baseline (week 4).
Resource use and cost
Participants in the EC group had fewer hospital admissions than participants in the SC group, and
admissions were of shorter duration (Table 16). The average length of stay in the SC and EC groups over
24 months was 5.8 days and 2.5 days, respectively, which equates to a mean per-patient cost of £1539
and £691, respectively (Table 17). A breakdown of length of stay and cost from baseline to month 24 is
shown in Tables 26 and 27 in Appendix 4. In addition to having fewer hospital admissions, participants in
the EC group were also reported to have fewer hospital emergency visits than participants in the SC group
(see Table 16). This led to a per-patient mean cost saving of £411 over the 24 months (see Table 17). In
general, over the 24 months, participants in the EC group had fewer hospital outpatient visits than those
in the SC group, and this led to a per-patient mean cost saving of £382 (see Table 17). Tables 16 and 17
also outline the disaggregated mean (SD) number of primary care visits and the corresponding mean
per-patient cost by treatment group. Tables 28 and 29 in Appendix 4 show the hospital emergency visits
and hospital outpatient visits at each follow-up time point until month 24. Overall, participants in the EC
group had fewer primary care visits than participants in the SC group.
Reported figures are for participants who returned study questionnaire at all time points over the
24-month period.
TABLE 15 Mean CHU-9D score at each follow-up time point and mean QALY per participant over 24 months by
treatment group
Time point
Group
Bootstrapped difference
(95% CI)SC EC
Unimputed CHU-9D score, mean (SD)
Baseline 0.9231 (0.0675) 0.9252 (0.0656) 0.0020 (–0.0162 to 0.0203)
Week 16 0.9333 (0.0567) 0.9391 (0.0760) 0.0058 (–0.0130 to 0.0246)
Month 12 0.9383 (0.0639) 0.9425 (0.0688) 0.0042 (–0.0141 to 0.0225)
Month 24 0.9316 (0.0708) 0.9492 (0.0624) 0.0176 (–0.0016 to 0.0368)
Unadjusted QALY over 24 months, mean (SE) 1.7940 (0.0105) 1.8046 (0.0105) 0.0107 (–0.0183 to 0.0396)
Adjusted QALY over 24 months, mean (SE) 1.7901 (0.0094) 1.8027 (0.0095) 0.0125 (–0.0137 to 0.0388)
Imputed CHU-9D score, mean (SD)
Baseline 0.9228 (0.0640) 0.9258 (0.0632) 0.0031 (–0.0139 to 0.0200)
Week 16 0.9315 (0.0555) 0.9404 (0.0725) 0.0089 (–0.0083 to 0.0261)
Month 12 0.9393 (0.0614) 0.9429 (0.0652) 0.0036 (–0.0135 to 0.0208)
Month 24 0.9306 (0.0672) 0.9488 (0.0594) 0.0181 (0.0013 to 0.0349)
Unadjusted QALY over 24 months, mean (SE) 1.7906 (0.0085) 1.8072 (0.0083) 0.0166 (–0.0067 to 0.0398)
Adjusted QALY over 24 months, mean (SE) 1.7908 (0.0076) 1.8070 (0.0074) 0.0162 (–0.0047 to 0.0372)
Adjusted values have controlled for age, gender and baseline utility score.
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TABLE 16 Mean resource use per participant over 24 months
Resource use
Group
Bootstrapped difference
(95% CI)SC (n= 92) EC (n= 94)
Primary care, n, mean (SD)
GP visits 0.576 (1.030) 0.383 (0.893) –0.193 (–0.474 to 0.088)
Practice nurse visits 1.554 (6.716) 0.564 (1.535) –0.991 (–2.369 to 0.388)
Other primary care staff visit 0.065 (0.440) 0.011 (0.103) –0.055 (–0.148 to 0.039)
Secondary care, n, mean (SD)
Hospital admission bed-days 5.826 (28.682) 2.526 (5.307) –3.299 (–8.742 to 2.144)
Hospital emergency visits 0.630 (1.155) 0.319 (0.832) –0.311 (–0.594 to –0.029)
Hospital outpatient visits 7.120 (11.607) 5.383 (5.187) –1.737 (–4.243 to 0.770)
Medication, mean (SD)
Ciclosporin (number of days) 8.685 (51.922) 0.638 (6.189) –8.046 (–19.088 to 2.995)
Cyclophosphamide
(number of days)
14.380 (30.161) 9.883 (23.684) –4.497 (–12.972 to 3.977)
Levamisole (number of days) 11.935 (44.831) 13.234 (46.566) 1.299 (–10.991 to 13.589)
Mycophenolate mofetil
(number of days)
6.696 (31.042) 1.011 (9.799) –5.685 (–12.541 to 1.171)
Rituximab (number of days) 0.272 (2.204) 0.000 (0.000) –0.272 (–0.761 to 0.218)
Tacrolimus (number of days) 0.500 (2.956) 7.670 (46.942) 7.170 (–2.617 to 16.957)
Prednisolone (mg consumed) 3851.83 (2918.22) 4274.81 (3311.25) 422.988
(–499.172 to 1345.148)
TABLE 17 Mean per participant cost over 24 months by treatment group
Cost component
Group, mean cost (£) (SD)
Bootstrapped difference
(95% CI)SC (n= 92) EC (n= 94)
Primary care visits
GP 28.24 (50.47) 18.77 (43.79) –9.47 (–23.00 to 4.07)
Practice nurse 14.46 (62.46) 5.24 (14.28) –9.21 (–21.99 to 3.57)
Other primary care staff 0.49 (3.30) 0.08 (0.77) –0.41 (–1.11 to 0.30)
Secondary care
Hospital admission 1539.36 (7603.47) 691.13 (1308.60) –848.23 (–2253.65 to 557.20)
Hospital emergency 832.80 (1525.99) 421.60 (1099.49) –411.21 (–804.67 to –17.75)
Hospital outpatient 1566.30 (2553.53) 1184.26 (1141.15) –382.05 (–946.98 to 182.88)
Medications
Ciclosporin 14.76 (88.27) 1.09 (10.52) –13.68 (–32.21 to 4.85)
Cyclophosphamide 19.99 (41.92) 13.74 (32.92) –6.25 (–17.43 to 4.93)
Levamisole 4.44 (16.68) 4.92 (17.32) 0.48 (–4.01 to 5.06)
Mycophenolate mofetil 2.49 (11.56) 0.38 (3.64) –2.11 (–4.42 to 0.191)
Rituximab 31.64 (256.64) 0.00 (0.00) –31.64 (–82.07 to 18.80)
Tacrolimus 4.09 (24.19) 62.77 (384.17) 58.68 (–19.51 to 136.88)
Prednisolone 44.30 (33.56) 49.16 (38.08) 4.86 (–5.04 to 14.77)
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Extending the course of prednisolone over a longer duration meant that all participants in the EC group
incurred a higher prednisolone drug cost over 24 months. The bootstrapped cost difference in Table 17
shows that mean cost difference (mean £4.86; 95% CI –£5.04 to £14.77) between the treatment groups
was not significant. Ciclosporin, cyclophosphamide, levamisole, mycophenolate mofetil, rituximab and
tacrolimus were the second-line immunosuppressants used in the treatment pathway. Table 16 shows that
participants in the EC group were given levamisole and tacrolimus for longer than participants in the SC
group and, overall, across the 24-month follow-up period, the per-patient mean cost difference attributed
to just second-line immunosuppressant therapy was £11 lower in the SC group than in the EC group.
The mean cost for other prescribed medications was £50 lower in the EC group.
The per-patient total mean cost was made up of costs associated with prednisolone prescriptions, hospital
admissions, hospital outpatient visits, emergency visits, primary care visits, second-line immunosuppressants
and other prescribed medications. To account for missing data, multiple imputation (5000 iterations)
was applied at each follow-up time point. To estimate the difference in the per-patient total mean cost
between the two treatment groups, adjustments were made for age, gender and the baseline (week 4)
utility score. Over the 24-month study period, participants in the EC group incurred less cost than those in
the SC group, by an average of £1673 per patient (Table 18).
Cost–utility analysis
The incremental difference in costs was then offset against the difference in QALYs for the SC group
versus the EC group. The EC group dominated the SC group, which means that, on average, participants
incurred less cost and gained more QALYs. Cost–utility analysis combines the incremental costs with the
incremental QALYs to produce an ICER, or a cost per additional QALY gained. In this situation, as costs
were lower and QALYs gained higher, the mean ICER values were not calculated. The EC group was both
more effective and cheaper (Table 19).
TABLE 18 Mean incremental cost per participant over 24 months
Imputed cost
Group, mean cost (£) (SD)
Bootstrapped cost difference (95% CI)SC (n= 109) EC (n= 114)
Baseline 45.54 (121.89) 78.94 (202.20) 35.24 (–7.57 to 78.05)
Week 8 132.10 (391.97) 116.56 (458.72) –21.53 (–137.43 to 94.38)
Week 12 401.43 (1285.11) 56.54 (189.02) –361.14 (–610.11 to –112.16)
Week 16 235.45 (410.97) 73.74 (217.51) –162.19 (–247.61 to –76.77)
Month 5 301.15 (700.77) 265.89 (526.68) –38 (–204.59 to 128.59)
Month 6 193.07 (435.69) 255.04 (648.82) 63.86 (–91.67 to 219.38)
Month 8 398.85 (624.72) 255.98 (522.45) –139.29 (–289.89 to 11.32)
Month 10 887.64 (5827.01) 287.69 (519.73) –653.39 (–1758.95 to 452.17)
Month 12 239.91 (434.46) 258.11 (500.91) 32.65 (–91.40 to 156.70)
Month 18 791.95 (1558.03) 566.72 (880.52) –225.15 (–569.61 to 119.32)
Month 24 666.18 (2103.73) 466.64 (803.76) –235.16 (–649.90 to 179.59)
Total imputed cost over 24 months
Unadjusted, mean (SE) 4462.21 (748.13) 2607.51 (731.46) –1854.70 (–3959.44 to 250.03)
Adjusted, mean (SE) 4369.20 (748.13) 2696.43 (731.37) –1672.77 (–3455.06 to 109.53)
Values are means unless stated otherwise. Adjusted values have controlled for age and gender.
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Values are mean (SE) unless stated otherwise. QALYs have been adjusted for age, gender and baseline
utility value. Costs have been adjusted for age and gender. All costs are in Great British pounds (£).
Sensitivity analysis
To account for the uncertainty around the point estimates, an incremental cost-effectiveness plane and a
CEAC were constructed using the net monetary benefit approach. The plane (Figure 15) shows 5000
jointly bootstrapped cost–QALY difference pairs scattered across all four quadrants.
The majority of the points are in the south-east quadrant, indicating that the extended prednisolone course
was less expensive and more effective than the standard prednisolone course. The dashed line represents
the willingness-to-pay threshold of £20,000 per QALY and the solid line represents the willingness-to-pay
threshold of £30,000 per QALY. Points to the right of both lines indicate situations when the extended
prednisolone course is the preferred option, while points to the left indicate instances in which the SC is
recommended. Figure 16 shows that the probability of extended prednisolone course being cost-effective
is 98.8% and 99.9% at £20,000 and £30,000 per QALY, respectively.
The EC group remained dominant at 24 months when the analysis was restricted to participants with
complete cost and outcome data (Table 20). The main difference from the base-case analysis was the
smaller incremental cost at 24 months (£582 vs £1673 cost saving). Overall, the probability of EC being
cost-effective compared with SC, remained high, at 89%.
TABLE 19 Incremental cost and QALY per participant over 24 months
Imputed values
Group
Bootstrapped difference (95% CI)SC (n= 109) EC (n= 114)
Mean QALYs (SE) 1.7908 (0.0076) 1.8070 (0.0074) 0.0162 (–0.0047 to 0.0372)
Mean cost, £ (SE) 4369.20 (748.13) 2696.43 (731.37) –1672.77 (–3455.06 to 109.53)
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FIGURE 15 Cost–utility plane for the comparison of extended prednisolone therapy with standard prednisolone
therapy, based on 5000 bootstrapped cost–effect pairs.
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
58
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 5 10 15 20 25 30 35 40
Pr
o
b
ab
ili
ty
 t
h
at
 E
C
 is
 c
o
st
-e
ff
ec
ti
ve
Willingness to pay (£000/QALY)
FIGURE 16 Cost-utility acceptability curve comparing extended and standard prednisolone therapy, based on 5000
bootstrapped cost–effect pairs.
TABLE 20 Incremental cost and QALYs by age category, ethnicity, and completeness of data
Incremental costs and QALYs
Group, mean (SE)
Bootstrapped difference (95% CI)SC (n= 109) EC (n= 114)
Base case
QALYs 1.7908 (0.0076) 1.8070 (0.0074) 0.0162 (–0.0047 to 0.0372)
Cost (£) 4369.20 (748.13) 2696.43 (731.37) –1672.77 (–3455.06 to 109.53)
Complete case
QALYs 1.7931 (0.0098) 1.8022 (0.0010) 0.0091 (–0.0169 to 0.0350)
Cost (£) 3078.10 (362.24) 2495.61 (358.26) –582.49 (–156.12 to 379.40)
Ethnicity
South Asian
QALYs 1.7784 (0.0168) 1.8290 (0.0154) 0.0507 (–0.0073 to 0.0941)
Cost (£) 2713.04 (527.78) 1737.51 (484.10) –975.52 (–2227.23 to 497.65)
White
QALYs 1.7862 (0.0010) 1.7968 (0.0095) 0.0106 (–0.0147 to 0.0359)
Cost (£) 3724.13 (376.31) 3024.11 (362.57) –700.02 (–1576.34 to 553.46)
Other
QALYs 1.8088 (0.0160) 1.8117 (0.0161) 0.0029 (–0.0402 to 0.0460)
Cost (£) 12,235.10 (4816.98) 4494.64 (4847.47) –7740.48 (–19,198.18 to 4017.14)
Age (years)
≤ 5
QALYs 1.7982 (0.0128) 1.8138 (0.0122) 0.0156 (–0.0073 to 0.0386)
Cost (£) 2381.26 (1621.93) 377.27 (1546.25) –2003.99 (–4235.41 to 427.12)
≥ 6
QALYs 1.7627 (0.0204) 1.7779 (0.0211) 0.0152 (–0.0253 to 0.0557)
Cost (£) 3534.97 (757.87) 2690.46 (783.96) –844.50 (–2400.28 to 629.32)
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Subgroup analysis
Participants from South Asian backgrounds had the highest QALY gains (see Table 20). Although the
mean cost of the EC group was highest for the ‘other’ ethnicities category (non-white and non-South
Asian), the intervention was associated with a considerable cost saving for this group. This group were also
least likely to gain QALYs from extended prednisolone treatment.
The base-case result was robust to subgroup analysis according to age group, with the extended
prednisolone therapy group retaining its dominance in participants who were ≤ 5 years at baseline
and in older participants. It was cheaper and more effective to treat the younger age group than older
participants, thereby making this population the more beneficial group to treat actively with extended
prednisolone course.
ECONOMIC EVALUATION
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Chapter 7 Discussion
The PREDNOS study has not shown any clinical benefit for a 16-week EC of prednisolone comparedwith the 8-week SC as described by the ISKDC in UK children presenting with SSNS. There was no
significant difference between the two treatment groups in time to first relapse of nephrotic syndrome or
in any other of the clinically important secondary end points, including the number of relapses experienced,
the proportion of participants who went on to develop FRNS or SDNS or the requirement for alternative
non-corticosteroid immunosuppressive therapies. However, despite showing no clinical benefit, the
cost-effectiveness analysis suggested that EC therapy may be cheaper, with the possibility of a small
QALY benefit.
These findings differ from the six studies published prior to the commencement of the PREDNOS
study, which had compared the ISKDC regimen with prednisolone regimens of > 3 months’ duration.
A Cochrane review29 of these studies performed in 2005 showed a benefit of longer-course prednisolone
therapy, with a lower rate of relapse at 12–24 months, and a significant reduction in the number of
children with FRNS. Based upon this, a recommendation was made that children presenting with SSNS
should be treated with a minimum of 3 months of prednisolone therapy. This did not, however, lead to
international consensus, and significant clinical equipoise and variation in practice persisted.
More recent studies have reported results that are consistent with PREDNOS. A Japanese study of
255 participants that compared the ISKDC regimen with a 6-month course of prednisolone found no
benefit associated with longer-duration prednisolone therapy.36 Yoshikawa et al.36 chose a primary end
point of time to the development of FRNS, a clinically important end point identifying those children who
have developed a complicated disease course and who are likely to develop disease- and treatment-related
morbidity and, therefore, require alternative, more potent, immunosuppressive therapies. There was no
difference in FRNS, and the time to first relapse and the incidence of adverse effects were also similar in
the two groups. An Indian study comparing 3 and 6 months of prednisolone did not show any benefit
associated with increased duration of prednisolone,35 and neither did the Dutch study by Teeninga et al.,33
which also compared 3 and 6 months of therapy. The inclusion of three well-designed studies in a 2015
update of the Cochrane review13 resulted in a change in the overall conclusions. It was noted that these
studies of longer versus shorter duration of corticosteroids had heterogeneous treatment effects, with the
older, higher risk of bias studies tending to overestimate the effect of longer-course therapy compared
with the more recently published, lower risk of bias studies. Among studies at low risk of bias, there was
no significant difference in the risk of FRNS between participants given prednisone for 2 or 3 months
and those receiving therapy of longer duration or higher total dose, indicating that there is no benefit of
increasing the duration of prednisone beyond 2 or 3 months in the initial episode of SSNS. However, when
the meta-analysis was restricted to those addressing the same question as the PREDNOS study, comparing
the 8-week ISKDC regimen with regimens of ≥ 3 months (i.e. adding the study of Yoshikawa et al.36 to the
six studies reported in the original Cochrane review), there remained a benefit for the longer (≥ 3 months)
treatment regimen, although this only just reached statistical significance. The risk of FRNS was significantly
lower (RR 0.68, 95% CI 0.47 to 1.00), as was the number of participants relapsing by 12–24 months
(RR 0.8, 95% CI 0.64 to 1.00). It is likely that once the results of the PREDNOS study are added to the
Cochrane review that the overall result will show no difference in outcome between the ISKDC and longer
treatment regimens.
The data reported in our study are similar to those reported in previous studies. The proportion of
participants experiencing a relapse was 80.3% (179/223) over a median follow-up of 37 months, which is
comparable to the rate of 60–90% reported in the literature.13,87 Teeninga et al.33 reported a relapse rate
of 78.6% (99/126) in a European population with a median follow-up of 47 months, with a median time
to first relapse of 6 months for the 3-month prednisolone group and 8 months for the 6-month group.
Sinha et al.35 reported a lower relapse rate of 57.8% (104/180); however, participants were followed up
for only 12 months. In the Japanese study, the overall relapse rate was not stated; however, the median
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time to relapse was 242 days and 243 days in the 2-month and 6-month groups, respectively, significantly
longer than the 87 days for the SC group and 139 days for EC group observed in the PREDNOS study.
It is noteworthy that Yoshikawa et al. used urine dipstick values of ++ or higher as their definition of relapse,
although, if anything, this would have overdiagnosed relapse and reduced the time to first relapse.36
We also found rates of FRNS similar (50% and 53%) to those previously reported. Using the same ISKDC
definition as used in PREDNOS, Sinha et al.35 reported a rate of FRNS at last follow-up of 50.4% in the
6-month group and 60.4% in the 3-month group. The time to FRNS was 23.0 months and 17.6 months,
respectively. Teeninga et al.33 reported FRNS in 45% of the 3-month prednisolone group and in 50% of the
6-month prednisolone group, commenting that this was higher than expected. In previous studies, FRNS
has been reported in 32–78% of participants who received a 2-month course of prednisolone15,19–21,47,88 and
in 18–44% of those who received prednisolone for 3 months.20,26,47 It has been proposed that this variation
may, in part, be explained by regional differences or variations in definitions of FRNS, length of observation
and relapse treatments.
Interestingly, although we found no clinical benefit for the EC prednisolone treatment regimen, we did
find that this regimen was cheaper and more effective in QALY terms. The cost analysis showed that,
over a 24-month period, the EC treatment regimen cost less because of a lower rate of hospital admission,
a shorter duration of hospital stay, fewer hospital emergency visits and fewer outpatient and primary
care visits; therefore, on average, it was cheaper than the SC treatment regimen by £1673 per patient.
Furthermore, the EC treatment regimen produced more QALYs than the SC treatment regimen. Using
commonly applied threshold values for how much society is willing to pay for a QALY gain, the EC
treatment regimen is cost-effective. At first glance, this result may seem surprising, as the clinical outcomes
have shown little or no benefit of extending prednisolone treatment, yet the heath economics reveals
possible evidence of cost-effectiveness. These differences, in part, relate to the differences in cost and
QALYs, but also to the different methods of analysis adopted in the health economic and clinical
evaluations.
Unlike the objectives of the clinical evaluation, which are about testing whether or not extending
prednisolone therapy leads to an improved patient outcome relative to a control group, the objectives
of the economic evaluation are to provide an estimation of the value of the extended therapy reflecting
both efficiency and equity, and, thus, an estimate of whether or not the difference in cost between
the treatment groups is worth the difference in effect, taking into account the opportunity cost of
that investment and the fact that the resources could have been invested elsewhere across all parts of
the NHS.
The key thing to note is that small insignificant clinical benefits can be cost-effective. The health
economics focus is about comparing two things: costs and effects. For the health economic analysis,
the effects are measured using QALYs, which reflect societal values and incorporate preferences for
domains of QoL. These values are measured using preference-based QoL instruments, for example the
CHU-9D questionnaire that was used in this study. Measuring cost differences between different treatment
therapies has no meaning until these are offset against differences in effects: it is the simultaneous
consideration of costs and effects and, therefore, the joint density of cost and effect differences76 that is
the focus of a health economic evaluation.
Within the PREDNOS study, the clinical analysis quantified the difference in time to first relapse, at the individual
participant level, using statistical inference. The economic analysis compared the per-participant cost of EC
versus SC therapy, and found that the cost was, on average, £1673 lower in the EC group, and the QALYs
gained were, on average, 0.0162 higher in the EC group. When the costs and QALY differences are assessed
separately, these differences are not statistically significant; however, when assessed simultaneously, the ICER
(the ratio of the mean cost and the mean QALY difference) produces a cost-effective result, as the EC regimen
is cheaper and produces more QALYs, on average. Therefore, it is dominant, as it is not only more effective in
QALY terms but also saves health-care resources, relative to the SC group.
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Furthermore, there are different methods within the health economic analysis for representing the
uncertainty in the cost and QALY differences. QALYs and cost data tend to have unusual distributional
properties and are often skewed, exhibiting ceiling effects or having a bimodal distribution; for this reason,
the stochastic bootstrapping method was applied. Bootstrapping generates multiple samples of joint cost
and effect estimates from the same trial data, and these cost and effect pairs are then represented on a
scatterplot on an incremental cost-effectiveness plane. Figure 15 in Chapter 6 presents the bootstrapped
cost and QALY pairs from the PREDNOS study. It shows that most of the pairs lie in the south-east
quadrant, indicating that there are cost-savings and QALY gains from the extended therapy versus the
standard therapy; however, there are some points spread within the north-east quadrant (indicating that
the extended therapy is more costly) and the south-west quadrant (indicating that the extended therapy
leads to a QALY loss). This reflects some uncertainty regarding the cost savings and QALY gains to be
achieved from extended therapy compared with standard therapy, which is consistent with the finding
of a non-significant difference for both costs and effects, when considered independently, between the
two treatment groups.
To account for the uncertainty in the cost and effect pairs, the proportions of points falling above and
below a willingness-to-pay threshold line are simply counted and then the threshold line is varied to
produce a CEAC. CEACs are regarded as an alternative method of calculating CIs and indicate the
probability that the extended therapy is cost-effective, compared with standard therapy, for different
threshold values of willingness to pay for a QALY gain. Using the PREDNOS trial data, the probability that
the extended therapy is cost-effective, at the commonly applied threshold value of £20,000 per QALY,
is 0.988. Therefore, despite there being no statistically significant differences in costs and effects for
extended therapy compared with standard therapy, the CEAC shows that there is very little uncertainty,
from a cost-effectiveness perspective, about the choice to treat patients with EC therapy compared with
SC therapy. It is also worth noting that, regardless of benefit measured in QALYs, parents and children
value avoidance of hospital admission. This is also valued by clinicians and reduces demand pressures
on the NHS.
Previous studies have been somewhat inconsistent in their reporting of the adverse effects associated with
using corticosteroids; however, the most recent (2015) Cochrane review13 found no significant differences
in the risk of adverse events between extended duration and 2 or 3 months of prednisolone. We found
no differences in the adverse effect profiles between the two treatment groups, with the exception of
parentally reported poor behaviour, which was significantly more common in the SC group. At 24 months,
the cumulative incidence of poor behaviour was 93% in the SC group, compared with 82% in the EC
group (RR 0.90, 95% CI 0.82 to 0.98). There was no difference in the incidence of any other adverse
effects including Cushingoid facies, striae, hypertrichosis, acne, increased appetite, glycosuria, cataract
and abdominal pain. These findings are broadly comparable with those of multiple other larger-36 and
smaller-scale20,21,23,25 trials addressing this same clinical question. The large majority of these have found no
significant difference in the incidence of adverse effects; however, there was significant heterogeneity in
the extent to which these were monitored. Most adverse events were transient and occurred relatively
early on during the course of treatment, when the prednisolone dose was at its highest.
We were particularly interested in the impact that the two prednisolone regimens had on behaviour,
as expert clinical opinion and advice from our patient and public involvement group indicated that this
was the adverse effect of greatest prevalence and significance to families. When the PREDNOS study was
designed, no previous study had objectively and systematically investigated this using a quantitative
measure. In PREDNOS, we collected quantitative data on behaviour using the ACBC. Although parentally
reported poor behaviour was significantly more common in the SC group, when behaviour was assessed
objectively through the ACBC questionnaire completed by the parents, there was no significant difference
in either the total behaviour score or t-score. The proportion of participants assessed as having abnormal
behaviour by the ACBC was also not different between the two groups and varied between 21% and
31% at different time points throughout the study. The proportion of participants whose parents reported
poor behaviour was higher than the proportion whose scores were outside the normal ACBC range.
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This provides some reassurance to parents that perceived poor behaviour is generally within normal
bounds and is not greatly impacted by corticosteroid treatment, a finding of relevance in other paediatric
conditions treated with corticosteroids. Teeninga et al.33 assessed behaviour using visual analogue scales.
Compared with baseline, participants scored significantly higher on eating, overactive behaviour and
aggressive behaviour at 3 months’ follow-up (p < 0.01); however, these scores returned to baseline within
1 year in both groups. Scores for happiness temporarily dropped in the first 6 months, while scores for
sleeping remained relatively stable over the entire observation period.
Subgroup analyses showed that there was no clear evidence to suggest that the treatment effect differed
according to ethnicity, age or gender, although we were not powered to detect differences in subgroups.
For age, there may be some suggestion that the time to first relapse was extended in those in the EC
group in participants aged ≤ 5 years, with no difference between the two groups in participants aged
≥ 6 years. This remains a topic of some debate, as a number of studies have reported young age at diagnosis
to be associated with an increased risk of FRNS and/or corticosteroid dependence,8,16,47,89 whereas others
have not reported this association.12,90,91 In a post hoc analysis of Sinha et al.’s study,40 Cox regression
suggested that participants aged ≤ 3 years benefited from prolonged therapy, with a reduction in the
risk of a first relapse, but not of frequent relapses, and Poisson regression confirmed a higher relative relapse
rate in younger participants. Other reports have strongly argued that age may be a predictor of disease
severity, including FRNS, corticosteroid dependence and response to cyclophosphamide therapy.92,93 A few
non-randomised studies have investigated the role of gender in the disease course and have reported males
to be at a disadvantage.16,47 Cox regression analysis in the study of Teeninga et al.33 did not identify boys
as being at significantly greater risk of developing FRNS. We found also no evidence of a difference in
treatment effect according to gender.
Systolic and diastolic blood pressure z-scores were similar in both treatment groups throughout the course
of the study. z-scores were relatively high at the time of the week 4 visit, presumably as a result of the
high dose of prednisolone being administered at this point. However, the z-scores decreased progressively
during study follow-up. These observations are entirely consistent with the findings of other similar studies.
Interestingly, over the course of the study, following an initial slight fall during the first 16 weeks, the
height z-scores increased in both treatment groups. This is an interesting observation, given the fact that
these participants received multiple courses of prednisolone for treatment of relapses, a treatment that is
known to have a negative impact on linear growth. Previous studies have also reported a fall in height
velocity during the first few months of high-dose prednisolone treatment, with a subsequent return to
baseline by 12 months.33 Others have described a dose-dependent effect of corticosteroids on growth in
children with SSNS.94–96 A small number of studies have noted the baseline height SDS to be relatively
low in children presenting with SSNS, although no satisfactory explanation has been found for this
observation.33,97 We did not observe this in PREDNOS study. Weight z-scores were relatively constant
throughout the study, and BMI z-scores decreased over time.
The main strength of the PREDNOS study is its randomised, double-blind, placebo-controlled design.
This ensured a low risk of selection, performance, detection and selective reporting bias. Inclusion criteria
were defined to ensure that the study population was representative of the population of children
presenting with SSNS in the UK. Outcomes were assessed using internationally accepted ISKDC definitions.
Our primary outcome measure of time to first relapse was felt by UK clinicians to be of clinical importance,
and previous studies88 have shown a link between timing of first relapse and subsequent clinical course.
Baseline features were well balanced and there was a low rate of attrition. Regular safety assessment was
ensured through regular clinical review. Prior to the commencement of PREDNOS, previous studies had
been small (largest 184 participants) and no previous double-blind placebo controlled RCTs had ever
been conducted in children with SSNS. PREDNOS successfully recruited 237 participants from 124 sites
throughout all regions of the UK into a double-blind, placebo-controlled RCT. Since then, the studies of
both Teeninga et al.33 and Sinha et al.35 were double-blinded, although one further study comparing the
ISKDC regimen with longer duration therapy was not blinded.36 The authors acknowledged that this
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may have introduced preconception bias; however, they proposed that because their design was a
non-inferiority trial with regular visits and with relapses being measured objectively, they could not assume
positive placebo effects. It must be remembered that this would not have been the case with the reporting
of AEs, for which there is considerable scope for bias.
The sample size calculations for the study were based on detecting an absolute difference of 20% in
relapse rate at 1 year from 60% in the SC group to 40% in the EC group using a log-rank test (80%
power, α = 0.05). The 1-year relapse rate observed in the SC group was 77%. This means that the study
has > 85% power to detect an absolute difference of 20% between groups (i.e. from 77% to 57%) using
a log-rank test. This makes the likelihood of our results being the result of a type 2 statistical error small.
An additional strength of the PREDNOS study is the generalisability of its findings. We recruited
participants with a first presentation of INS from across the UK with broad inclusion criteria. We selected
an age range of 1–14 years as this is the range in which the large majority of patients present and are
treated empirically with a course of corticosteroids without recourse to renal biopsy. One of the key
purposes of the PREDNOS study was to ascertain the optimal prednisolone treatment regimen for UK
children by comparing the 8-week SC ISKDC regimen with a longer 16-week EC regimen. We chose the
ISKDC SC regimen for one group because this was the regimen in use in the very large majority of UK
centres at the time of the planning of the PREDNOS study and chose a 16-week EC regimen as a
comparator because longer duration treatment regimens have previously been shown to result in lower
rates of relapse and FRNS. The ethnic mix of the study population broadly represented that of the wider
population of children with nephrotic syndrome, including significant representation from the South
Asian community. We recruited 44 participants (20% of the study population) from families of South Asian
origin and 31 (14%) from families recorded as other non-white ethnic origin. This is a very similar figure to
that reported in the study of Teeninga et al.,33 which included 35% of participants of non-Western
European descent. This is an important achievement, as the UK South Asian community in particular is
significantly over-represented in the SSNS population, the incidence being around six times greater than in
the UK white population. Furthermore, the UK South Asian population is generally under-represented in
clinical trials and recruitment poses a number of particular challenges.98 Finally, although formal screening
logs were requested, in keeping with other studies these were not kept well; however, based on known
epidemiological data, we estimate that we have managed to include 34% of newly presenting patients
over a recruitment period of 3 years and 2 months. This indicates a high level of acceptability of the trial
among both families and clinicians.
One of the greatest challenges in setting up the PREDNOS study was facilitating the recruitment of
participants in district general hospitals. Children with INS have traditionally been, and continue to be,
investigated and managed within district general hospitals rather than tertiary paediatric nephrology
centres. Referral to tertiary centres generally takes place only if the presenting features are atypical or
when investigation or management proves problematic. For this reason, any study that recruited solely
from tertiary centres would not reach the large majority of potential participants and would risk sampling
a preselected, somewhat atypical group of participants. In the early 2000s, when the PREDNOS study was
being planned, there was little paediatric experience in the conduct of RCTs involving an investigational
medicinal product and little funded infrastructure to support this work. Our Kidney Research UK and Kids
Kidney Research jointly funded pilot study confirmed that there was great willingness among principal
investigators to participate in the study and similar interest in the study from participants from both the
white and South Asian communities. The pilot study allowed the trial design and infrastructure to be
tested, including aspects such as the provision of study medication from a single national clinical trials
pharmacy with delivery direct to the participant, attendance rates for study visits and the completion of
questionnaires and the study case report forms. The success of the pilot study was significantly enhanced
by the development of the NIHR Clinical Research Network: Children (formerly the NIHR MCRN), which
commenced operating in 2005.99 The PREDNOS pilot study was one of the first studies to be adopted
onto the MCRN study portfolio and the infrastructure put in place facilitated study set-up and participant
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recruitment in many sites. The main PREDNOS study was also adopted onto the study portfolio and
similarly benefited.
Possible weaknesses of the study include the possibility that the choice and preparation of study drug
might have influenced the age profile of the population under study, with a potential trend towards the
relative overinclusion of older participants. Because the PREDNOS study drug was supplied in crushable
tablet form rather than in suspension or in a soluble or dispersible form, this may have resulted in
younger children not participating in the study because of inability or perceived inability to swallow the
crushed tablets. The initial ISKDC studies reported that the median age at presentation of MCD nephrotic
syndrome was 3 years,2 and a UK series from the county of Yorkshire reported the incidence to be greatest
in the 1–4 years age group.1 The mean age of participants in our study was 4.9 years, with 65% of
the study participants being < 6 years of age. This rather suggests that there was a trend towards the
recruitment of slightly older participants, perhaps as a result of this study medication formulation issue.
However, our study participant age profile is broadly comparable to those reported in the three most
recent RCTs of corticosteroid therapy in SSNS by Teeninga et al.33 (median age 4.2 years, IQR 3.2 to
6.2 years), Yoshikawa et al.36 (mean age 6.7 years, SD 4.1 years, in the SC group and mean age 6.3 years,
SD 4.1 years, in the EC group) and Sinha et al.35 (median 42.4 months in 3-month treatment group and
median 44.2 months in the 6-month treatment group).
The parents of two participants recruited at the chief investigator’s site commented that they felt that they
knew which group their child had been randomised to because their child had noticed slight differences in
taste between the active prednisolone and placebo tablets. Prednisolone and other oral corticosteroids
tend to have a somewhat bitter taste and it may be that other study participants noticed this same
phenomenon. This was not, however, reported by other principal investigators and, therefore, it seems
unlikely that this would have had a significant impact on the study results.
One further potential minor limitation is the fact that study participants were, in the majority of cases,
observed and treated at their local hospital, where the study visits took place. As such, observation and
scoring of adverse effects in the study was performed by multiple observers. To avoid this issue would have
meant that all study participants would have had to travel to a single or small number of centres, which
would have proved a very significant barrier to participation. Randomisation was not minimised by centre,
as individual centre contributions were difficult to predict.
In designing the study, we wanted to ensure that we objectively and comprehensively collected
prednisolone-related AEs to adequately compare the two treatment regimens. Earlier studies lacked
consistency in the level of information that was recorded and none reported quantitative data regarding
behavioural change. Our adverse event reporting was, however, somewhat less comprehensive than that
of some more recent studies and this warrants some further discussion. Yoshikawa et al.36 performed
formal ophthalmological assessment, including measurement of intraocular pressure, which was found to
be elevated in 32 out of 246 participants (13%).36 In the study of Teeninga et al.,33 participants underwent
formal ophthalmological assessment at diagnosis and after 6 months, specifically looking for evidence of
cataract and glaucoma.33 No cases of glaucoma were detected and only one single case of posterior
subcapsular cataract was detected in the 3-month prednisolone group. In the PREDNOS study, we did not
ask for participants to have a formal ophthalmological review, although principal investigators screened
participants for cataract on an annual basis. Only one case of cataract was detected in each group,
a similar frequency to the single case in the study of Sinha et al.35 On the basis of their observations,
Teeninga et al.33 commented that cataract and glaucoma have been reported with much greater frequency
in cohorts of Japanese children than those from other races and that their findings indicate that routine
ophthalmological screening was not indicated at an early stage in Dutch children.
Yoshikawa et al. additionally performed regular blood tests and detected minor abnormalities of liver function
tests and plasma amylase in up to 21% of participants.36 We elected not to perform regular blood tests as
part of the study protocol, principally because this is not routine clinical practice in the UK; children with SSNS
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generally have very few blood tests performed unless they are commenced on alternative immunosuppressive
therapies mandating monitoring of drug levels or adverse effects. Furthermore, we were of the opinion
that the introduction of regular blood tests into the study protocol would have a negative impact on study
participation. We did include a single episode of blood sampling for the purpose of collecting deoxyribonucleic
(DNA) samples for a separate study aiming to identify potential genetic changes associated with SSNS.
A recommendation was made that this be performed at the time of venepuncture for other clinical reasons
if this occurred, although our Research Ethics Committee approval permitted us to perform a standalone
venepuncture solely for this sample. Sampling was successfully performed in 173 study participants.
In the study by Teeninga et al.33 of Dutch children, lumbar spine bone mineral density was measured
using dual-energy X-ray absorptiometry (DEXA) at baseline and after 6 months. We did not perform this
investigation, principally because there is little in the published literature that indicates that significant
abnormality of bone mineral density is likely to occur within the first 24 months of treatment, particularly
in an unselected cohort of newly presenting SSNS patients. Although our own work has reported a minor
reduction in trabecular bone mineral density in adult ‘survivors’ of childhood relapsing nephrotic syndrome,
such changes required the use of peripheral quantitative computerised tomography, which is not widely
available and would not have been detected using DEXA alone.100 Many of the district general hospitals
participating in PREDNOS would have also experienced difficulties in providing DEXA services for paediatric
study participants. Furthermore, a high-quality prospective study examined 60 children with INS and 195
control children and found no deficits in spine or whole body bone mineral content.101 In the study of
Teeninga et al., no difference was detected in bone mineral density from baseline to 6 months in either
group, and they were not able to achieve bone assessment in all participants.33
Conclusion
On the basis of the results of the PREDNOS study, it can be concluded that extending the duration of
prednisolone beyond the 2-month ISKDC regimen that is currently being used in the large majority of UK
centres does not result in a reduction in the time to first relapse, the number of participants developing
FRNS or SDNS or the total dose of prednisolone administered. There were no differences between the two
treatment regimens in the incidence of corticosteroid AEs. The cost-effectiveness analysis suggested that
EC therapy may be cheaper, with the possibility of a small QALY benefit.
Future research recommendations
Our results, although not adequately powered to show a difference, suggest that children presenting with
SSNS at < 6 years of age may benefit from receiving EC therapy, and this requires further investigation.
This observation has previously been reported in other RCTs35 and is currently being investigated in an
Indian trial that is ongoing (Professor Arvind Bagga, All India Institute of Medical Sciences, 2017, personal
communication). This is of particular importance given that younger children appear to be at increased risk
of FRNS and SDNS.21,35,90,91
The lack of benefit of EC compared with SC therapy raises the issue of whether or not further studies
should investigate if it is safe and efficacious to use even shorter corticosteroid regimens. This strategy
has only once been previously addressed in a RCT, which showed the relapse rate and incidence of FRNS
to be higher in those who received shorter course rather than SC therapy. However, like many of the
earlier studies in this disease group, this was at significant risk of a number of areas of trial bias.19 Finally,
the disparate results between the health economic analysis and the clinical analysis requires further
evaluation; the difficult question here is whether or not further RCTs comparing SC and EC are justified
given the clear lack of clinical benefit.
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Site recruitment
Site name
Date
Number of
participants
randomisedSite opened
First participant
randomised
Last participant
randomised
Addenbrooke’s Hospital,
Cambridge
27 October 2011 14 October 2013 14 October 2013 1
Airedale General Hospital, Keighley 30 November 2011 16 January 2014 16 January 2014 1
Alder Hey Children’s Hospital,
Liverpool
18 July 2011 22 August 2011 24 September 2014 10
Alexandra Hospital, Redditch 5 September 2013 – – 0
Altnagelvin Area Hospital, Derry 3 September 2012 – – 0
Arrowe Park Hospital, Wirral 19 July 2011 28 November 2011 28 November 2011 1
Barnsley District General Hospital 19 August 2011 25 August 2011 25 August 2011 1
Basildon Hospital 18 October 2011 – – 0
Bassetlaw Hospital 9 August 2011 – – 0
Birmingham Children’s Hospital 28 July 2011 2 December 2011 2 April 2014 5
Bradford Royal Infirmary 25 August 2011 7 September 2011 20 May 2013 5
Bristol Royal Hospital for Children 16 September 2011 10 October 2011 28 January 2014 8
Calderdale Royal Hospital 18 July 2012 12 February 2014 12 February 2014 1
Chesterfield Royal Hospital 26 July 2011 – – 0
City General Hospital, Stoke on
Trent
21 July 2011 2 August 2011 25 July 2013 2
Colchester General Hospital 10 February 2012 1 March 2012 3 April 2013 2
Countess of Chester Hospital 29 June 2011 27 October 2011 28 August 2014 3
Craigavon Area Hospital 18 April 2012 11 August 2014 11 August 2014 1
Crosshouse Hospital, Kilmarnock 23 January 2012 – – 0
Croydon University Hospital 11 December 2013 – – 0
Cumberland Infirmary 22 January 2013 – – 0
Darent Valley Hospital 12 December 2013 – – 0
Darlington Memorial Hospital 27 March 2013 – – 0
Derriford Hospital, Plymouth 17 October 2011 20 October 2011 24 September 2014 2
Dewsbury and District Hospital 18 October 2011 29 May 2013 15 January 2014 2
Diana, Princess of Wales Hospital,
Grimsby
14 November 2012 18 December 2013 8 July 2014 2
Doncaster Royal Infirmary 9 August 2011 11 June 2012 11 June 2012 1
Dorset County Hospital 30 June 2011 6 January 2014 6 January 2014 1
Dumfries & Galloway Royal
Infirmary
30 November 2011 – – 0
Epsom Hospital 24 May 2013 – – 0
Evelina Children’s Hospital, London 2 November 2011 4 June 2013 13 June 2014 3
Forth Park Hospital 30 November 2011 18 June 2014 16 September 2014 2
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Site name
Date
Number of
participants
randomisedSite opened
First participant
randomised
Last participant
randomised
Forth Valley Royal Hospital 10 August 2011 – – 0
Furness General Hospital 27 October 2011 – – 0
Glan Clwyd Hospital, Rhyl 6 July 2012 17 January 2013 21 May 2014 3
Gloucestershire Royal Hospital 29 July 2011 29 January 2013 10 June 2014 6
Great Ormond Street Hospital,
London
6 December 2011 21 May 2012 21 May 2012 1
Great Western Hospital, Swindon 16 August 2012 21 October 2013 21 October 2013 1
Harrogate District Hospital 17 July 2013 – – 0
Hereford County Hospital 17 October 2011 29 November 2011 29 November 2011 1
Homerton University Hospital,
London
11 November 2011 8 October 2012 25 March 2014 2
Huddersfield Royal Infirmary 27 April 2012 – – 0
Hull Royal Infirmary 9 December 2011 16 May 2012 16 May 2012 1
John Radcliffe Hospital, Oxford 6 February 2012 11 April 2012 30 October 2013 4
Kettering General Hospital 7 October 2011 14 August 2012 8 September 2014 4
King’s Mill Hospital, Mansfield 11 November 2011 31 May 2012 31 May 2012 1
Kingston Hospital 5 September 2014 – – 0
Leeds General Infirmary 25 January 2012 7 November 2012 2 September 2013 3
Leicester Royal Infirmary 1 July 2011 23 August 2011 29 July 2014 16
Leighton Hospital 16 December 2011 – – 0
Lincoln County Hospital 4 July 2012 20 November 2012 20 November 2012 1
Lister Hospital, Stevenage 2 June 2014 – – 0
Luton & Dunstable Hospital 26 August 2011 14 December 2011 25 February 2013 2
Macclesfield District General
Hospital
5 October 2011 – – 0
Maidstone Hospital 10 August 2012 11 September 2012 15 May 2014 3
Medway Maritime Hospital,
Gillingham
2 May 2014 – – 0
Morriston Hospital, Swansea 14 May 2013 15 May 2013 15 May 2013 1
Musgrove Park Hospital, Taunton 27 July 2011 16 April 2012 16 April 2012 1
New Cross Hospital,
Wolverhampton
27 April 2012 21 May 2012 28 June 2012 2
Newham University Hospital,
London
28 August 2012 10 May 2013 12 July 2013 3
Norfolk and Norwich University
Hospital
7 July 2011 17 December 2012 5 June 2013 3
North Devon District Hospital 7 August 2012 21 June 2013 21 June 2013 1
North Manchester General Hospital 5 March 2012 17 September 2012 17 September 2012 1
Northampton General Hospital 30 May 2012 10 September 2012 10 September 2012 1
Nottingham Children’s Hospital 2 August 2011 5 October 2011 25 June 2014 9
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Site name
Date
Number of
participants
randomisedSite opened
First participant
randomised
Last participant
randomised
Ormskirk & District General
Hospital
14 June 2012 – – 0
Peterborough District Hospital 8 September 2011 26 March 2012 26 March 2012 1
Pilgrim Hospital, Boston 12 July 2012 3 September 2012 1 September 2014 3
Pinderfields General Hospital,
Wakefield
18 October 2011 26 March 2013 26 March 2013 1
Poole Hospital 18 March 2013 4 October 2013 9 July 2014 2
Princess Royal Hospital, Kent 18 October 2011 – – 0
Queen Alexandra Hospital,
Portsmouth
24 April 2012 21 November 2013 20 May 2014 3
Queen Elizabeth Hospital, King’s
Lynn
11 January 2012 27 May 2014 27 May 2014 1
Queen’s Hospital, Burton 26 July 2011 15 July 2013 15 July 2013 1
Raigmore Hospital 12 March 2012 – – 0
Rotherham General Hospital 4 October 2011 9 February 2012 9 February 2012 1
Royal Aberdeen Children’s Hospital 8 February 2013 – – 0
Royal Albert Edward Infirmary,
Wigan
6 March 2012 25 May 2012 25 September 2014 2
Royal Alexandra Hospital, Paisley 29 May 2012 26 June 6012 26 June 6012 1
Royal Belfast Hospital for Sick
Children
12 August 2013 16 September 2013 23 September 2014 4
Royal Berkshire Hospital 1 December 2011 8 August 2013 14 April 2013 3
Royal Blackburn Hospital 2 August 2011 16 March 2012 11 January 2013 5
Royal Cornwall Hospital, Treliske 2 February 2012 4 April 2013 4 April 2013 1
Royal Derby Hospital 7 November 2011 26 February 2014 15 July 2014 3
Royal Devon & Exeter Hospital,
Wonford
26 July 2011 7 May 2014 7 May 2014 1
Royal Hospital For Sick Children,
Edinburgh
23 May 2012 18 February 2013 27 March 2013 2
Royal Hospital For Sick Children,
Glasgow
15 December 2011 28 June 2012 30 June 2014 7
Royal Lancaster Infirmary 1 March 2012 3 April 2012 28 August 2014 2
Royal Manchester Children’s
Hospital
28 June 2011 23 February 2012 8 October 2014 19
Royal Oldham Hospital 8 March 2012 12 November 2012 25 September 2013 2
Royal Preston Hospital 28 March 2012 – – 0
Royal Shrewsbury Hospital 18 October 2011 – – 0
Royal United Hospital, Bath 7 July 2011 16 August 2012 16 August 2012 1
Russells Hall Hospital, Dudley 5 September 2011 3 December 2012 16 April 2013 2
Scarborough Hospital 7 February 2013 19 March 2013 19 March 2013 1
Sheffield Children’s Hospital 8 February 2013 – – 0
Southampton General Hospital 24 February 2012 10 August 2012 10 August 2012 1
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Site name
Date
Number of
participants
randomisedSite opened
First participant
randomised
Last participant
randomised
St Peter’s Hospital, Chertsey 2 August 2011 12 August 2011 28 March 2012 4
St Richard’s Hospital, Chichester 18 July 2012 – – 0
Stafford Hospital 24 May 2012 24 May 2012 25 September 2012 2
Stepping Hill Hospital, Stockport 7 October 2011 – – 0
Tameside General Hospital 19 August 2011 12 September 2011 7 June 2013 3
The Great North Children’s
Hospital, Newcastle
13 October 2011 21 December 2011 20 February 2013 5
The Ipswich Hospital 13 July 2012 19 June 2013 19 June 2013 1
The Royal Bolton Hospital 24 August 2011 18 November 2011 21 January 2014 4
The Royal London Hospital 6 January 2012 2 February 2012 30 July 2012 2
Tunbridge Wells Hospital 26 September 2012 22 November 2012 23 September 2013 2
University Hospital Coventry,
Walsgrave
26 October 2011 14 March 2012 6 June 2012 2
University Hospital of North
Durham
27 March 2013 – – 0
University Hospital of North Tees 6 September 2011 2 November 2011 23 September 2014 2
University Hospital Of Wales,
Cardiff
7 October 2011 13 October 2011 17 September 2014 6
Warrington Hospital 8 September 2011 11 July 2012 11 July 2012 1
West Middlesex University Hospital 4 February 2014 – – 0
West Suffolk Hospital 3 August 2011 13 March 2014 13 March 2014 1
Wexham Park Hospital 27 February 2013 – – 0
Whipps Cross Hospital, London 30 April 2012 – – 0
Whiston Hospital, Merseyside 29 May 2012 – – 0
Wishaw General Hospital 29 September 2014 – – 0
Worcestershire Royal Hospital 13 October 2011 10 February 2012 14 March 2014 2
Worthing Hospital 10 February 2012 – – 0
Wythenshawe Hospital 8 July 2011 5 December 2011 5 December 2011 1
Yeovil District Hospital 30 September 2011 17 October 2011 30 April 2014 2
York Hospital 6 September 2011 – – 0
Ysbyty Gwynedd, Bangor 4 May 2012 26 November 2012 7 December 2012 2
Total 124 sites 86 sites 237 patients
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Appendix 2 Achenbach Child Behaviour Checklist
TABLE 21 Mean ACBC t-scores and total scores
Score
Group
Mean difference (95% CI) p-valueSC EC
t-score
4 weeks
n 104 109
Mean (SD) 53.28 (12.37) 52.36 (12.36) –0.92 (–4.26 to 2.42) 0.6
16 weeks
n 97 104
Mean (SD) 51.47 (13.10) 50.21 (13.91) –1.26 (–5.03 to 2.50) 0.5
12 months
n 98 102
Mean (SD) 50.84 (15.52) 49.31 (13.31) –1.52 (–5.55 to 2.50) 0.5
24 months
n 92 94
Mean (SD) 48.95 (13.81) 49.36 (13.54) 0.42 (–3.54 to 4.37) 0.8
36 months
n 61 61
Mean (SD) 49.07 (13.50) 48.87 (13.74) –0.20 (–5.08 to 4.69) 0.9
48 months
n 32 28
Mean (SD) 50.13 (15.18) 46.61 (13.06) –3.52 (–10.89 to 3.86) 0.3
Total
4 weeks
n 105 111
Mean (SD) 37.28 (26.83) 35.32 (25.86) –1.96 (–9.03 to 5.11) 0.6
16 weeks
n 97 105
Mean (SD) 34.30 (27.37) 31.20 (27.10) –3.10 (–10.66 to 4.46) 0.4
12 months
n 98 102
Mean (SD) 34.34 (31.67) 29.22 (24.88) –5.12 (–13.09 to 2.85) 0.2
24 months
n 93 95
Mean (SD) 28.92 (26.37) 28.08 (25.15) –0.84 (–8.25 to 6.57) 0.8
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TABLE 21 Mean ACBC t-scores and total scores (continued )
Score
Group
Mean difference (95% CI) p-valueSC EC
36 months
n 61 61
Mean (SD) 27.11 (25.11) 26.90 (26.15) –0.21 (–9.40 to 8.98) 1.0
48 months
n 32 28
Mean (SD) 29.56 (27.77) 21.25 (21.06) –8.31 (–21.20 to 4.57) 0.2
A higher score is worse. A negative difference favours the EC group.
TABLE 22 Achenbach Child Behaviour Checklist normal scores
Score
Group
RRa (95% CI) p-valueSC EC
Normal/abnormal scores
4 weeks
n 104 109
Normal score (%) 72 (69) 79 (72)
16 weeks
n 97 104
Normal score (%) 71 (73) 77 (74) 0.98 (0.86 to 1.10) 0.9
12 months
n 98 102
Normal score (%) 69 (70) 78 (76) 0.97 (0.84 to 1.12) 0.3
24 months
n 92 94
Normal score (%) 72 (78) 70 (74) 1.06 (0.92 to 1.23) 0.8
36 months
n 61 61
Normal score (%) 47 (77) 47 (77) 0.98 (0.83 to 1.14) 1.0
48 months
n 32 28
Normal score (%) 22 (69) 22 (79) 0.99 (0.73 to 1.35) 0.4
ACBC t-scores are categorised as normal < 60 or abnormal ≥ 60.
a Adjusting for 4-week ‘normal score’ status.
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Appendix 3 Economic analysis: the mapping
exercise
TABLE 23 Distribution of CHU-9D responses across the estimation sample
Characteristics
Time point, n (%)
Baseline
(N= 55)
16 weeks
(N= 47)
12 months
(N= 58)
24 months
(N= 54)
36 months
(N= 39)
48 months
(N= 26)
Worried
Doesn’t feel worried today 41 (74.55) 42 (89.36) 47 (81.03) 48 (88.89) 32 (82.05) 21 (80.77)
Feels a little bit worried today 10 (18.18) 5 (10.64) 7 (12.07) 5 (9.26) 5 (12.82) 5 (19.23)
Feels a bit worried today 3 (5.45) 0 (0.00) 3 (5.17) 1 (1.85) 1 (2.56) 0 (0.00)
Feels quite worried today 1 (1.82) 0 (0.00) 1 (1.72) 0 (0.00) 0 (0.00) 0 (0.00)
Feels very worried today 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 1 (2.56) 0 (0.00)
Sad
Doesn’t feel sad today 50 (90.91) 42 (89.36) 49 (84.48) 49 (90.74) 37 (94.87) 25 (96.15)
Feels a little bit sad today 3 (5.45) 1 (2.13) 6 (10.34) 4 (7.41) 1 (2.56) 1 (3.85)
Feels a bit sad today 1 (1.82) 2 (4.26) 3 (5.17) 1 (1.85) 0 (0.00) 0 (0.00)
Feels quite sad today 1 (1.82) 2 (4.26) 0 (0.00) 0 (0.00) 1 (2.56) 0 (0.00)
Feels very sad today 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Pain
Doesn’t have any pain today 48 (87.27) 41 (87.23) 54 (93.1) 48 (88.89) 33 (84.62) 20 (76.92)
Has a little bit of pain today 6 (10.91) 3 (6.38) 3 (5.17) 4 (7.41) 6 (15.38) 5 (19.23)
Has a bit of pain today 0 (0.00) 0 (0.00) 0 (0.00) 2 (3.7) 0 (0.00) 1 (3.85)
Has quite a lot of pain today 1 (1.82) 3 (6.38) 1 (1.72) 0 (0.00) 0 (0.00) 0 (0.00)
Has a lot of pain today 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Tired
Doesn’t feel tired today 33 (60.00) 27 (57.45) 33 (56.90) 38 (70.37) 22 (56.41) 16 (61.54)
Feels a little bit tired today 15 (27.27) 13 (27.66) 18 (31.03) 11 (20.37) 12 (30.77) 7 (26.92)
Feels a bit tired today 3 (5.45) 5 (10.64) 6 (10.34) 3 (5.56) 3 (7.69) 3 (11.54)
Feels quite tired today 2 (3.64) 1 (2.13) 1 (1.72) 2 (3.7) 2 (5.13) 0 (0.00)
Feels very tired today 2 (3.64) 1 (2.13) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Annoyed
Doesn’t feel annoyed today 44 (80) 37 (78.72) 52 (89.66) 48 (88.89) 36 (92.31) 21 (80.77)
Feels a little bit annoyed today 4 (7.27) 6 (12.77) 5 (8.62) 5 (9.26) 3 (7.69) 3 (11.54)
Feels a bit annoyed today 5 (9.09) 1 (2.13) 1 (1.72) 1 (1.85) 0 (0.00) 2 (7.69)
Feels quite annoyed today 0 (0.00) 1 (2.13) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Feels very annoyed today 2 (3.64) 2 (4.26) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
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TABLE 23 Distribution of CHU-9D responses across the estimation sample (continued )
Characteristics
Time point, n (%)
Baseline
(N= 55)
16 weeks
(N= 47)
12 months
(N= 58)
24 months
(N= 54)
36 months
(N= 39)
48 months
(N= 26)
School
Has no problems with schoolwork/
homework today
52 (94.55) 41 (87.23) 52 (89.66) 45 (83.33) 29 (74.36) 23 (88.46)
Has a few problems with schoolwork/
homework today
1 (1.82) 6 (12.77) 3 (5.17) 7 (12.96) 6 (15.38) 1 (3.85)
Has some problems with schoolwork/
homework today
1 (1.82) 0 (0.00) 2 (3.45) 1 (1.85) 3 (7.69) 1 (3.85)
Has many problems with schoolwork/
homework today
0 (0.00) 0 (0.00) 0 (0.00) 1 (1.85) 1 (2.56) 1 (3.85)
Cannot do schoolwork/homework
today
1 (1.82) 0 (0.00) 1 (1.72) 0 (0.00) 0 (0.00) 0 (0.00)
Sleep
Had no problems sleeping last night 43 (78.18) 38 (80.85) 40 (68.97) 44 (81.48) 25 (64.1) 17 (65.38)
Had a few problems sleeping last
night
9 (16.36) 5 (10.64) 11 (18.97) 5 (9.26) 7 (17.95) 4 (15.38)
Had some problems sleeping last night 2 (3.64) 2 (4.26) 5 (8.62) 3 (5.56) 4 (10.26) 0 (0.00)
Had many problems sleeping last night 1 (1.82) 2 (4.26) 2 (3.45) 2 (3.7) 3 (7.69) 5 (19.23)
Could not sleep at all last night 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Routine
Has no problems with daily routine
today
47 (85.45) 38 (80.85) 53 (91.38) 49 (90.74) 29 (74.36) 23 (88.46)
Has a few problems with daily routine
today
8 (14.55) 4 (8.51) 4 (6.90) 3 (5.56) 6 (15.38) 3 (11.54)
Has some problems with daily routine
today
0 (0.00) 5 (10.64) 1 (1.72) 2 (3.7) 2 (5.13) 0 (0.00)
Has many problems with daily routine
today
0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 2 (5.13) 0 (0.00)
Cannot do daily routine today 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Activity
Can join in with any activities today 47 (85.45) 41 (87.23) 54 (93.1) 48 (88.89) 33 (84.62) 25 (96.15)
Can join in with most activities today 6 (10.91) 2 (4.26) 3 (5.17) 4 (7.41) 2 (5.13) 1 (3.85)
Can join in with some activities today 0 (0.00) 2 (4.26) 0 (0.00) 1 (1.85) 1 (2.56) 0 (0.00)
Can join in with a few activities today 2 (3.64) 2 (4.26) 0 (0.00) 1 (1.85) 2 (5.13) 0 (0.00)
Can join in with no activities today 0 (0.00) 0 (0.00) 1 (1.72) 0 (0.00) 1 (2.56) 0 (0.00)
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TABLE 24 Distribution of CHU-9D responses across the validation sample
Characteristics
Time point, n (%)
Baseline
(N= 36)
16 weeks
(N= 46)
12 months
(N= 50)
24 months
(N= 70)
36 months
(N= 56)
48 months
(N= 26)
Worried
Doesn’t feel worried today 28 (77.78) 34 (73.91) 42 (84) 59 (84.29) 48 (85.71) 24 (92.31)
Feels a little bit worried today 7 (19.44) 11 (23.91) 5 (10) 6 (8.57) 5 (8.93) 2 (7.69)
Feels a bit worried today 0 (0.00) 1 (2.17) 2 (4) 3 (4.29) 1 (1.79) 0 (0.00)
Feels quite worried today 1 (2.78) 0 (0.00) 1 (2) 2 (2.86) 1 (1.79) 0 (0.00)
Feels very worried today 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 1 (1.79) 0 (0.00)
Sad
Doesn’t feel sad today 32 (88.89) 41 (89.13) 48 (96.00) 64 (91.43) 52 (92.86) 25 (96.15)
Feels a little bit sad today 2 (5.56) 4 (8.70) 2 (4.00) 3 (4.29) 4 (7.14) 1 (3.85)
Feels a bit sad today 1 (2.78) 1 (2.17) 0 (0.00) 3 (4.29) 0 (0.00) 0 (0.00)
Feels quite sad today 1 (2.78) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Feels very sad today 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Pain
Doesn’t have any pain today 29 (80.56) 39 (84.78) 45 (90) 61 (87.14) 51 (91.07) 21 (80.77)
Has a little bit of pain today 5 (13.89) 6 (13.04) 4 (8) 6 (8.57) 5 (8.93) 2 (7.69)
Has a bit of pain today 1 (2.78) 1 (2.17) 1 (2) 3 (4.29) 0 (0.00) 3 (11.54)
Has quite a lot of pain today 1 (2.78) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Has a lot of pain today 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Tired
Doesn’t feel tired today 17 (47.22) 32 (69.57) 29 (58) 43 (61.43) 37 (66.07) 17 (65.38)
Feels a little bit tired today 9 (25) 10 (21.74) 16 (32) 21 (30) 14 (25) 7 (26.92)
Feels a bit tired today 4 (11.11) 2 (4.35) 3 (6) 3 (4.29) 4 (7.14) 1 (3.85)
Feels quite tired today 6 (16.67) 2 (4.35) 2 (4) 2 (2.86) 1 (1.79) 1 (3.85)
Feels very tired today 0 (0.00) 0 (0.00) 0 (0.00) 1 (1.43) 0 (0.00) 0 (0.00)
Annoyed
Doesn’t feel annoyed today 29 (80.56) 37 (80.43) 45 (90) 60 (85.71) 54 (96.43) 24 (92.31)
Feels a little bit annoyed today 3 (8.33) 6 (13.04) 4 (8.00) 7 (10.00) 1 (1.79) 2 (7.69)
Feels a bit annoyed today 2 (5.56) 1 (2.17) 1 (2.00) 2 (2.86) 1 (1.79) 0 (0.00)
Feels quite annoyed today 0 (0.00) 2 (4.35) 0 (0.00) 1 (1.43) 0 (0.00) 0 (0.00)
Feels very annoyed today 2 (5.56) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
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TABLE 24 Distribution of CHU-9D responses across the validation sample (continued )
Characteristics
Time point, n (%)
Baseline
(N= 36)
16 weeks
(N= 46)
12 months
(N= 50)
24 months
(N= 70)
36 months
(N= 56)
48 months
(N= 26)
School
Has no problems with schoolwork/
homework today
34 (94.44) 43 (93.48) 41 (82.00) 59 (84.29) 48 (85.71) 21 (80.77)
Has a few problems with schoolwork/
homework today
1 (2.78) 1 (2.17) 5 (10.00) 8 (11.43) 4 (7.14) 4 (15.38)
Has some problems with schoolwork/
homework today
1 (2.78) 2 (4.35) 4 (8.00) 1 (1.43) 2 (3.57) 0 (0.00)
Has many problems with schoolwork/
homework today
0 (0.00) 0 (0.00) 0 (0.00) 2 (2.86) 2 (3.57) 1 (3.85)
Cannot do schoolwork/homework
today
0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Sleep
Had no problems sleeping last night 30 (83.33) 37 (80.43) 40 (80.00) 54 (77.14) 49 (87.5) 21 (80.77)
Had a few problems sleeping last
night
4 (11.11) 6 (13.04) 6 (12.00) 6 (8.57) 4 (7.14) 2 (7.69)
Had some problems sleeping last night 0 (0.00) 2 (4.35) 2 (4.00) 5 (7.14) 1 (1.79) 2 (7.69)
Had many problems sleeping last night 2 (5.56) 1 (2.17) 1 (2.00) 5 (7.14) 2 (3.57) 1 (3.85)
Could not sleep at all last night 0 (0.00) 0 (0.00) 1 (2.00) 0 (0.00) 0 (0.00) 0 (0.00)
Routine
Has no problems with daily routine
today
31 (86.11) 39 (84.78) 44 (88.00) 62 (88.57) 48 (85.71) 24 (92.31)
Has a few problems with daily routine
today
3 (8.33) 4 (8.70) 4 (8.00) 7 (10.00) 6 (10.71) 0 (0.00)
Has some problems with daily routine
today
2 (5.56) 2 (4.35) 2 (4.00) 1 (1.43) 1 (1.79) 1 (3.85)
Has many problems with daily routine
today
0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 1 (1.79) 1 (3.85)
Cannot do daily routine today 0 (0.00) 1 (2.17) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Activity
Can join in with any activities today 27 (75.00) 42 (91.3) 43 (86) 56 (80) 49 (87.50) 22 (84.62)
Can join in with most activities today 5 (13.88) 1 (2.17) 3 (6) 9 (12.86) 4 (7.14) 2 (7.69)
Can join in with some activities today 2 (5.56) 2 (4.35) 2 (4) 4 (5.71) 3 (5.36) 0 (0.00)
Can join in with a few activities today 1 (2.78) 1 (2.17) 1 (2) 0 (0.00) 0 (0.00) 2 (7.69)
Can join in with no activities today 1 (2.78) 0 (0.00) 1 (2) 1 (1.43) 0 (0.00) 0 (0.00)
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TABLE 25 Performance of PedsQL to CHU-9D index score models in the estimation and validation samples
Models
Sample
Average
MAE across
samples
Estimation Validation
Mean (SD)
Minimum
value
Maximum
value MSE MAE AIC BIC Mean (SD)
Minimum
value
Maximum
value MSE MAE
Observed 0.93742
(0.07898)
0.50940 1.00000 – – – – 0.94094
(0.07174)
0.65000 1.00000 – – –
GLM_1 0.93742
(0.04433)
0.74143 0.97345 0.00466 0.04789 98.12 105.38 0.93462
(0.05026)
0.66582 0.97345 0.00366 0.04525 0.04657
GLM_2 0.93742
(0.04535)
0.72021 0.98126 0.00446 0.04704 101.78 116.30 0.93409
(0.05250)
0.66769 0.98006 0.00372 0.04579 0.04642
GLM_3 0.93742
(0.04978)
0.72956 0.98071 0.00403 0.04313 101.91 120.06 0.93936
(0.05009)
0.64983 0.97949 0.00326 0.04046 0.04180
GLM_4 0.93742
(0.05019)
0.73330 0.98309 0.00393 0.04254 105.77 131.19 0.93907
(0.05061)
0.65902 0.98256 0.00324 0.04060 0.04157
GLM_5 0.93742
(0.05176)
0.65715 0.98975 0.00356 0.04109 112.75 152.70 0.93756
(0.05431)
0.71233 0.98512 0.00344 0.04172 0.04141
GLM_6 0.93742
(0.05193)
0.66093 0.98935 0.00353 0.04078 116.70 163.90 0.93761
(0.05476)
0.70516 0.98550 0.00345 0.04182 0.04130
OLS_1 0.93742
(0.04266)
0.81166 0.98597 0.00440 0.04595 –718.03 –710.77 0.93586
(0.04530)
0.78676 0.98597 0.00348 0.04429 0.04512
OLS_2 0.93742
(0.04338)
0.80481 1.00366 0.00434 0.04575 –717.97 –703.44 0.93579
(0.04651)
0.78818 1.00054 0.00348 0.04460 0.04518
OLS_3 0.93742
(0.04732)
0.81207 0.99522 0.00398 0.04245 –739.82 –721.67 0.93902
(0.04632)
0.78872 0.99389 0.00310 0.03981 0.04113
OLS_4 0.93742
(0.04762)
0.81562 1.00483 0.00396 0.04236 –737.82 –712.40 0.93884
(0.04693)
0.79050 1.00305 0.00310 0.03989 0.04113
OLS_5 0.93742
(0.04924)
0.76241 1.01474 0.00380 0.04218 –741.10 –701.16 0.93777
(0.05063)
0.77988 1.01377 0.00327 0.04050 0.04134
OLS_6 0.93742
(0.04935)
0.76394 1.01301 0.00379 0.04219 –737.88 –690.67 0.93778
(0.05071)
0.77576 1.01234 0.00326 0.04052 0.04136
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TABLE 25 Performance of PedsQL to CHU-9D index score models in the estimation and validation samples (continued )
Models
Sample
Average
MAE across
samples
Estimation Validation
Mean (SD)
Minimum
value
Maximum
value MSE MAE AIC BIC Mean (SD)
Minimum
value
Maximum
value MSE MAE
Tobit_1 0.96369
(0.05818)
0.79220 1.02990 0.00533 0.05285 –185.28 –174.39 0.96156
(0.06177)
0.75824 1.02990 0.00428 0.05003 0.05144
Tobit_2 0.96348
(0.05855)
0.78748 1.04827 0.00526 0.05242 –183.12 –164.97 0.96136
(0.06271)
0.75878 1.04466 0.00431 0.05063 0.05153
Tobit_3 0.96319
(0.06452)
0.79299 1.04910 0.00496 0.05195 –205.65 –183.86 0.96575
(0.06269)
0.76089 1.04170 0.00405 0.04816 0.05006
Tobit_4 0.96307
(0.06456)
0.79396 1.05047 0.00492 0.05159 –202.25 –173.20 0.96549
(0.06296)
0.76257 1.04897 0.00403 0.04806 0.04983
Tobit_5 0.96304
(0.06735)
0.74322 1.07926 0.00482 0.05284 –205.81 –162.23 0.96387
(0.06842)
0.76384 1.04872 0.00434 0.05107 0.05196
Tobit_6 0.96300
(0.06734)
0.74480 1.07843 0.00481 0.05270 –201.93 –151.09 0.96385
(0.06838)
0.76169 1.05209 0.00433 0.05099 0.05185
AIC, Akaike information criterion; BIC, Bayesian information criterion.
A model had the best prediction accuracy for its functional form if it had the lowest MAE across the estimation and validation sample.
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FIGURE 17 Distribution in the estimation and validation samples. Observed CHU-9D score, (a) estimation group
and (b) validation group; GLM_6-predicted CHU-9D score, (c) estimation group and (d) validation group; and
OLS_3-predicted CHU-9D score, (e) estimation group and (f) validation group.
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Appendix 4 Economic evaluation
TABLE 26 Mean number of hospital admission bed-days, by treatment group
Time point
Group
Difference (bootstrapped 95% CI)
SC EC
n Bed-days n Bed-days
Week 4 109 0.009 (0.096) 113 0.027 (0.21) 0.017 (–0.025 to 0.060)
Week 8 108 0.046 (0.317) 106 0.34 (1.995) 0.293 (–0.083 to 0.669)
Week 12 104 0.769 (4.282) 109 0.018 (0.135) –0.751 (–1.583 to 0.082)
Week 16 104 0.163 (0.698) 107 0.112 (0.828) –0.051 (–0.253 to 0.150)
Month 5 97 0.67 (2.688) 109 0.312 (1.338) –0.358 (–0.946 to 0.230)
Month 6 102 0.225 (1.052) 109 0.56 (2.132) 0.334 (–0.12 to 0.788)
Month 8 100 0.29 (1.233) 109 0.165 (0.764) –0.125 (–0.400 to 0.150)
Month 10 100 2.41 (21.408) 107 0.271 (1.154) –2.139 (–6.253 to 1.975)
Month 12 101 0.109 (0.527) 106 0.33 (1.666) 0.221 (–0.098 to 0.541)
Month 18 99 1.01 (3.663) 105 0.352 (1.467) –0.658 (–1.452 to 0.137)
Month 24 100 0.64 (3.463) 103 0.233 (1.031) –0.407 (–1.108 to 0.294)
Resource use (complete cases only).
TABLE 27 Mean number of hospital admission episodes, by treatment group
Time point
Group
Difference (bootstrapped 95% CI)
SC EC
n Episodes n Episodes
Week 4 109 0.009 (0.096) 113 0.018 (0.132) 0.009 (–0.021 to 0.038)
Week 8 108 0.046 (0.317) 106 0.047 (0.213) 0.001 (–0.074 to 0.075)
Week 12 104 0.096 (0.327) 109 0.018 (0.135) –0.078 (–0.144 to –0.012)
Week 16 104 0.067 (0.252) 107 0.028 (0.166) –0.039 (–0.096 to 0.017)
Month 5 97 0.093 (0.325) 109 0.083 (0.277) –0.01 (–0.091 to 0.071)
Month 6 102 0.078 (0.305) 109 0.128 (0.363) 0.05 (–0.042 to 0.142)
Month 8 100 0.08 (0.273) 109 0.128 (0.579) 0.048 (–0.077 to 0.174)
Month 10 100 0.11 (0.399) 107 0.121 (0.428) 0.011 (–0.103 to 0.126)
Month 12 101 0.069 (0.292) 106 0.075 (0.299) 0.006 (–0.07 to 0.083)
Month 18 99 0.202 (0.534) 105 0.124 (0.409) –0.078 (–0.212 to 0.056)
Month 24 100 0.2 (0.696) 103 0.117 (0.449) –0.083 (–0.243 to 0.076)
Resource use (complete cases only).
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TABLE 28 Mean number of hospital emergency visits and corresponding cost, by treatment group
Time point
Group, mean (SD)
Bootstrapped cost
difference (95% CI)
SC EC
Visits Cost (£) Visits Cost (£)
Week 4 0 (0) 0 (0) 0.009 (0.094) 11.69 (124.269) 11.69 (–11.34 to 34.72)
Week 8 0.037 (0.234) 48.926 (308.928) 0.009 (0.097) 12.462 (128.307) –36.46 (–99.35 to 26.43)
Week 12 0.115 (0.425) 152.423 (561.591) 0.009 (0.096) 12.119 (126.529) –140.3 (–250.88 to –29.73)
Week 16 0.058 (0.234) 76.212 (309.497) 0.009 (0.097) 12.346 (127.706) –63.87 (–128.76 to 1.03)
Month 5 0.01 (0.102) 13.619 (134.127) 0.073 (0.262) 96.954 (346.085) 83.34 (11.05 to 155.62)
Month 6 0.029 (0.221) 38.853 (291.314) 0.037 (0.302) 48.477 (399.006) 9.62 (–85.76 to 105.01)
Month 8 0.08 (0.339) 105.68 (447.481) 0.028 (0.164) 36.358 (217.116) –69.32 (–162.81 to 24.17)
Month 10 0.08 (0.339) 105.68 (447.481) 0.028 (0.166) 37.037 (219.096) –68.64 (–168.73 to 31.44)
Month 12 0.04 (0.196) 52.317 (258.915) 0.019 (0.137) 24.925 (180.587) –27.39 (–90.65 to 35.87)
Month 18 0.091 (0.353) 120.091 (465.742) 0.086 (0.462) 113.229 (610.72) –6.86 (–152.1 to 138.37)
Month 24 0.11 (0.567) 145.31 (748.567) 0.078 (0.362) 102.602 (478.419) –42.71 (–213.66 to 128.24)
TABLE 29 Mean number of hospital outpatient visits and corresponding cost, by treatment group
Time point
Group, mean (SD)
Bootstrapped cost
difference (95% CI)
SC EC
Visits Cost (£) Visits Cost (£)
Week 4 0.165 (0.481) 36.33 (105.906) 0.239 (0.555) 52.566 (122.188) 16.24 (–12.73 to 45.2)
Week 8 0.204 (0.448) 44.815 (98.659) 0.094 (0.325) 20.755 (71.39) –24.06 (–47.25 to –0.87)
Week 12 0.24 (0.566) 52.885 (124.508) 0.119 (0.424) 26.239 (93.361) –26.65 (–56.68 to 3.39)
Week 16 0.433 (1.086) 95.192 (238.97) 0.112 (0.372) 24.673 (81.8) –70.52 (–119.18 to –21.86)
Month 5 0.546 (1.267) 120.206 (278.68) 0.385 (0.815) 84.771 (179.4) –35.44 (–100.04 to 29.17)
Month 6 0.314 (0.731) 69.02 (160.806) 0.294 (0.724) 64.587 (159.272) –4.43 (–49.65 to 40.79)
Month 8 0.84 (1.461) 184.8 (321.513) 0.56 (0.966) 123.119 (212.606) –61.68 (–138.9 to 15.54)
Month 10 0.56 (1.175) 123.2 (258.46) 0.673 (1.472) 148.037 (323.75) 24.84 (–53.66 to 103.34)
Month 12 0.455 (0.985) 100.198 (216.73) 0.519 (1.08) 114.151 (237.591) 13.95 (–49 to 76.9)
Month 18 1.566 (2.639) 344.444 (580.503) 1.324 (1.842) 291.238 (405.31) –53.21 (–191.51 to 85.1)
Month 24 1.71 (7.55) 376.2 (1660.903) 1.155 (1.696) 254.175 (373.196) –122.03 (–448.77 to 204.72)
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